Patent Publication Number: US-2004058365-A1

Title: Molecules for disease detection and treatment

Description:
TECHNICAL FIELD  
       [0001] The present invention relates to molecules for disease detection and treatment and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.  
       BACKGROUND OF THE INVENTION  
       [0002] The human genome is comprised of thousands of genes, many encoding gene products that function in the maintenance and growth of the various cells and tissues in the body. Aberrant expression or mutations in these genes and their products is the cause of, or is associated with, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases, and targets for their prevention and treatment.  
       [0003] For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. A wide variety of molecules, either aberrantly expressed or mutated, can be the cause of, or involved with, various cancers because tissue growth involves complex and ordered patterns of cell proliferation, cell differentiation, and apoptosis. Cell proliferation must be regulated to maintain both the number of cells and their spatial organization. This regulation depends upon the appropriate expression of proteins which control cell cycle progression in response to extracellular signals such as growth factors and other mitogens, and intracellular cues such as DNA damage or nutrient starvation. Molecules which directly or indirectly modulate cell cycle progression fall into several categories, including growth factors and their receptors, second messenger and signal transduction proteins, oncogene products, tumor-suppressor proteins, and mitosis-promoting factors. Aberrant expression or mutations in any of these gene products can result in cell proliferative disorders such as cancer. Oncogenes are genes generally derived from normal genes that, through abnormal expression or mutation, can effect the transformation of a normal cell to a malignant one (oncogenesis). Oncoproteins, encoded by oncogenes, can affect cell proliferation in a variety of ways and include growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which cause reduced or loss of function in tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered.  
       [0004] DNA-based arrays can provide a simple way to explore the expression of a single polymorphic gene or a large number of genes. When the expression of a single gene is explored, DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.  
       [0005] DNA-based array technology is especially relevant for the rapid screening of expression of a large number of genes. There is a growing awareness that gene expression is affected in a global fashion. A genetic predisposition, disease or therapeutic treatment may affect, directly or indirectly, the expression of a large number of genes. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes.  
       [0006] The discovery of new molecules for disease detection and treatment satisfies a need in the art by providing new compositions which are useful in the diagnosis, study, prevention, and treatment of diseases associated with, as well as effects of exogenous compounds on, the expression of molecules for disease detection and treatment.  
       SUMMARY OF THE INVENTION  
       [0007] The present invention relates to human disease detection and treatment molecule polynucleotides (mddt) as presented in the Sequence Listing. The mddt uniquely identify genes encoding structural, functional, and regulatory disease detection and treatment molecules.  
       [0008] The invention provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36. In another alternative, the polynucleotide comprises at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In another alternative, the polynucleotide comprises at least 60 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The invention further provides a composition for the detection of expression of disease detection and treatment molecule polynucleotides comprising at least one isolated polynucleotide comprising a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d); and a detectable label.  
       [0009] The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.  
       [0010] The invention also provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 30 contiguous nucleotides. In one alternative, the invention provides a composition comprising a target polynucleotide of the method, wherein said probe comprises at least 60 contiguous nucleotides.  
       [0011] The invention further provides a recombinant polynucleotide comprising a promoter sequence operably linked to an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.  
       [0012] The invention also provides a method for producing a disease detection and treatment molecule polypeptide, the method comprising a) culturing a cell under conditions suitable for expression of the disease detection and treatment molecule polypeptide, wherein said cell is transformed with a recombinant polynucleotide, said recombinant polynucleotide comprising an isolated polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and b) recovering the disease detection and treatment molecule polypeptide so expressed. The invention additionally provides a method wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:37-72.  
       [0013] The invention also provides an isolated disease detection and treatment molecule polypeptide (MDDT) encoded by at least one polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36. The invention further provides a method of screening for a test compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) combining the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72 to the test compound, thereby identifying a compound that specifically binds to the polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.  
       [0014] The invention further provides a microarray wherein at least one element of the microarray is an isolated polynucleotide comprising at least 30 contiguous nucleotides of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The invention also provides a method for generating a transcript image of a sample which contains polynucleotides. The method comprises a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.  
       [0015] Additionally, the invention provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; c) a polynucleotide complementary to the polynucleotide of a); d) a polynucleotide complementary to the polynucleotide of b); and e) an RNA equivalent of a) through d). The method comprises a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.  
       [0016] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36; iii) a polynucleotide complementary to the polynucleotide of i); iv) a polynucleotide complementary to the polynucleotide of ii); and v) an RNA equivalent of i) through iv), and alternatively, the target polynucleotide comprises a polynucleotide sequence of a fragment of a polynucleotide selected from the group consisting of i-v above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.  
       [0017] The invention further provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In one alternative, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.  
       [0018] The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In one alternative, the polynucleotide encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. In another alternative, the polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1-36.  
       [0019] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72.  
       [0020] The invention further provides a composition comprising a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.  
       [0021] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.  
       [0022] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional MDDT, comprising administering to a patient in need of such treatment the composition.  
       [0023] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 37-72. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.  
       DESCRIPTION OF THE TABLES  
       [0024] Table 1 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with the sequence identification numbers (SEQ ID NO:s) and open reading frame identification numbers (ORF IDs) corresponding to polypeptides encoded by the template ID.  
       [0025] Table 2 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with their GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.  
       [0026] Table 3 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions. The reading frames of the polynucleotide segments and the Pfam hits, Pfam descriptions, and E-values corresponding to the polypeptide domains encoded by the polynucleotide segments are indicated.  
       [0027] Table 4 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with polynucleotide segments of each template sequence as defined by the indicated “start” and “stop” nucleotide positions. The reading frames of the polynucleotide segments are shown, and the polypeptides encoded by the polynucleotide segments constitute either signal peptide (SP) or transmembrane (TM) domains, as indicated. For TM domains, the membrane topology of the encoded polypeptide sequence is indicated as being transmembrane or on the cytosolic or non-cytosolic side of the cell membrane or organelle.  
       [0028] Table 5 shows the sequence identification numbers (SEQ ID NO:s) and template identification numbers (template IDs) corresponding to the polynucleotides of the present invention, along with component sequence identification numbers (component IDs) corresponding to each template. The component sequences, which were used to assemble the template sequences, are defined by the indicated “start” and “stop” nucleotide positions along each template.  
       [0029] Table 6 shows the tissue distribution profiles for the templates of the invention.  
       [0030] Table 7 shows the sequence identification numbers (SEQ ID NO:s) corresponding to the polypeptides of the present invention, along with the reading frames used to obtain the polypeptide segments, the lengths of the polypeptide segments, the “start” and “stop” nucleotide positions of the polynucleotide sequences used to define the encoded polypeptide segments, the GenBank hits (GI Numbers), probability scores, and functional annotations corresponding to the GenBank hits.  
       [0031] Table 8 summarizes the bioinformatics tools which are useful for analysis of the polynucleotides of the present invention. The first column of Table 8 lists analytical tools, programs, and algorithms, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences).  
       DETAILED DESCRIPTION OF THE INVENTION  
       [0032] Before the nucleic acid sequences and methods are presented, it is to be understood that this invention is not limited to the particular machines, methods, and materials described. Although particular embodiments are described, machines, methods, and materials similar or equivalent to these embodiments may be used to practice the invention. The preferred machines, methods, and materials set forth are not intended to limit the scope of the invention which is limited only by the appended claims.  
       [0033] The singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. All technical and scientific terms have the meanings commonly understood by one of ordinary skill in the art. All publications are incorporated by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are presented and which might be used in connection with the invention. Nothing in the specification is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.  
       [0034] Definitions  
       [0035] As used herein, the lower case “mddt” refers to a nucleic acid sequence, while the upper case “MDDT” refers to an amino acid sequence encoded by mddt. A “full-length” mddt refers to a nucleic acid sequence containing the entire coding region of a gene endogenously expressed in human tissue.  
       [0036] “Adjuvants” are materials such as Freund&#39;s adjuvant, mineral gels (aluminum hydroxide), and surface active substances (lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol) which may be administered to increase a host&#39;s immunological response.  
       [0037] “Allele” refers to an alternative form of a nucleic acid sequence. Alleles result from a “mutation,” a change or an alternative reading of the genetic code. Any given gene may have none, one, or many allelic forms. Mutations which give rise to alleles include deletions, additions, or substitutions of nucleotides. Each of these changes may occur alone, or in combination with the others, one or more times in a given nucleic acid sequence. The present invention encompasses allelic mddt.  
       [0038] An “allelic variant” is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.  
       [0039] “Altered” nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MDDT. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.  
       [0040] “Amino acid sequence” refers to a peptide, a polypeptide, or a protein of either natural or synthetic origin. The amino acid sequence is not limited to the complete, endogenous amino acid sequence and may be a fragment, epitope, variant, or derivative of a protein expressed by a nucleic acid sequence.  
       [0041] “Amplification” refers to the production of additional copies of a sequence and is carried out using polymerase chain reaction (PCR) technologies well known in the art.  
       [0042] “Antibody” refers to intact molecules as well as to fragments thereof, such as Fab, F(ab′) 2 , and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.  
       [0043] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH 2 ), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13.)  
       [0044] The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).  
       [0045] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.  
       [0046] “Antisense sequence” refers to a sequence capable of specifically hybridizing to a target sequence. The antisense sequence may include DNA, RNA, or any nucleic acid mimic or analog such as peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine.  
       [0047] “Antisense technology” refers to any technology which relies on the specific hybridization of an antisense sequence to a target sequence.  
       [0048] A “bin” is a portion of computer memory space used by a computer program for storage of data, and bounded in such a manner that data stored in a bin may be retrieved by the program.  
       [0049] “Biologically active” refers to an amino acid sequence having a structural, regulatory, or biochemical function of a naturally occurring amino acid sequence.  
       [0050] “Clone joining” is a process for combining gene bins based upon the bins&#39; containing sequence information from the same clone. The sequences may assemble into a primary gene transcript as well as one or more splice variants.  
       [0051] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing (5′-A-G-T-3′ pairs with its complement 3′-T-C-A-5′).  
       [0052] A “component sequence” is a nucleic acid sequence selected by a computer program such as PHRED and used to assemble a consensus or template sequence from one or more component sequences.  
       [0053] A “consensus sequence” or “template sequence” is a nucleic acid sequence which has been assembled from overlapping sequences, using a computer program for fragment assembly such as the GEL VIEW fragment assembly system (Genetics Computer Group (GCG), Madison Wis.) or using a relational database management system (RDMS).  
       [0054] “Conservative amino acid substitutions” are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative substitutions.  
                                                   Original Residue   Conservative Substitution                          Ala   Gly, Ser           Arg   His, Lys           Asn   Asp, Gln, His           Asp   Asn, Glu           Cys   Ala, Ser           Gln   Asn, Glu, His           Glu   Asp, Gln, His           Gly   Ala           His   Asn, Arg, Gln, Glu           Ile   Leu, Val           Leu   Ile, Val           Lys   Arg, Gln, Glu           Met   Leu, Ile           Phe   His, Met, Leu, Trp, Tyr           Ser   Cys, Thr           Thr   Ser, Val           Trp   Phe, Tyr           Tyr   His, Phe, Trp           Val   Ile, Leu, Thr                      
 
       [0055] Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.  
       [0056] “Deletion” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or amino acid residue, respectively, is absent.  
       [0057] “Derivative” refers to the chemical modification of a nucleic acid sequence, such as by replacement of hydrogen by an alkyl, acyl, amino, hydroxyl, or other group.  
       [0058] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.  
       [0059] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.  
       [0060] The term “modulate” refers to a change in the activity of MDDT. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.  
       [0061] “E-value” refers to the statistical probability that a match between two sequences occurred by chance.  
       [0062] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.  
       [0063] A “fragment” is a unique portion of mddt or MDDT which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 10 to 1000 contiguous amino acid residues or nucleotides. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous amino acid residues or nucleotides in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing and the figures, may be encompassed by the present embodiments.  
       [0064] A fragment of mddt comprises a region of unique polynucleotide sequence that specifically identifies mddt, for example, as distinct from any other sequence in the same genome. A fragment of mddt is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish mddt from related polynucleotide sequences. The precise length of a fragment of mddt and the region of mddt to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.  
       [0065] A fragment of MDDT is encoded by a fragment of mddt. A fragment of MDDT comprises a region of unique amino acid sequence that specifically identifies MDDT. For example, a fragment of MDDT is useful as an immunogenic peptide for the development of antibodies that specifically recognize MDDT. The precise length of a fragment of MDDT and the region of MDDT to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.  
       [0066] A “full length” nucleotide sequence is one containing at least a start site for translation to a protein sequence, followed by an open reading frame and a stop site, and encoding a “full length” polypeptide.  
       [0067] “Hit” refers to a sequence whose annotation will be used to describe a given template. Criteria for selecting the top hit are as follows: if the template has one or more exact nucleic acid matches, the top hit is the exact match with highest percent identity. If the template has no exact matches but has significant protein hits, the top hit is the protein hit with the lowest E-value. If the template has no significant protein hits, but does have significant non-exact nucleotide hits, the top hit is the nucleotide hit with the lowest E-value.  
       [0068] “Homology” refers to sequence similarity either between a reference nucleic acid sequence and at least a fragment of an mddt or between a reference amino acid sequence and a fragment of an MDDT.  
       [0069] “Hybridization” refers to the process by which a strand of nucleotides anneals with a complementary strand through base pairing. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under defined annealing conditions, and remain hybridized after the “washing” step. The defined hybridization conditions include the annealing conditions and the washing step(s), the latter of which is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid probes that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency.  
       [0070] Generally, stringency of hybridization is expressed with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5° C. to 20° C. lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH. The T m  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T m  and conditions for nucleic acid hybridization is well known and can be found in Sambrook et al., 1989,  Molecular Cloning: A Laboratory Manual,  2 nd  ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.  
       [0071] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., or 55° C. may be used. SSC concentration may be varied from about 0.2 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 μg/ml. Useful variations on these conditions will be readily apparent to those skilled in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their resultant proteins.  
       [0072] Other parameters, such as temperature, salt concentration, and detergent concentration may be varied to achieve the desired stringency. Denaturants, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as RNA:DNA hybridizations. Appropriate hybridization conditions are routinely determinable by one of ordinary skill in the art.  
       [0073] “Immunologically active” or “immunogenic” describes the potential for a natural, recombinant, or synthetic peptide, epitope, polypeptide, or protein to induce antibody production in appropriate animals, cells, or cell lines.  
       [0074] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.  
       [0075] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of MDDT which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of MDDT which is useful in any of the antibody production methods disclosed herein or known in the art.  
       [0076] “Insertion” or “addition” refers to a change in either a nucleic or amino acid sequence in which at least one nucleotide or residue, respectively, is added to the sequence.  
       [0077] “Labeling” refers to the covalent or noncovalent joining of a polynucleotide, polypeptide, or antibody with a reporter molecule capable of producing a detectable or measurable signal.  
       [0078] “Microarray” is any arrangement of nucleic acids, amino acids, antibodies, etc., on a substrate. The substrate may be a solid support such as beads, glass, paper, nitrocellulose, nylon, or an appropriate membrane.  
       [0079] “Linkers” are short stretches of nucleotide sequence which may be added to a vector or an mddt to create restriction endonuclease sites to facilitate cloning. “Polylinkers” are engineered to incorporate multiple restriction enzyme sites and to provide for the use of enzymes which leave 5′ or 3′ overhangs (e.g., BamHI, EcoRI and HindIII) and those which provide blunt ends (e.g., EcoRV, SnaBI, and StuI).  
       [0080] “naturally occurring” refers to an endogenous polynucleotide or polypeptide that may be isolated from viruses or prokaryotic or eukaryotic cells.  
       [0081] “Nucleic acid sequence” refers to the specific order of nucleotides joined by phosphodiester bonds in a linear, polymeric arrangement. Depending on the number of nucleotides, the nucleic acid sequence can be considered an oligomer, oligonucleotide, or polynucleotide. The nucleic acid can be DNA, RNA, or any nucleic acid analog, such as PNA, may be of genomic or synthetic origin, may be either double-stranded or single-stranded, and can represent either the sense or antisense (complementary) strand.  
       [0082] “Oligomer” refers to a nucleic acid sequence of at least about 6 nucleotides and as many as about 60 nucleotides, preferably about 15 to 40 nucleotides, and most preferably between about 20 and 30 nucleotides, that may be used in hybridization or amplification technologies. Oligomers may be used as, e.g., primers for PCR, and are usually chemically synthesized.  
       [0083] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.  
       [0084] “Peptide nucleic acid” (PNA) refers to a DNA mimic in which nucleotide bases are attached to a pseudopeptide backbone to increase stability. PNAs, also designated antigene agents, can prevent gene expression by targeting complementary messenger RNA.  
       [0085] The phrases “percent identity” and “% identity”, as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.  
       [0086] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequence pairs.  
       [0087] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “BLASTN,” that is used to determine alignment between a known polynucleotide sequence and other sequences on a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2/. The “BLAST 2 Sequences” tool can be used for both BLASTN and BLASTP (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use BLASTN with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such default parameters may be, for example:  
       [0088] Matrix: BLOSUM62  
       [0089] Reward for match: 1  
       [0090] Penalty for mismatch: −2  
       [0091] Open Gap: 5 and Extension Gap: 2 penalties  
       [0092] Gap×drop-off: 50  
       [0093] Expect: 10  
       [0094] Word Size: 11  
       [0095] Filter: on  
       [0096] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.  
       [0097] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.  
       [0098] The phrases “percent identity” and “% identity”, as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity of the substituted residue, thus preserving the structure (and therefore function) of the folded polypeptide.  
       [0099] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.  
       [0100] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) with BLASTP set at default parameters. Such default parameters may be, for 15 example:  
       [0101] Matrix: BLOSUM62  
       [0102] Open Gap: 11 and Extension Gap: 1 penalty  
       [0103] Gap×drop-off: 50  
       [0104] Expect: 10  
       [0105] Word Size: 3  
       [0106] Filter: on  
       [0107] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in figures or Sequence Listings, may be used to describe a length over which percentage identity may be measured.  
       [0108] “Post-translational modification” of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu and the MDDT.  
       [0109] “Probe” refers to mddt or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).  
       [0110] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the figures and Sequence Listing, may be used.  
       [0111] Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989,  Molecular Cloning: A Laboratory Manual,  2 nd  ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel et al.,1987,  Current Protocols in Molecular Biology , Greene Publ. Assoc. &amp; Wiley-Intersciences, New York N.Y.; Innis et al., 1990,  PCR Protocols, A Guide to Methods and Applications , Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).  
       [0112] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide-scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user&#39;s specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.  
       [0113] “Purified” refers to molecules, either polynucleotides or polypeptides that are isolated or separated from their natural environment and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other compounds with which they are naturally associated.  
       [0114] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.  
       [0115] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.  
       [0116] “Regulatory element” refers to a nucleic acid sequence from nontranslated regions of a gene, and includes enhancers, promoters, introns, and 3′ untranslated regions, which interact with host proteins to carry out or regulate transcription or translation.  
       [0117] “Reporter” molecules are chemical or biochemical moieties used for labeling a nucleic acid, an amino acid, or an antibody. They include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.  
       [0118] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.  
       [0119] “Sample” is used in its broadest sense. Samples may contain nucleic or amino acids, antibodies, or other materials, and may be derived from any source (e.g., bodily fluids including, but not limited to, saliva, blood, and urine; chromosome(s), organelles, or membranes isolated from a cell; genomic DNA, RNA, or cDNA in solution or bound to a substrate; and cleared cells or tissues or blots or imprints from such cells or tissues).  
       [0120] “Specific binding” or “specifically binding” refers to the interaction between a protein or peptide and its agonist, antibody, antagonist, or other binding partner. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide containing epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.  
       [0121] “Substitution” refers to the replacement of at least one nucleotide or amino acid by a different nucleotide or amino acid.  
       [0122] “Substrate” refers to any suitable rigid or semi-rigid support including, e.g., membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles or capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.  
       [0123] A “transcript image” refers to the collective pattern of gene expression by a particular tissue or cell type under given conditions at a given time.  
       [0124] “Transformation” refers to a process by which exogenous DNA enters a recipient cell. Transformation may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed.  
       [0125] “Transformants” include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as cells which transiently express inserted DNA or RNA.  
       [0126] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.  
       [0127] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 25% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using BLASTN with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. The variant may result in “conservative” amino acid changes which do not affect structural and/or chemical properties. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.  
       [0128] In an alternative, variants of the polynucleotides of the present invention may be generated through recombinant methods. One possible method is a DNA shuffling technique such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C. -C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.  
       [0129] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using BLASTP with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.  
       THE INVENTION  
       [0130] In a particular embodiment, cDNA sequences derived from human tissues and cell lines were aligned based on nucleotide sequence identity and assembled into “consensus” or “template” sequences which are designated by the template identification numbers (template IDs) in column 2 of Table 2. The sequence identification numbers (SEQ ID NO:s) corresponding to the template IDs are shown in column 1. The template sequences have similarity to GenBank sequences, or “hits,” as designated by the GI Numbers in column 3. The statistical probability of each GeniBank hit is indicated by a probability score in column 4, and the functional annotation corresponding to each GenBank hit is listed in column 5.  
       [0131] The invention incorporates the nucleic acid sequences of these templates as disclosed in the Sequence Listing and the use of these sequences in the diagnosis and treatment of disease states characterized by defects in disease detection and treatment molecules. The invention further utilizes these sequences in hybridization and amplification technologies, and in particular, in technologies which assess gene expression patterns correlated with specific cells or tissues and their responses in vivo or in vitro to pharmaceutical agents, toxins, and other treatments. In this manner, the sequences of the present invention are used to develop a transcript image for a particular cell or tissue.  
       [0132] Derivation of Nucleic Acid Sequences  
       [0133] cDNA was isolated from libraries constructed using RNA derived from normal and diseased human tissues and cell lines. The human tissues and cell lines used for cDNA library construction were selected from a broad range of sources to provide a diverse population of cDNAs representative of gene transcription throughout the human body. Descriptions of the human tissues and cell lines used for cDNA library construction are provided in the LIESEQ database (Incyte Genomics, Inc. (Incyte), Palo Alto Calif.). Human tissues were broadly selected from, for example,cardiovascular, dermatologic, endocrine, gastrointestinal, hematopoietic/immune system, musculoskeletal, neural, reproductive, and urologic sources.  
       [0134] Cell lines used for cDNA library construction were derived from, for example, leukemic cells, teratocarcinomas, neuroepitheliomas, cervical carcinoma, lung fibroblasts, and endothelial cells. Such cell lines include, for example, THP-1, Jurkat, HUVEC, hNT2, WI38, HeLa, and other cell lines commonly used and available from public depositories (American Type Culture Collection, Manassas Va.). Prior to mRNA isolation, cell lines were untreated, treated with a pharmaceutical agent such as 5′-aza-2′-deoxycytidine, treated with an activating agent such as lipopolysaccharide in the case of leukocytic cell lines, or, in the case of endothelial cell lines, subjected to shear stress.  
       [0135] Sequencing of the cDNAs  
       [0136] Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ the Klenow fragment of DNA polymerase I, SEQUENASE DNA polymerase (U.S. Biochemical Corporation, Cleveland Ohio), Taq polymerase (Applied Biosystems, Foster City Calif.), thermostable T7 polymerase (Amersham Pharmacia Biotech, Inc. (Amersham Pharmacia Biotech), Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies Inc. (Life Technologies), Gaithersburg Md.), to extend the nucleic acid sequence from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single-stranded and double-stranded templates. Chain termination reaction products may be electrophoresed on urea-polyacrylamide gels and detected either by autoradiography (for radioisotope-labeled nucleotides) or by fluorescence (for fluorophore-labeled nucleotides). Automated methods for mechanized reaction preparation, sequencing, and analysis using fluorescence detection methods have been developed. Machines used to prepare cDNAs for sequencing can include the MICROLAB 2200 liquid transfer system (Hamilton Company (Hamilton), Reno Nev.), Peltier thermal cycler (PTC200; MJ Research, Inc. (MJ Research), Watertown Mass.), and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing can be carried out using, for example, the ABI 373 or 377 (Applied Biosystems) or MEGABACE 1000 (Molecular Dynamics, Inc. (Molecular Dynamics), Sunnyvale Calif.) DNA sequencing systems, or other automated and manual sequencing systems well known in the art.  
       [0137] The nucleotide sequences of the Sequence Listing have been prepared by current, state-of-the-art, automated methods and, as such, may contain occasional sequencing errors or unidentified nucleotides. Such unidentified nucleotides are designated by an N. These infrequent unidentified bases do not represent a hindrance to practicing the invention for those skilled in the art. Several methods employing standard recombinant techniques may be used to correct errors and complete the missing sequence information. (See, e.g., those described in Ausubel, F. M. et al. (1997)  Short Protocols in Molecular Biology , John Wiley &amp; Sons, New York N.Y.; and Sambrook, J. et al. (1989)  Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Press, Plainview N.Y.)  
       [0138] Assembly of cDNA Sequences  
       [0139] Human polynucleotide sequences may be assembled using programs or algorithms well known in the art. Sequences to be assembled are related, wholly or in part, and may be derived from a single or many different transcripts. Assembly of the sequences can be performed using such programs as PHRAP (Phils Revised Assembly Program) and the GELVIEW fragment assembly system (GCG), or other methods known in the art.  
       [0140] Alternatively, cDNA sequences are used as “component” sequences that are assembled into “template” or “consensus” sequences as follows. Sequence chromatograms are processed, verified, and quality scores are obtained using PHRED. Raw sequences are edited using an editing pathway known as Block 1 (See, e.g., the LIFESEQ Assembled User Guide, Incyte Genomics, Palo Alto, Calif.). A series of BLAST comparisons is performed and low-information segments and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) are replaced by “n&#39;s”, or masked, to prevent spurious matches. Mitochondrial and ribosomal RNA sequences are also removed. The processed sequences are then loaded into a relational database management system (RDMS) which assigns edited sequences to existing templates, if available. When additional sequences are added into the RDMS, a process is initiated which modifies existing templates or creates new templates from works in progress (i.e., nonfinal assembled sequences) containing queued sequences or the sequences themselves. After the new sequences have been assigned to templates, the templates can be merged into bins. If multiple templates exist in one bin, the bin can be split and the templates reannotated.  
       [0141] Once gene bins have been generated based upon sequence alignments, bins are “clone joined” based upon clone information. Clone joining occurs when the 5′ sequence of one clone is present in one bin and the 3′ sequence from the same clone is present in a different bin, indicating that the two bins should be merged into a: single bin. Only bins which share at least two different clones are merged.  
       [0142] A resultant template sequence may contain either a partial or a full length open reading frame, or all or part of a genetic regulatory element. This variation is due in part to the fact that the full length cDNAs of many genes are several hundred, and sometimes several thousand, bases in length. With current technology, cDNAs comprising the coding regions of large genes cannot be cloned because of vector limitations, incomplete reverse transcription of the mRNA, or incomplete “second strand” synthesis. Template sequences may be extended to include additional contiguous sequences derived from the parent RNA transcript using a variety of methods known to those of skill in the art. Extension may thus be used to achieve the full length coding sequence of a gene.  
       [0143] Analysis of the cDNA Sequences  
       [0144] The cDNA sequences are analyzed using a variety of programs and algorithms which are well known in the art. (See, e.g., Ausubel, 1997, supra, Chapter 7.7; Meyers, R. A. (Ed.) (1995)  Molecular Biology and Biotechnology , Wiley VCH, New York N.Y., pp. 856-853; and Table 8.) These analyses comprise both reading frame determinations, e.g., based on triplet codon periodicity for particular organisms (Fickett, J. W. (1982) Nucleic Acids Res. 10:5303-5318); analyses of potential start and stop codons; and homology searches.  
       [0145] Computer programs known to those of skill in the art for performing computer-assisted searches for amino acid and nucleic acid sequence similarity, include, for example, Basic Local Alignment Search Tool (BLAST; Altschul, S. F. (1993) J. Mol. Evol. 36:290-300; Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410). BLAST is especially useful in determining exact matches and comparing two sequence fragments of arbitrary but equal lengths, whose alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user (Karlin, S. et al. (1988) Proc. Natl. Acad. Sci. USA 85:841-845). Using an appropriate search tool (e.g., BLAST or HMM), GenBank, SwissProt, BLOCKS, PFAM and other databases may be searched for sequences containing regions of homology to a query mddt or MDDT of the present invention.  
       [0146] Other approaches to the identification, assembly, storage, and display of nucleotide and polypeptide sequences are provided in “Relational Database for Storing Biomolecule Information,” U.S. Ser. No. 08/947,845, filed Oct. 9, 1997; “Project-Based Full-Length Biomolecular Sequence Database,” U.S. Pat. No. 5,953,727, and “Relational Database and System for Storing Information Relating to Biomolecular Sequences,“U.S. Ser. No. 09/034,807, filed Mar. 4, 1998, all of which are incorporated by reference herein in their entirety.  
       [0147] Protein hierarchies can be assigned to the putative encoded polypeptide based on, e.g., motif, BLAST, or biological analysis. Methods for assigning these hierarchies are described, for example, in “Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data,” U.S. Pat. No. 6,023,659, incorporated herein by reference.  
       [0148] Human Disease Detection and Treatment Molecule Sequences  
       [0149] The mddt of the present invention may be used for a variety of diagnostic and therapeutic purposes. For example, an mddt may be used to diagnose a particular condition, disease, or disorder associated with disease detection and treatment molecules. Such conditions, diseases, and disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, a cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder, such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison&#39;s disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn&#39;s disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture&#39;s syndrome, gout, Graves&#39; disease, Hashimoto&#39;s thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter&#39;s syndrome, rheumatoid arthritis, scleroderma, Sjögren&#39;s syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, trauma, and hematopoietic cancer including lymphoma, leukemia, and myeloma. The mddt can be used to detect the presence of, or to quantify the amount of, an mddt-related polynucleotide in a sample. This information is then compared to information obtained from appropriate reference samples, and a diagnosis is established. Alternatively, a polynucleotide complementary to a given mddt can inhibit or inactivate a therapeutically relevant gene related to the mddt.  
       [0150] Analysis of mddt Expression Patterns  
       [0151] The expression of mddt may be routinely assessed by hybridization-based methods to determine, for example, the tissue-specificity, disease-specificity, or developmental stage-specificity of mddt expression. For example, the level of expression of mddt may be compared among different cell types or tissues, among diseased and normal cell types or tissues, among cell types or tissues at different developmental stages, or among cell types or tissues undergoing various treatments. This type of analysis is useful, for example, to assess the relative levels of mddt expression in fully or partially differentiated cells or tissues, to determine if changes in mddt expression levels are correlated with the development or progression of specific disease states, and to assess the response of a cell or tissue to a specific therapy, for example, in pharmacological or toxicological studies. Methods for the analysis of mddt expression are based on hybridization and amplification technologies and include membrane-based procedures such as northern blot analysis, high-throughput procedures that utilize, for example, microarrays, and PCR-based procedures.  
       [0152] Hybridization and Genetic Analysis  
       [0153] The mddt, their fragments, or complementary sequences, may be used to identify the presence of and/or to determine the degree of similarity between two (or more) nucleic acid sequences. The mddt may be hybridized to naturally occurring or recombinant nucleic acid sequences under appropriately selected temperatures and salt concentrations. Hybridization with a probe based on the nucleic acid sequence of at least one of the mddt allows for the detection of nucleic acid sequences, including genomic sequences, which are identical or related to the mddt of the Sequence Listing. Probes may be selected from non-conserved or unique regions of at least one of the polynucleotides of SEQ ID NO: 1-36 and tested for their ability to identify or amplify the target nucleic acid sequence using standard protocols.  
       [0154] Polynucleotide sequences that are capable of hybridizing, in particular, to those shown in SEQ ID NO: 1-36 and fragments thereof, can be identified using various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399-407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions are discussed in “Definitions.” 
       [0155] A probe for use in Southern or northern hybridization may be derived from a fragment of an mddt sequence, or its complement, that is up to several hundred nucleotides in length and is either single-stranded or double-stranded. Such probes may be hybridized in solution to biological materials such as plasmids, bacterial, yeast, or human artificial chromosomes, cleared or sectioned tissues, or to artificial substrates containing mddt. Microarrays are particularly suitable for identifying the presence of and detecting the level of expression for multiple genes of interest by examining gene expression correlated with, e.g., various stages of development, treatment with a drug or compound, or disease progression. An array analogous to a dot or slot blot may be used to arrange and link polynucleotides to the surface of a substrate using one or more of the following: mechanical (vacuum), chemical, thermal, or UV bonding procedures. Such an array may contain any number of mddt and may be produced by hand or by using available devices, materials, and machines.  
       [0156] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)  
       [0157] Probes may be labeled by either PCR or enzymatic techniques using a variety of commercially available reporter molecules. For example, commercial kits are available for radioactive and chemiluminescent labeling (Amersham Pharmacia Biotech) and for alkaline phosphatase labeling (Life Technologies). Alternatively, mddt may be cloned into commercially available vectors for the production of RNA probes. Such probes may be transcribed in the presence of at least one labeled nucleotide (e.g.,  32 P-ATP, Amersham Pharmacia Biotech).  
       [0158] Additionally the polynucleotides of SEQ ID NO: 1-36 or suitable fragments thereof can be used to isolate full length cDNA sequences utilizing hybridization and/or amplification procedures well known in the art, e.g., cDNA library screening, PCR amplification, etc. The molecular cloning of such full length cDNA sequences may employ the method of cDNA library screening with probes using the hybridization, stringency, washing, and probing strategies described above and in Ausubel, supra, Chapters 3, 5, and 6. These procedures may also be employed with genomic libraries to isolate genomic sequences of mddt in order to analyze, e.g., regulatory elements.  
       [0159] Genetic Mapping  
       [0160] Gene identification and mapping are important in the investigation and treatment of almost all conditions, diseases, and disorders. Cancer, cardiovascular disease, Alzheimer&#39;s disease, arthritis, diabetes, and mental illnesses are of particular interest. Each of these conditions is more complex than the single gene defects of sickle cell anemia or cystic fibrosis, with select groups of genes being predictive of predisposition for a particular condition, disease, or disorder. For example, cardiovascular disease may result from malfunctioning receptor molecules that fail to clear cholesterol from the bloodstream, and diabetes may result when a particular individual&#39;s immune system is activated by an infection and attacks the insulin-producing cells of the pancreas. In some studies, Alzheimer&#39;s disease has been linked to a gene on chromosome 21; other studies predict a different gene and location. Mapping of disease genes is a complex and reiterative process and generally proceeds from genetic linkage analysis to physical mapping.  
       [0161] As a condition is noted among members of a family, a genetic linkage map traces parts of chromosomes that are inherited in the same pattern as the condition. Statistics link the inheritance of particular conditions to particular regions of chromosomes, as defined by RFLP or other markers. (See, for example, Lander, E. S. and Botstein, D. (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Occasionally, genetic markers and their locations are known from previous studies. More often, however, the markers are simply stretches of DNA that differ among individuals. Examples of genetic linkage maps can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site.  
       [0162] In another embodiment of the invention, mddt sequences may be used to generate hybridization probes useful in chromosomal mapping of naturally occurring genomic sequences. Either coding or noncoding sequences of mddt may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of an mddt coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.)  
       [0163] Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Meyers, supra, pp. 965-968.) Correlation between the location of mddt on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The mddt sequences may also be used to detect polymorphisms that are genetically linked to the inheritance of a particular condition, disease, or disorder.  
       [0164] In situ hybridization of chromosomal preparations and genetic mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending existing genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of the corresponding human chromosome is not known. These new marker sequences can be mapped to human chromosomes and may provide valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome has been crudely correlated by genetic linkage with a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequences of the subject invention may also be used to detect differences in chromosomal architecture due to translocation, inversion, etc., among normal, carrier, or affected individuals.  
       [0165] Once a disease-associated gene is mapped to a chromosomal region, the gene must be cloned in order to identify mutations or other alterations (e.g., translocations or inversions) that may be correlated with disease. This process requires a physical map of the chromosomal region containing the disease-gene of interest along with associated markers. A physical map is necessary for determining the nucleotide sequence of and order of marker genes on a particular chromosomal region. Physical mapping techniques are well known in the art and require the generation of overlapping sets of cloned DNA fragments from a particular organelle, chromosome, or genome. These clones are analyzed to reconstruct and catalog their order. Once the position of a marker is determined, the DNA from that region is obtained by consulting the catalog and selecting clones from that region. The gene of interest is located through positional cloning techniques using hybridization or similar methods.  
       [0166] Diagnostic Uses  
       [0167] The mddt of the present invention may be used to design probes useful in diagnostic assays. Such assays, well known to those skilled in the art, may be used to detect or confirm conditions, disorders, or diseases associated with abnormal levels of mddt expression. Labeled probes developed from mddt sequences are added to a sample under hybridizing conditions of desired stringency. In some instances, mddt, or fragments or oligonucleotides derived from mddt, may be used as primers in amplification steps prior to hybridization. The amount of hybridization complex formed is quantified and compared with standards for that cell or tissue. If mddt expression varies significantly from the standard, the assay indicates the presence of the condition, disorder, or disease. Qualitative or quantitative diagnostic methods may include northern, dot blot, or other membrane or dip-stick based technologies or multiple-sample format technologies such as PCR, enzyme-linked immunosorbent assay (ELISA)-like, pin, or chip-based assays.  
       [0168] The probes described above may also be used to monitor the progress of conditions, disorders, or diseases associated with abnormal levels of mddt expression, or to evaluate the efficacy of a particular therapeutic treatment. The candidate probe may be identified from the mddt that are specific to a given human tissue and have not been observed in GenBank or other genome databases. Such a probe may be used in animal studies, preclinical tests, clinical trials, or in monitoring the treatment of an individual patient. In a typical process, standard expression is established by methods well known in the art for use as a basis of comparison, samples from patients affected by the disorder or disease are combined with the probe to evaluate any deviation from the standard profile, and a therapeutic agent is administered and effects are monitored to generate a treatment profile. Efficacy is evaluated by determining whether the expression progresses toward or returns to the standard normal pattern. Treatment profiles may be generated over a period of several days or several months. Statistical methods well known to those skilled in the art may be use to determine the significance of such therapeutic agents.  
       [0169] The polynucleotides are also useful for identifying individuals from minute biological samples, for example, by matching the RFLP pattern of a sample&#39;s DNA to that of an individual&#39;s DNA. The polynucleotides of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual&#39;s genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, an individual can be identified through a unique set of DNA sequences. Once a unique ID database is established for an individual, positive identification of that individual can be made from extremely small tissue samples.  
       [0170] In a particular aspect, oligonucleotide primers derived from the mddt of the invention may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from mddt are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequences of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).  
       [0171] DNA-based identification techniques are critical in forensic technology. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using, e.g., PCR, to identify individuals. (See, e.g., Erlich, H. (1992)  PCR Technology , Freeman and Co., New York, N.Y.). Similarly, polynucleotides of the present invention can be used as polymorphic markers.  
       [0172] There is also a need for reagents capable of identifying the source of a particular tissue. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention that are specific for particular tissues. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.  
       [0173] The polynucleotides of the present invention can also be used as molecular weight markers on nucleic acid gels or Southern blots, as diagnostic probes for the presence of a specific mRNA in a particular cell type, in the creation of subtracted cDNA libraries which aid in the discovery of novel polynucleotides, in selection and synthesis of oligomers for attachment to an array or other support, and as an antigen to elicit an immune response.  
       [0174] Disease Model Systems Using mddt  
       [0175] The mddt of the invention or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.  
       [0176] The mddt of the invention may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).  
       [0177] The mddt of the invention can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of mddt is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress mddt, resulting, e.g., in the secretion of MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).  
       [0178] Screening Assays  
       [0179] MDDT encoded by polynucleotides of the present invention may be used to screen for molecules that bind to or are bound by the encoded polypeptides. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the bound molecule. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.  
       [0180] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a ligand or fragment thereof, a natural substrate, or a structural or functional mimetic. (See, Coligan et al., (1991)  Current Protocols in Immunology  1(2): Chapter 5.) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or to at least a fragment of the receptor, e.g., the active site. In either case, the molecule can be rationally designed using known techniques. Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or  E coli . Cells expressing the polypeptide or cell membrane fractions which contain the expressed polypeptide are then contacted with a test compound and binding, stimulation, or inhibition of activity of either the polypeptide or the molecule is analyzed.  
       [0181] An assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. Alternatively, the assay may assess binding in the presence of a labeled competitor.  
       [0182] Additionally, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.  
       [0183] Preferably, an ELISA assay using, e.g., a monoclonal or polyclonal antibody, can measure polypeptide level in a sample. The antibody can measure polypeptide level by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.  
       [0184] All of the above assays can be used in a diagnostic or prognostic context. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.  
       [0185] Transcript Imaging and Toxicological Testing  
       [0186] Another embodiment relates to the use of mddt to develop a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity pertaining to disease detection and treatment molecules.  
       [0187] Transcript images which profile mddt expression may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect mddt expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.  
       [0188] Transcript images which profile mddt expression may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and Anderson, N. L. (2000) Toxicol. Lett. 112-113:467-71, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.  
       [0189] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.  
       [0190] Another particular embodiment relates to the use of MDDT encoded by polynucleotides of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell&#39;s proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra. The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.  
       [0191] A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-11; Mendoze, L. G. et al. (1999) Biotechniques 27:778-88). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.  
       [0192] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and Seilhamer, J. (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.  
       [0193] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the MDDT encoded by polynucleotides of the present invention.  
       [0194] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the MDDT encoded by polynucleotides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.  
       [0195] Transcript images may be used to profile mddt expression in distinct tissue types. This process can be used to determine disease detection and treatment molecule activity in a particular tissue type relative to this activity in a different tissue type. Transcript images may be used to generate a profile of mddt expression characteristic of diseased tissue. Transcript images of tissues before and after treatment may be used for diagnostic purposes, to monitor the progression of disease, and to monitor the efficacy of drug treatments for diseases which affect the activity of disease detection and treatment molecules.  
       [0196] Transcript images of cell lines can be used to assess disease detection and treatment molecule activity and/or to identify cell lines that lack or misregulate this activity. Such cell lines may then be treated with pharmaceutical agents, and a transcript image following treatment may indicate the efficacy of these agents in restoring desired levels of this activity. A similar approach may be used to assess the toxicity of pharmaceutical agents as reflected by undesirable changes in disease detection and treatment molecule activity. Candidate pharmaceutical agents may be evaluated by comparing their associated transcript images with those of pharmaceutical agents of known effectiveness.  
       [0197] Antisense Molecules  
       [0198] The polynucleotides of the present invention are useful in antisense technology. Antisense technology or therapy relies on the modulation of expression of a target protein through the specific binding of an antisense sequence to a target sequence encoding the target protein or directing its expression. (See, e.g., Agrawal, S., ed. (1996)  Antisense Therapeutics , Humana Press Inc., Totawa N.J.; Alama, A. et al. (1997) Pharmacol. Res. 36(3):171-178; Crooke, S. T. (1997) Adv. Pharmacol. 40:149; Sharma, H. W. and R. Narayanan (1995) Bioessays 17(12):1055-1063; and Lavrosky, Y. et al. (1997) Biochem. Mol. Med. 62(1):11-22.) An antisense sequence is a polynucleotide sequence capable of specifically hybridizing to at least a portion of the target sequence. Antisense sequences bind to cellular mRNA and/or genomic DNA, affecting translation and/or transcription. Antisense sequences can be DNA, RNA, or nucleic acid mimics and analogs. (See, e.g., Rossi, J. J. et al. (1991) Antisense Res. Dev. 1(3):285-288; Lee, R. et al. (1998) Biochemistry 37(3):900-1010; Pardridge, W. M. et al. (1995) Proc. Natl. Acad. Sci. USA 92(12):5592-5596; and Nielsen, P. E. and Haaima, G. (1997) Chem. Soc. Rev. 96:73-78.) Typically, the binding which results in modulation of expression occurs through hybridization or binding of complementary base pairs. Antisense sequences can also bind to DNA duplexes through specific interactions in the major groove of the double helix.  
       [0199] The polynucleotides of the present invention and fragments thereof can be used as antisense sequences to modify the expression of the polypeptide encoded by mddt. The antisense sequences can be produced ex vivo, such as by using any of the ABI nucleic acid synthesizer series (Applied Biosystems) or other automated systems known in the art. Antisense sequences can also be produced biologically, such as by transforming an appropriate host cell with an expression vector containing the sequence of interest. (See, e.g., Agrawal, supra.)  
       [0200] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E., et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K. J., et al. (1995) 9(13):1288-1296.). Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, F. M. et al. (1995)  Current Protocols in Molecular Biology , John Wiley &amp; Sons, New York N.Y.; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)  
       [0201] Expression  
       [0202] In order to express a biologically active MDDT, the nucleotide sequences encoding MDDT or fragments thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, supra, Chapters 4, 8, 16, and 17; and Ausubel, supra, Chapters 9, 10, 13, and 16.)  
       [0203] A variety of expression vector/host systems may be utilized to contain and express sequences encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal (mammalian) cell systems. (See, e.g., Sambrook, supra; Ausubel, 1995, supra, Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C. A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105;  The McGraw Hill Yearbook of Science and Technology  (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al., (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.  
       [0204] For long term production of recombinant proteins in mammalian systems, stable expression of MDDT in cell lines is preferred. For example, sequences encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Any number of selection systems may be used to recover transformed cell lines. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.; Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14; Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051; Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)  
       [0205] Therapeutic Uses of mddt  
       [0206] The mddt of the invention may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404-410; Verma, I. M. and Somia, N. (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as  Candida albicans  and  Paracoccidioides brasiliensis ; and protozoan parasites such as  Plasmodium falciparum  and  Trypanosoma cruzi ). In the case where a genetic deficiency in mddt expression or regulation causes disease, the expression of mddt from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.  
       [0207] In a further embodiment of the invention, diseases or disorders caused by deficiencies in mddt are treated by constructing mammalian expression vectors comprising mddt and introducing these vectors by mechanical means into mddt-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and Anderson, W. F. (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J -L. and Récipon, H. (1998) Curr. Opin. Biotechnol. 9:445-450).  
       [0208] Expression vectors that may be effective for the expression of mddt include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). The mddt of the invention may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and Bujard, H. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al., (1995) Science 268:1766-1769; Rossi, F. M. V. and Blau, H. M. (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and Blau, H. M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual.  
       [0209] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and Eb, A. J. (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.  
       [0210] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to mddt expression are treated by constructing a retrovirus vector consisting of (i) mddt under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. U.S.A. 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and Miller, A. D. (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4 +  T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. U.S.A. 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).  
       [0211] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver mddt to cells which have one or more genetic abnormalities with respect to the expression of mddt. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I. M. and Somia, N. (1997) Nature 18:389:239-242, both incorporated by reference herein.  
       [0212] In another alternative, a herpes-based, gene therapy delivery system is used to deliver mddt to target cells which have one or more genetic abnormalities with respect to the expression of mddt. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing mddt to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. 1999 J. Virol. 73:519-532 and Xu, H. et al., (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.  
       [0213] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver mddt to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and Li, K -J. (1998) Curr. Opin. Biotech. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting mddt into the alphavirus genome in place of the capsid-coding region results in the production of a large number of mddt RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of mddt into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.  
       [0214] Antibodies  
       [0215] Anti-MDDT antibodies may be used to analyze protein expression levels. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, and Fab fragments. For descriptions of and protocols of antibody technologies, see, e.g., Pound J. D. (1998)  Immunochemical Protocols , Humana Press, Totowa, N.J.  
       [0216] The amino acid sequence encoded by the mddt of the Sequence Listing may be analyzed by appropriate software (e.g., LASERGENE NAVIGATOR software, DNASTAR) to determine regions of high immunogenicity. The optimal sequences for immunization are selected from the C-terminus, the N-terminus, and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the polypeptide is in its natural conformation. Analysis used to select appropriate epitopes is also described by Ausubel (1997, supra, Chapter 11.7). Peptides used for antibody induction do not need to have biological activity; however, they must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, and most preferably at least 15 amino acids. A peptide which mimics an antigenic fragment of the natural polypeptide may be fused with another protein such as keyhole hemolimpet cyanin (KLH; Sigma, St. Louis Mo.) for antibody production. A peptide encompassing an antigenic region may be expressed from an mddt, synthesized as described above, or purified from human cells.  
       [0217] Procedures well known in the art may be used for the production of antibodies. Various hosts including mice, goats, and rabbits, may be immunized by injection with a peptide. Depending on the host species, various adjuvants may be used to increase immunological response.  
       [0218] In one procedure, peptides about 15 residues in length may be synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (Ausubel, 1995, supra). Rabbits are immunized with the peptide-KLH complex in complete Freund&#39;s adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin (BSA), reacting with rabbit antisera, washing, and reacting with radioiodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, radioimmunoassay (RIA), and immunoblotting.  
       [0219] In another procedure, isolated and purified peptide may be used to immunize mice (about 100 μg of peptide) or rabbits (about 1 mg of peptide). Subsequently, the peptide is radioiodinated and used to screen the immunized animals&#39; B-lymphocytes for production of antipeptide antibodies. Positive cells are then used to produce hybridomas using standard techniques. About 20 mg of peptide is sufficient for labeling and screening several thousand clones. Hybridomas of interest are detected by screening with radioiodinated peptide to identify those fusions producing peptide-specific monoclonal antibody. In a typical protocol, wells of a multi-well plate (FAST, Becton-Dickinson, Palo Alto, Calif.) are coated with affinity-purified, specific rabbit-anti-mouse (or suitable anti-species IgG) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA and washed and exposed to supernatants from hybridomas. After incubation, the wells are exposed to radiolabeled peptide at 1 mg/ml.  
       [0220] Clones producing antibodies bind a quantity of labeled peptide that is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from the ascitic fluid by affinity chromatography on protein A (Amersham Pharmacia Biotech). Several procedures for the production of monoclonal antibodies, including in vitro production, are described in Pound (supra). Monoclonal antibodies with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.  
       [0221] Antibody fragments containing specific binding sites for an epitope may also be generated. For example, such fragments include, but are not limited to, the F(ab′)2 fragments produced by pepsin digestion of the antibody molecule, and the Fab fragments generated by reducing the disulfide bridges of the F(ab′)2 fragments. Alternatively, construction of Fab expression libraries in filamentous bacteriophage allows rapid and easy identification of monoclonal fragments with desired specificity (Pound, supra, Chaps. 45-47). Antibodies generated against polypeptide encoded by mddt can be used to purify and characterize full-length MDDT protein and its activity, binding partners, etc.  
       [0222] Assays Using Antibodies  
       [0223] Anti-MDDT antibodies may be used in assays to quantify the amount of MDDT found in a particular human cell. Such assays include methods utilizing the antibody and a label to detect expression level under normal or disease conditions. The peptides and antibodies of the invention may be used with or without modification or labeled by joining them, either covalently or noncovalently, with a reporter molecule.  
       [0224] Protocols for detecting and measuring protein expression using either polyclonal or monoclonal antibodies are well known in the art. Examples include ELISA, RIA, and fluorescent activated cell sorting (FACS). Such immunoassays typically involve the formation of complexes between the MDDT and its specific antibody and the measurement of such complexes. These and other assays are described in Pound (supra).  
       [0225] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.  
       [0226] The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No.60/261,865, U.S. Ser. No.60/263,065, U.S. Ser. No.60/263,329, U.S. Ser. No. 60/262,209, U.S. Ser. No. 60/262,208, U.S. Ser. No. 60/262,326, U.S. Ser. No. 60/263,063, and U.S. Ser. No. 60/261,622 are hereby expressly incorporated by reference. 
     
    
    
     EXAMPLES  
     [0227] I. Construction of cDNA Libraries  
     [0228] RNA was purchased from CLONTECH Laboratories, Inc. (Palo Alto Calif.) or isolated from various tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated with either isopropanol or sodium acetate and ethanol, or by other routine methods.  
     [0229] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In most cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega Corporation (Promega), Madison Wis.), OLIGOTEX latex particles (QIAGEN, Inc. (QIAGEN), Valencia Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Inc., Austin Tex.).  
     [0230] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene Cloning Systems, Inc. (Stratagene), La Jolla Calif.) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, Chapters 5.1 through 6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent  E. coli  cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.  
     [0231] H. Isolation f cDNA Clones  
     [0232] Plasmids were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: the Magic or WIZARD Minipreps DNA purification system (Promega); the AGTC Miniprep purification kit (Edge BioSystems, Gaithersburg Md.); and the QIAWELL 8, QIAWELL 8 Plus, and QIAWELL 8 Ultra plasmid purification systems or the R.E.A.L; PREP 96 plasmid purification kit (QIAGEN). Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.  
     [0233] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format. (Rao, V. B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Inc. (Molecular Probes), Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).  
     [0234] III. Sequencing and Analysis  
     [0235] cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 thermal cycler (Applied Biosystems) or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific Corp., Sunnyvale Calif.) or the MICROLAB 2200 liquid transfer system (Hamilton). cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, Chapter 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII  
     [0236] IV. Assembly and Analysis of Sequences  
     [0237] Component sequences from chromatograms were subject to PHRED analysis and assigned a quality score. The sequences having at least a required quality score were subject to various pre-processing editing pathways to eliminate, e.g., low quality 3′ ends, vector and linker sequences, polyA tails, Alu repeats, mitochondrial and ribosomal sequences, bacterial contamination sequences, and sequences smaller than 50 base pairs. In particular, low-information sequences and repetitive elements (e.g., dinucleotide repeats, Alu repeats, etc.) were replaced by “n&#39;s”, or masked, to prevent spurious matches.  
     [0238] Processed sequences were then subject to assembly procedures in which the sequences were assigned to gene bins (bins). Each sequence could only belong to one bin. Sequences in each gene bin were assembled to produce consensus sequences (templates). Subsequent new sequences were added to existing bins using BLASTN (v.1.4 WashU) and CROSSMATCH. Candidate pairs were identified as all BLAST hits having a quality score greater than or equal to 150. Alignments of at least 82% local identity were accepted into the bin. The component sequences from each bin were assembled using a version of PHRAP. Bins with several overlapping component sequences were assembled using DEEP PHRAP. The orientation (sense or antisense) of each assembled template was determined based on the number and orientation of its component sequences. Template sequences as disclosed in the sequence listing correspond to sense strand sequences (the “forward” reading frames), to the best determination. The complementary (antisense) strands are inherently disclosed herein. The component sequences which were used to assemble each template consensus sequence are listed in Table 5, along with their positions along the template nucleotide sequences.  
     [0239] Bins were compared against each other and those having local similarity of at least 82% were combined and reassembled. Reassembled bins having templates of insufficient overlap (less than 95% local identity) were re-split. Assembled templates were also subject to analysis by STITCHER/EXON MAPPER algorithms which analyze the probabilities of the presence of splice variants, alternatively spliced exons, splice junctions, differential expression of alternative spliced genes across tissue types or disease states, etc. These resulting bins were subject to several rounds of the above assembly procedures.  
     [0240] Once gene bins were generated based upon sequence alignments, bins were clone joined based upon clone information. If the 5′ sequence of one clone was present in one bin and the 3′ sequence from the same clone was present in a different bin, it was likely that the two bins actually belonged together in a single bin. The resulting combined bins underwent assembly procedures to regenerate the consensus sequences.  
     [0241] The final assembled templates were subsequently annotated using the following procedure. Template sequences were analyzed using BLASTN (v2.0, NCBI) versus gbpri (GenBank version 126). “Hits” were defined as an exact match having from 95% local identity over 200 base pairs through 100% local identity over 100 base pairs, or a homolog match having an E-value, i.e. a probability score, of ≦1×10 −8 . The hits were subject to frameshift FASTx versus GENPEPT (GenBank version 126). (See Table 8). In this analysis, a homolog match was defined as having an E-value of ≦1×10 −8 . The assembly method used above was described in “System and Methods for Analyzing Biomolecular Sequences,” U.S. Ser. No. 09/276,534, filed Mar. 25, 1999, and the LIFESEQ Gold user manual (Incyte) both incorporated by reference herein.  
     [0242] Following assembly, template sequences were subjected to motif, BLAST, and functional analyses, and categorized in protein hierarchies using methods described in, e.g., “Database System Employing Protein Function Hierarchies for Viewing Biomolecular Sequence Data,” U.S. Pat. No. 6,023,659; “Relational Database for Storing Biomolecule Information,” U.S. Ser. No. 08/947,845, filed Oct. 9, 1997; “Project-Based Full-Length Biomolecular Sequence Database,” U.S. Pat. No. 5,953,727; and “Relational Database and System for Storing Information Relating to Biomolecular Sequences,” U.S. Ser. No. 09/034,807, filed Mar. 4, 1998, all of which are incorporated by reference herein.  
     [0243] The template sequences were further analyzed by translating each template in all three forward reading frames and searching each translation against the Pfam database of hidden Markov model-based protein families and domains using the HMMER software package (available to the public from Washington University School of Medicine, St. Louis Mo.). Regions of templates which, when translated, contain similarity to Pfam consensus sequences are reported in Table 3, along with descriptions of Pfam protein domains and families. Only those Pfam hits with an E-value of ≦1×10 31 3  are reported. (See also World Wide Web site http://pfam.wustl.edu/for detailed descriptions of Pfam protein domains and families.)  
     [0244] Additionally, the template sequences were translated in all three forward reading frames, and each translation was searched against hidden Markov models for signal peptides using the HMMER software package. Construction of hidden Markov models and their usage in sequence analysis has been described. (See, for example, Eddy, S. R. (1996) Curr. Opin. Str. Biol. 6:361-365.) Only those signal peptide hits with a cutoff score of 11 bits or greater are reported. A cutoff score of 11 bits or greater corresponds to at least about 91-94% true-positives in signal peptide prediction. Template sequences were also translated in all three forward reading frames, and each translation was searched against TMHMMER, a program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation (Sonnhammer, E. L. et al. (1998) Proc. Sixth Intl. Conf. On Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence (AAAI) Press, Menlo Park, Calif., and MIT Press, Cambridge, Mass., pp. 175-182.) Regions of templates which, when translated, contain similarity to signal peptide or transmembrane consensus sequences are reported in Table 4.  
     [0245] The results of HMMER analysis as reported in Tables 3 and 4 may support the results of BLAST analysis as reported in Table 2 or may suggest alternative or additional properties of template-encoded polypeptides not previously uncovered by BLAST or other analyses.  
     [0246] Template sequences are further analyzed using the bioinformatics tools listed in Table 8, or using sequence analysis software known in the art such as MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Template sequences may be further queried against public databases such as the GenBank rodent, mammalian, vertebrate, prokaryote, and eukaryote databases.  
     [0247] The template sequences were translated to derive the corresponding longest open reading frame as presented by the polypeptide sequences as reported in Table 7. Alternatively, a polypeptide of the invention may begin at any of the methionine residues within the full length translated polypeptide. Polypeptide sequences were subsequently analyzed by querying against the GenBank protein database (GENPEPT, (GenBank version 126)). Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.  
     [0248] Table 7 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (GENPEPT) database. Column 1 shows the polypeptide sequence identification number (SEQ ID NO:) for the polypeptide segments of the invention. Column 2 shows the reading frame used in the translation of the polynucleotide sequences encoding the polypeptide segments. Column 3 shows the length of the translated polypeptide segments. Columns 4 and 5 show the start and stop nucleotide positions of the polynucleotide sequences encoding the polypeptide segments. Column 6 shows the GenBank identification number (GI Number) of the nearest GenBank homolog. Column 7 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 8 shows the annotation of the GenBank homolog.  
     [0249] V. Analysis of Polynucleotide Expression  
     [0250] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)  
     [0251] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:  
           BLAST Score     ×     Percent  Identity         5   ×     minimum          {     length(Seq.  1),  length(Seq.  2)     }                     
 
     [0252] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and −4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.  
     [0253] VI. Tissue Distribution Profiling  
     [0254] A tissue distribution profile is determined for each template by compiling the cDNA library tissue classifications of its component cDNA sequences. Each component sequence, is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. Template sequences, component sequences, and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).  
     [0255] Table 6 shows the tissue distribution profile for the templates of the invention. For each template, the three most frequently observed tissue categories are shown in column 3, along with the percentage of component sequences belonging to each category. Only tissue categories with percentage values of ≧10% are shown. A tissue distribution of “widely distributed” in column 3 indicates percentage values of &lt;10% in all tissue categories.  
     [0256] VII. Transcript Image Analysis  
     [0257] Transcript images are generated as described in Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, incorporated herein by reference.  
     [0258] VIII. Extension of Polynucleotide Sequences and Is Lation f a Full-Length cDNA  
     [0259] Oligonucleotide primers designed using an mddt of the Sequence Listing are used to extend the nucleic acid sequence. One primer is synthesized to initiate 5′ extension of the template, and the other primer, to initiate 3′ extension of the template. The initial primers may be designed using OLIGO 4.06 software (National Biosciences, Inc. (National Biosciences), Plymouth Minn.), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations are avoided. Selected human cDNA libraries are used to extend the sequence. If more than one extension is necessary or desired, additional or nested sets of primers are designed.  
     [0260] High fidelity amplification is obtained by PCR using methods well known in the art. PCR is performed in 96-well plates using the PTC-200 thermal cycler (MJ Research). The reaction mix contains DNA template, 200 nmol of each primer, reaction buffer containing Mg 2+ , (NH 4 ) 2 SO 4 , and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C. 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ are as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.  
     [0261] The concentration of DNA in each well is determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v); Molecular Probes) dissolved in 1X Tris-EDTA (TE) and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Incorporated (Corning), Corning N.Y.), allowing the DNA to bind to the reagent. The plate is scanned in a FLUOROSKAN II (Labsystems Oy) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture is analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions are successful in extending the sequence.  
     [0262] The extended nucleotides are desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides are separated on low concentration (0.6 to 0.8%) agarose gels, fragments are excised, and agar digested with AGAR ACE (Promega). Extended clones are religated using T4 ligase (New England Biolabs, Inc., Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent  E. coli  cells. Transformed cells are selected on antibiotic-containing media, individual colonies are picked and cultured overnight at 37° C. in 384-well plates in LB/2× carbenicillin liquid media.  
     [0263] The cells are lysed, and DNA is amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: Step 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA is quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries are reamplified using the same conditions as described above. Samples are diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).  
     [0264] In like manner, the mddt is used to obtain regulatory sequences (promoters, introns, and enhancers) using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.  
     [0265] IX. Labeling of Probes and Southern Hybridization Analyses  
     [0266] Hybridization probes derived from the mddt of the Sequence Listing are employed for screening cDNAs, mRNAs, or genomic DNA. The labeling of probe nucleotides between 100 and 1000 nucleotides in length is specifically described, but essentially the same procedure may be used with larger cDNA fragments. Probe sequences are labeled at room temperature for 30 minutes using a T4 polynucleotide kinase, γ 32 P-ATP, and 0.5× One-Phor-All Plus (Amersham Pharmacia Biotech) buffer and purified using a ProbeQuant G-50 Microcolumn (Amersham Pharmacia Biotech). The probe mixture is diluted to 10 7  dpm/μg/ml hybridization buffer and used in a typical membrane-based hybridization analysis.  
     [0267] The DNA is digested with a restriction endonuclease such as Eco RV and is electrophoresed through a 0.7% agarose gel. The DNA fragments are transferred from the agarose to nylon membrane (NYTRAN Plus, Schleicher &amp; Schuell, Inc., Keene N.H.) using procedures specified by the manufacturer of the membrane. Prehybridization is carried out for three or more hours at 68° C., and hybridization is carried out overnight at 68° C. To remove non-specific signals, blots are sequentially washed at room temperature under increasingly stringent conditions, up to 0.1× saline sodium citrate (SSC) and 0.5% sodium dodecyl sulfate. After the blots are placed in a PHOSPHORIMAGER cassette (Molecular Dynamics) or are exposed to autoradiography film, hybridization patterns of standard and experimental lanes are compared. Essentially the same procedure is employed when screening RNA.  
     [0268] X. Chromosome Mapping of mddt  
     [0269] The cDNA sequences which were used to assemble SEQ ID NO: 1-36 are compared with sequences from the Incyte LIEESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that match SEQ ID NO: 1-36 are assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as PHRAP (Table 8). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon are used to determine if any of the clustered sequences have been previously mapped. Inclusion of a mapped sequence in a cluster will result in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location. The genetic map locations of SEQ ID NO: 1-36 are described as ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome&#39;s p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters.  
     [0270] XI. Microarray Analysis  
     [0271] Probe Preparation from Tissue or Cell Samples  
     [0272] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and polyA +  RNA is purified using the oligo (dT) cellulose method. Each polyA +  RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-dT primer (21mer), 1× first strand buffer, 0.03 units/μI RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng polyA +  RNA with GEMBRIGHT kits (Incyte). Specific control polyA +  RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA (W. Lei, unpublished). As quantitative controls, the control mRNAs at 0.002 ng, 0.02 ng, 0.2 ng, and 2 ng are diluted into reverse transcription reaction at ratios of 1:100,000, 1:10,000, 1:1000, 1:100 (w/w) to sample mRNA respectively. The control mRNAs are diluted into reverse transcription reaction at ratios of 1:3, 3:1, 1:10, 10:1, 1:25, 25:1 (w/w) to sample mRNA differential expression patterns. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Probes are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The probe is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.  
     [0273] Microarray Preparation  
     [0274] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).  
     [0275] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester, Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.  
     [0276] Array elements are applied to the coated glass substrate using a procedure described in US Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.  
     [0277] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford, Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.  
     [0278] Hybridization  
     [0279] Hybridization reactions contain 9 μl of probe mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridization buffer. The probe mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm 2  coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.  
     [0280] Detection  
     [0281] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.  
     [0282] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.  
     [0283] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the probe mix at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two probes from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.  
     [0284] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood, Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore&#39;s emission spectrum  
     [0285] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).  
     [0286] XII. Complementary Nucleic Acids  
     [0287] Sequences complementary to the mddt are used to detect, decrease, or inhibit expression of the naturally occurring nucleotide. The use of oligonucleotides comprising from about 15 to 30 base pairs is typical in the art. However, smaller or larger sequence fragments can also be used. Appropriate oligonucleotides are designed from the mddt using OLIGO 4.06 software (National Biosciences) or other appropriate programs and are synthesized using methods standard in the art or ordered from a commercial supplier. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent transcription factor binding to the promoter sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding and processing of the transcript.  
     [0288] XIII. Expression of MDDT  
     [0289] Expression and purification of MDDT is accomplished using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA encoding MDDT is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the typ-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant  Autographica californica  nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect  Spodoptera frugiperda  (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See e.g., Engelhard, supra; and Sandig, supra.)  
     [0290] In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from  Schistosoma japonicum , enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak Company, Rochester N.Y.). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, Chapters 10 and 16). Purified MDDT obtained by these methods can be used directly in the following activity assay.  
     [0291] XIV. Demonstration of MDDT Activity  
     [0292] MDDT, or biologically active fragments thereof, are labeled with  125 I Bolton-Hunter reagent. (See, e.g., Bolton, A. E. and W. M. Hunter (1973) Biochem J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.  
     [0293] Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (CLONTECH).  
     [0294] MDDT may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).  
     [0295] XV. Functional Assays  
     [0296] MDDT function is assessed by expressing mddt at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen Corporation, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected.  
     [0297] Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; CLONTECH), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties.  
     [0298] FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994)  Flow Cytometry , Oxford, New York N.Y.  
     [0299] The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Inc., Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.  
     [0300] XVI. Production of Antibodies  
     [0301] MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.  
     [0302] Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding peptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, Chapter 11.)  
     [0303] Typically, peptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using fmoc-chemistry and coupled to KLH (Sigma) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, supra.) Rabbits are immunized with the peptide-KLH complex in complete Freund&#39;s adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG. Antisera with antipeptide activity are tested for anti-MDDT activity using protocols well known in the art, including ELISA, RIA, and immunoblotting.  
     [0304] XVII. Purification of Naturally Occurring MDDT Using Specific Antibodies  
     [0305] Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer&#39;s instructions.  
     [0306] Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.  
     [0307] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.  
                           TABLE 1                       SEQ ID NO:   Template ID   SEQ ID NO:   ORF ID                                                1   LI:180252.16:2001JAN12   37   LI:180252.16.orf2:2001JAN12       2   LI:1072919.1:2001JAN12   38   LI:1072919.1.orf1:2001JAN12       3   LI:477130.1:2001JAN12   39   LI:477130.1.orf2:2001JAN12       4   LI:351355.1:2001JAN12   40   LI:351355.1.orf1:2001JAN12       5   LI:038285.2:2001JAN12   41   LI:038285.2.orf1:2001JAN12       6   LI:1079031.1:2001JAN12   42   LI:1079031.1.orf1:2001JAN12       7   LI:306216.1:2001JAN12   43   LI:306216.1.orf1:2001JAN12       8   LI:011799.1:2001JAN12   44   LI:011799.1.orf2:2001JAN12       9   LI:109467.1:2001JAN12   45   LI:109467.1.orf1:2001JAN12       10   LI:1175250.1:2001JAN12   46   LI:1175250.1.orf2:2001JAN12       11   LI:2121744.1:2001JAN12   47   LI:2121744.1.orf2:2001JAN12       12   LI:1170908.1:2001JAN12   48   LI:1170908.1.orf3:2001JAN12       13   LI:1173119.1:2001JAN12   49   LI:1173119.1.orf3:2001JAN12       14   LI:1175131.1:2001JAN12   50   LI:1175131.1.orf2:2001JAN12       15   LI:1174107.2:2001JAN12   51   LI:1174107.2.orf3:2001JAN12       16   LI:901832.1:2001JAN12   52   LI:901832.1.orf1:2001JAN12       17   LI:1091903.1:2001JAN12   53   LI:1091903.1.orf2:2001JAN12       18   LI:1089543.2:2001JAN12   54   LI:1089543.2.orf2:2001JAN12       19   LI:2049137.1:2001JAN12   55   LI:2049137.1.orf1:2001JAN12       20   LI:1171755.9:2001JAN12   56   LI:1171755.9.orf3:2001JAN12       21   LI:208529.12:2001JAN12   57   LI:208529.12.orf3:2001JAN12       22   LI:024125.6:2001JAN12   58   LI:024125.6.orf1:2001JAN12       23   LI:235557.12:2001JAN12   59   LI:235557.12.orf2:2001JAN12       24   LI:178860.1:2001JAN12   60   LI:178860.1.orf1:2001JAN12       25   LI:405798.1:2001JAN12   61   LI:405798.1.orf2:2001JAN12       26   LI:1071427.101:2001JAN12   62   LI:1071427.101.orf1:2001JAN12       27   LI:1072276.1:2001JAN12   63   LI:1072276.1.orf1:2001JAN12       28   LI:198296.1:2001JAN12   64   LI:198296.1.orf1:2001JAN12       29   LI:202943.4:2001JAN12   65   LI:202943.4.orf2:2001JAN12       30   LI:2121848.1:2001JAN12   66   LI:2121848.1.orf3:2001JAN12       31   LI:796992.1:2001JAN12   67   LI:796992.1.orf3:2001JAN12       32   LI:1183014.7:2001JAN12   68   LI:1183014.7.orf2:2001JAN12       33   LI:1171219.2:2001JAN12   69   LI:1171219.2.orf3:2001JAN12       34   LI:428428.4:2001JAN12   70   LI:428428.4.orf3:2001JAN12       35   LI:230711.5:2001JAN12   71   LI:230711.5.orf2:2001JAN12       36   LI:199716.6:2001JAN12   72   LI:199716.6.orf2:2001JAN12                  
 
     [0308]                               TABLE 2                       SEQ ID NO:   Template ID   GI Number   Probability Score   Annotation                                                    1   LI:180252.16:2001JAN12   g12060855   9.00E−78   serologically defined breast cancer                       antigen NY-BR-96 ( Homo sapiens )       2   LI:1072919.1:2001JAN12   g929913   2.00E−14   ribosomal protein S8 ( Xenopus laevis )       3   LI:477130.1:2001JAN12   g6650751   8.00E−43   ribosomal protein I (Ceratopteris       4   LI:351355.1:2001JAN12   g14547146   3.00E−13   EGLN1 protein ( Homo sapiens )       5   LI:038285.2:2001JAN12   g14250235   8.00E−17   RIKEN cDNA 4633401C23 gene ( Mus                           musculus )       6   LI:1079031.1:2001JAN12   g5670324   1.00E−100   Gps1 ( Homo sapiens )       7   LI:306216.1:2001JAN12   g12856149   1.00E−51   putative ( Mus musculus )       8   LI:011799.1:2001JAN12   g7022971   1.00E−80   unnamed protein product (Homo       9   LI:109467.1:2001JAN12   g182977   1.00E−110   glyceraldehyde-3-phosphate                       dehydrogenase (EC 1.2.1.12) ( Homo                           sapiens )       10   LI:1175250.1:2001JAN12   g15929781   5.00E−89   hypothetical protein FLJ12606 ( Homo                           sapiens )       11   LI:2121744.1:2001JAN12   g10435738   3.00E−70   unnamed protein product (Homo       12   LI:1170908.1:2001JAN12   g5262560   3.00E−59   hypothetical protein ( Homo sapiens )       13   LI:1173119.1:2001JAN12   g9968290   1.00E−110   zinc finger protein 304 ( Homo sapiens )       14   LI:1175131.1:2001JAN12   g12483906   0   zinc finger protein HIT-40 ( Rattus                           norvegicus )       15   LI:1174107.2:2001JAN12   g10435738   2.00E−60   unnamed protein product (Homo       16   LI:901832.1:2001JAN12   g16198398   0   Unknown (protein for MGC: 27353) ( Homo                           sapiens )       17   LI:1091903.1:2001JAN12   g14042373   4.00E−24   unnamed protein product (Homo       18   LI:1089543.2:2001JAN12   g14348588   0   KRAB zinc finger protein ( Homo sapiens )       19   LI:2049137.1:2001JAN12   g13937909   1.00E−108   Similar to KIAA0961 protein ( Homo                           sapiens )       20   LI:1171755.9:2001JAN12   g14249844   2.00E−64   Similar to hypothetical protein FLJ23233                       ( Homo sapiens )       21   LI:208529.12:2001JAN12   g15430613   1.00E−177   clipin E/coronin 6 type B ( Mus musculus )       22   LI:024125.6:2001JAN12   g12052959   1.00E−129   hypothetical protein ( Homo sapiens         23   LI:235557.12:2001JAN12   g13506765   3.00E−84   uridine-cytidine kinase 1 ( Homo sapiens )       24   LI:178860.1:2001JAN12   g14133223   4.00E−29   KIAA0876 protein ( Homo sapiens )       25   LI:405798.1:2001JAN12   g193830   3.00E−26   helix-loop-helix protein ( Mus musculus )       26   LI:1071427.101:2001JAN12   g5663   1.00E−77   actin (AA 1-376) (Artemia sp.)       27   LI:1072276.1:2001JAN12   g2828710   6.00E−39   matrin cyclophilin ( Rattus norvegicus )       28   LI:198296.1:2001JAN12   g12853497   1.00E−147   putative ( Mus musculus )       29   LI:202943.4:2001JAN12   g11177164   0   polydom protein ( Mus musculus )       30   LI:2121848.1:2001JAN12   g12654199   1.00E−47   Similar to zinc finger protein 137 (clone                       pHZ-30) ( Homo sapiens )       31   LI:796992.1:2001JAN12   g13543419   3.00E−98   Similar to zinc finger protein 304 ( Homo                           sapiens )       32   LI:1183014.7:2001JAN12   g16198398   9.00E−39   Unknown (protein for MGC: 27353) ( Homo                           sapiens )       33   LI:1171219.2:2001JAN12   g13121525   1.00E−104   Synthetic sequence (synthetic construct)       34   LI:428428.4:2001JAN12   g12053161   6.00E−94   hypothetical protein ( Homo sapiens )       35   LI:230711.5:2001JAN12   g1002424   1.00E−101   YSPL-1 form 1 ( Mus musculus )       36   LI:199716.6:2001JAN12   g14198276   0   hypothetical protein FLJ12496 ( Homo                           sapiens )                    
     [0309]                                           TABLE 3                       SEQ ID NO:   Template ID   Start   Stop   Frame   Pfam Hit   Pfam Description   E-value                                                                1   LI:180252.16:2001JAN12   36   224   forward 3   pkinase   Protein kinase domain   7.00E−05       2   LI:1072919.1:2001JAN12   160   714   forward 1   Ribosomal —     Ribosomal protein S7e   4.30E−06                           S7e       3   LI:477130.1:2001JAN12   173   547   forward 2   Ribosomal —     Ribosomal protein L13   1.20E−35                           L13       4   LI:351355.1:2001JAN12   118   231   forward 1   zf-MYND   MYND finger   8.90E−07       5   LI:038285.2:2001JAN12   85   273   forward 1   KRAB   KRAB box   2.40E−34       6   LI:1079031.1:2001JAN12   1829   2041   forward 2   PCI   PCI domain   2.30E−08       7   LI:306216.1:2001JAN12   455   841   forward 2   mutT   MutT-like domain   6.00E−06       8   LI:011799.1:2001JAN12   1595   1735   forward 2   Kelch   Kelch motif   4.80E−08       9   LI:109467.1:2001JAN12   211   651   forward 1   gpdh   Glyceraldehyde 3-phosphate   2.30E−36                               dehydrogenase, NAD binding domain       9   LI:109467.1:2001JAN12   735   974   forward 3   gpdh_C   Glyceraldehyde 3-phosphate   2.70E−24                               dehydrogenase, C-terminal domain       9   LI:109467.1:2001JAN12   974   1111   forward 2   gpdh_C   Glyceraldehyde 3-phosphate   2.10E−13                               dehydrogenase, C-terminal domain       10   LI:1175250.1:2001JAN12   159   311   forward 3   KRAB   KRAB box   1.10E−16       10   LI:1175250.1:2001JAN12   632   700   forward 2   zf-C2H2   Zinc finger, C2H2 type   3.80E−05       11   LI:2121744.1:2001JAN12   83   274   forward 2   KRAB   KRAB box   5.00E−41       12   LI:1170908.1:2001JAN12   115   183   forward 1   zf-C2H2   Zinc finger, C2H2 type   1.30E−06       13   LI:1173119.1:2001JAN12   642   710   forward 3   zf-C2H2   Zinc finger, C2H2 type   9.30E−06       14   LI:1175131.1:2001JAN12   169   381   forward 1   KRAB   KRAB box   9.00E−16       14   LI:1175131.1:2001JAN12   658   726   forward 1   zf-C2H2   Zinc finger, C2H2 type   1.00E−06       14   LI:1175131.1:2001JAN12   1686   1754   forward 3   zf-C2H2   Zinc finger, C2H2 type   1.90E−06       14   LI:1175131.1:2001JAN12   1214   1282   forward 2   zf-C2H2   Zinc finger, C2H2 type   3.70E−06       15   LI:1174107.2:2001JAN12   111   302   forward 3   KRAB   KRAB box   2.00E−43       16   LI:901832.1:2001JAN12   1183   1368   forward 1   KRAB   KRAB box   7.10E−39       16   LI:901832.1:2001JAN12   2390   2458   forward 2   zf-C2H2   Zinc finger, C2H2 type   9.70E−08       16   LI:901832.1:2001JAN12   1978   2046   forward 1   zf-C2H2   Zinc finger, C2H2 type   4.00E−05       17   LI:1091903.1:2001JAN12   182   370   forward 2   KRAB   KRAB box   6.20E−39       18   LI:1089543.2:2001JAN12   89   277   forward 2   KRAB   KRAB box   2.60E−37       18   LI:1089543.2:2001JAN12   836   904   forward 2   zf-C2H2   Zinc finger, C2H2 type   8.00E−08       19   LI:2049137.1:2001JAN12   262   450   forward 1   KRAB   KRAB box   1.60E−41       19   LI:2049137.1:2001JAN12   877   945   forward 1   zf-C2H2   Zinc finger, C2H2 type   1.90E−06       20   LI:1171755.9:2001JAN12   159   227   forward 3   zf-C2H2   Zinc finger, C2H2 type   1.40E−05       21   LI:208529.12:2001JAN12   78   191   forward 3   WD40   WD domain, G-beta repeat   3.70E−05       22   LI:024125.6:2001JAN12   895   1398   forward 1   FAA —     Fumarylacetoacetate (FAA) hydrolase   1.20E−83                           hydrolase   family       23   LI:235557.12:2001JAN12   17   352   forward 2   PRK   Phosphoribulokinase/Uridine kinase   4.30E−31                               family       24   LI:178860.1:2001JAN12   241   384   forward 1   jmjN   jmjN domain   6.00E−17       25   LI:405798.1:2001JAN12   620   778   forward 2   HLH   Helix-loop-helix DNA-binding domain   9.40E−16       26   LI:1071427.101:2001JAN12   558   755   forward 3   actin   Actin   9.50E−47       26   LI:1071427.101:2001JAN12   101   280   forward 2   actin   Actin   5.30E−32       26   LI:1071427.101:2001JAN12   412   555   forward 1   actin   Actin   8.50E−25       27   LI:1072276.1:2001JAN12   172   549   forward 1   pro —     Cyclophilin type peptidyl-prolyl cis-   1.50E−29                           isomerase   trans Isomerase       27   LI:1072276.1:2001JAN12   228   320   forward 3   pro —     Cyclophilin type peptidyl-prolyl cis-   7.70E−08                           isomerase   trans isomerase       28   LI:198296.1:2001JAN12   629   766   forward 2   Kelch   Kelch motif   2.00E−08       29   LI:202943.4:2001JAN12   1912   2073   forward 1   sushi   Sushi domain (SCR repeat)   3.80E−18       29   LI:202943.4:2001JAN12   2249   2413   forward 2   sushi   Sushi domain (SCR repeat)   9.40E−17       29   LI:202943.4:2001JAN12   2712   2873   forward 3   sushi   Sushi domain (SCR repeat)   4.90E−11       30   LI:2121848.1:2001JAN12   450   518   forward 3   zf-C2H2   Zinc finger, C2H2 type   1.20E−05       30   LI:2121848.1:2001JAN12   133   201   forward 1   zf-C2H2   Zinc finger, C2H2 type   9.30E−05       31   LI:796992.1:2001JAN12   582   650   forward 3   zf-C2H2   Zinc finger, C2H2 type   6.70E−08       32   LI:1183014.7:2001JAN12   92   280   forward 2   KRAB   KRAB box   3.00E−46       33   LI:1171219.2:2001JAN12   132   371   forward 3   ig   Immunoglobulin domain   2.20E−09       34   LI:428428.4:2001JAN12   168   374   forward 3   zf-UBP   Zn-finger in ubiquitin-hydrolases and   4.80E−14                               other protein       35   LI:230711.5:2001JAN12   170   1147   forward 2   xan —     Xanthine/uracil permeases family   5.80E−06                           ur —                             permease       36   LI:199716.6:2001JAN12   377   1321   forward 2   Cation —     Cation efflux family   1.30E−53                           efflux                    
     [0310]                                       TABLE 4                       SEQ ID NO:   Template ID   Start   Stop   Frame   Domain Type   Topology                                                            25   LI:405798.1:2001JAN12   1   670   forward 1   TM   Non-cytosolic       25   LI:405798.1:2001JAN12   671   689   forward 1   TM   Transmembrane       25   LI:405798.1:2001JAN12   690   709   forward 1   TM   Cytosolic       25   LI:405798.1:2001JAN12   710   732   forward 1   TM   Transmembrane       25   LI:405798.1:2001JAN12   733   845   forward 1   TM   Non-cytosolic       25   LI:405798.1:2001JAN12   1   671   forward 2   TM   Non-cytosolic       25   LI:405798.1:2001JAN12   672   694   forward 2   TM   Transmembrane       25   LI:405798.1:2001JAN12   695   845   forward 2   TM   Cytosolic       25   LI:405798.1:2001JAN12   1   583   forward 3   TM   Non-cytosolic       25   LI:405798.1:2001JAN12   584   606   forward 3   TM   Transmembrane       25   LI:405798.1:2001JAN12   607   671   forward 3   TM   Cytosolic       25   LI:405798.1:2001JAN12   672   694   forward 3   TM   Transmembrane       25   LI:405798.1:2001JAN12   695   845   forward 3   TM   Non-cytosolic       26   LI:1071427.101:2001JAN12   1   282   forward 1   TM   Non-cytosolic       26   LI:1071427.101:2001JAN12   283   302   forward 1   TM   Transmembrane       26   LI:1071427.101:2001JAN12   303   347   forward 1   TM   Cytosolic       26   LI:1071427.101:2001JAN12   1   282   forward 2   TM   Non-cytosolic       26   LI:1071427.101:2001JAN12   283   302   forward 2   TM   Transmembrane       26   LI:1071427.101:2001JAN12   303   346   forward 2   TM   Cytosolic       26   LI:1071427.101:2001JAN12   1   283   forward 3   TM   Non-cytosolic       26   LI:1071427.101:2001JAN12   284   306   forward 3   TM   Transmembrane       26   LI:1071427.101:2001JAN12   307   346   forward 3   TM   Cytosolic       27   LI:1072276.1:2001JAN12   1   28   forward 1   TM   Non-cytosolic       27   LI:1072276.1:2001JAN12   29   51   forward 1   TM   Transmembrane       27   LI:1072276.1:2001JAN12   52   316   forward 1   TM   Cytosolic       27   LI:1072276.1:2001JAN12   1   184   forward 2   TM   Cytosolic       27   LI:1072276.1:2001JAN12   185   202   forward 2   TM   Transmembrane       27   LI:1072276.1:2001JAN12   203   250   forward 2   TM   Non-cytosolic       27   LI:1072276.1:2001JAN12   251   273   forward 2   TM   Transmembrane       27   LI:1072276.1:2001JAN12   274   316   forward 2   TM   Cytosolic       27   LI:1072276.1:2001JAN12   1   19   forward 3   TM   Cytosolic       27   LI:1072276.1:2001JAN12   20   42   forward 3   TM   Transmembrane       27   LI:1072276.1:2001JAN12   43   316   forward 3   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1   470   forward 1   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   471   493   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   494   497   forward 1   TM   Cytosolic       28   LI:198296.1:2001JAN12   498   520   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   521   539   forward 1   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   540   559   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   560   1070   forward 1   TM   Cytosolic       28   LI:198296.1:2001JAN12   1071   1093   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   1094   1107   forward 1   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1108   1130   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   1131   1142   forward 1   TM   Cytosolic       28   LI:198296.1:2001JAN12   1143   1165   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   1166   1228   forward 1   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1229   1251   forward 1   TM   Transmembrane       28   LI:198296.1:2001JAN12   1252   1410   forward 1   TM   Cytosolic       28   LI:198296.1:2001JAN12   1   20   forward 2   TM   Cytosolic       28   LI:198296.1:2001JAN12   21   43   forward 2   TM   Transmembrane       28   LI:198296.1:2001JAN12   44   934   forward 2   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   935   957   forward 2   TM   Transmembrane       28   LI:198296.1:2001JAN12   958   1153   forward 2   TM   Cytosolic       28   LI:198296.1:2001JAN12   1154   1176   forward 2   TM   Transmembrane       28   LI:198296.1:2001JAN12   1177   1302   forward 2   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1303   1325   forward 2   TM   Transmembrane       28   LI:198296.1:2001JAN12   1326   1409   forward 2   TM   Cytosolic       28   LI:198296.1:2001JAN12   1   905   forward 3   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   906   925   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   926   931   forward 3   TM   Cytosolic       28   LI:198296.1:2001JAN12   932   954   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   955   1152   forward 3   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1153   1172   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   1173   1192   forward 3   TM   Cytosolic       28   LI:198296.1:2001JAN12   1193   1215   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   1216   1234   forward 3   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1235   1257   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   1258   1291   forward 3   TM   Cytosolic       28   LI:198296.1:2001JAN12   1292   1314   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   1315   1346   forward 3   TM   Non-cytosolic       28   LI:198296.1:2001JAN12   1347   1369   forward 3   TM   Transmembrane       28   LI:198296.1:2001JAN12   1370   1409   forward 3   TM   Cytosolic       29   LI:202943.4:2001JAN12   1   893   forward 3   TM   Non-cytosolic       29   LI:202943.4:2001JAN12   894   916   forward 3   TM   Transmembrane       29   LI:202943.4:2001JAN12   917   1086   forward 3   TM   Cytosolic       30   LI:2121848.1:2001JAN12   1   292   forward 1   TM   Non-cytosolic       30   LI:2121848.1:2001JAN12   293   315   forward 1   TM   Transmembrane       30   LI:2121848.1:2001JAN12   316   325   forward 1   TM   Cytosolic       30   LI:2121848.1:2001JAN12   1   263   forward 2   TM   Non-cytosolic       30   LI:2121848.1:2001JAN12   264   286   forward 2   TM   Transmembrane       30   LI:2121848.1:2001JAN12   287   292   forward 2   TM   Cytosolic       30   LI:2121848.1:2001JAN12   293   315   forward 2   TM   Transmembrane       30   LI:2121848.1:2001JAN12   316   324   forward 2   TM   Non-cytosolic       30   LI:2121848.1:2001JAN12   1   262   forward 3   TM   Non-cytosolic       30   LI:2121848.1:2001JAN12   263   285   forward 3   TM   Transmembrane       30   LI:2121848.1:2001JAN12   286   291   forward 3   TM   Cytosolic       30   LI:2121848.1:2001JAN12   292   314   forward 3   TM   Transmembrane       30   LI:2121848.1:2001JAN12   315   324   forward 3   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   1   647   forward 2   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   648   670   forward 2   TM   Transmembrane       31   LI:796992.1:2001JAN12   671   744   forward 2   TM   Cytosolic       31   LI:796992.1:2001JAN12   745   767   forward 2   TM   Transmembrane       31   LI:796992.1:2001JAN12   768   786   forward 2   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   787   809   forward 2   TM   Transmembrane       31   LI:796992.1:2001JAN12   810   821   forward 2   TM   Cytosolic       31   LI:796992.1:2001JAN12   822   844   forward 2   TM   Transmembrane       31   LI:796992.1:2001JAN12   845   848   forward 2   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   849   871   forward 2   TM   Transmembrane       31   LI:796992.1:2001JAN12   872   880   forward 2   TM   Cytosolic       31   LI:796992.1:2001JAN12   1   403   forward 3   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   404   421   forward 3   TM   Transmembrane       31   LI:796992.1:2001JAN12   422   425   forward 3   TM   Cytosolic       31   LI:796992.1:2001JAN12   426   448   forward 3   TM   Transmembrane       31   LI:796992.1:2001JAN12   449   735   forward 3   TM   Non-cytosolic       31   LI:796992.1:2001JAN12   736   758   forward 3   TM   Transmembrane       31   LI:796992.1:2001JAN12   759   847   forward 3   TM   Cytosolic       31   LI:796992.1:2001JAN12   848   870   forward 3   TM   Transmembrane       31   LI:796992.1:2001JAN12   871   879   forward 3   TM   Non-cytosolic       32   LI:1183014.7:2001JAN12   1   161   forward 1   TM   Cytosolic       32   LI:1183014.7:2001JAN12   162   184   forward 1   TM   Transmembrane       32   LI:1183014.7:2001JAN12   185   201   forward 1   TM   Non-cytosolic       33   LI:1171219.2:2001JAN12   1   279   forward 2   TM   Non-cytosolic       33   LI:1171219.2:2001JAN12   280   302   forward 2   TM   Transmembrane       33   LI:1171219.2:2001JAN12   303   360   forward 2   TM   Cytosolic       34   LI:428428.4:2001JAN12   1   95   forward 1   TM   Cytosolic       34   LI:428428.4:2001JAN12   96   118   forward 1   TM   Transmembrane       34   LI:428428.4:2001JAN12   119   137   forward 1   TM   Non-cytosolic       34   LI:428428.4:2001JAN12   138   160   forward 1   TM   Transmembrane       34   LI:428428.4:2001JAN12   161   215   forward 1   TM   Cytosolic       35   LI:230711.5:2001JAN12   1   197   forward 2   TM   Non-cytosolic       35   LI:230711.5:2001JAN12   198   220   forward 2   TM   Transmembrane       35   LI:230711.5:2001JAN12   221   226   forward 2   TM   Cytosolic       35   LI:230711.5:2001JAN12   227   249   forward 2   TM   Transmembrane       35   LI:230711.5:2001JAN12   250   274   forward 2   TM   Non-cytosolic       35   LI:230711.5:2001JAN12   275   297   forward 2   TM   Transmembrane       35   LI:230711.5:2001JAN12   298   362   forward 2   TM   Cytosolic       35   LI:230711.5:2001JAN12   363   380   forward 2   TM   Transmembrane       35   LI:230711.5:2001JAN12   381   671   forward 2   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   1   4   forward 1   TM   Cytosolic       36   LI:199716.6:2001JAN12   5   27   forward 1   TM   Transmembrane       36   LI:199716.6:2001JAN12   28   468   forward 1   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   1   1   forward 2   TM   Cytosolic       36   LI:199716.6:2001JAN12   2   24   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   25   45   forward 2   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   46   68   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   69   128   forward 2   TM   Cytosolic       36   LI:199716.6:2001JAN12   129   149   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   150   158   forward 2   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   159   181   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   182   193   forward 2   TM   Cytosolic       36   LI:199716.6:2001JAN12   194   216   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   217   230   forward 2   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   231   253   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   254   300   forward 2   TM   Cytosolic       36   LI:199716.6:2001JAN12   301   323   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   324   327   forward 2   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   328   350   forward 2   TM   Transmembrane       36   LI:199716.6:2001JAN12   351   467   forward 2   TM   Cytosolic       36   LI:199716.6:2001JAN12   1   11   forward 3   TM   Cytosolic       36   LI:199716.6:2001JAN12   12   34   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   35   92   forward 3   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   93   112   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   113   132   forward 3   TM   Cytosolic       36   LI:199716.6:2001JAN12   133   155   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   156   264   forward 3   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   265   287   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   288   299   forward 3   TM   Cytosolic       36   LI:199716.6:2001JAN12   300   322   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   323   331   forward 3   TM   Non-cytosolic       36   LI:199716.6:2001JAN12   332   351   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   352   440   forward 3   TM   Cytosolic       36   LI:199716.6:2001JAN12   441   458   forward 3   TM   Transmembrane       36   LI:199716.6:2001JAN12   459   467   forward 3   TM   Non-cytosolic                    
     [0311]                               TABLE 5                       SEQ ID NO:   Template ID   Component ID   Start   Stop                                                    1   LI:180252.16:2001JAN12   3865849H1   145   293       1   LI:180252.16:2001JAN12   5682509H1   185   466       1   LI:180252.16:2001JAN12   4347176F6   271   817       1   LI:180252.16:2001JAN12   4347176H1   271   516       1   LI:180252.16:2001JAN12   71791503V1   529   805       1   LI:180252.16:2001JAN12   g6571938   65   489       1   LI:180252.16:2001JAN12   3765678H1   1   171       2   LI:1072919.1:2001JAN12   2749973H1   523   777       2   LI:1072919.1:2001JAN12   2659333H1   528   774       2   LI:1072919.1:2001JAN12   2046131H1   541   724       2   LI:1072919.1:2001JAN12   2456648H1   547   772       2   LI:1072919.1:2001JAN12   2046931H1   588   724       2   LI:1072919.1:2001JAN12   2547732H1   598   781       2   LI:1072919.1:2001JAN12   2625384H1   605   777       2   LI:1072919.1:2001JAN12   g5672166   610   776       2   LI:1072919.1:2001JAN12   2251571H1   612   770       2   LI:1072919.1:2001JAN12   2257870H1   612   731       2   LI:1072919.1:2001JAN12   g6463553   639   777       2   LI:1072919.1:2001JAN12   2510459T6   644   741       2   LI:1072919.1:2001JAN12   2470443H1   658   762       2   LI:1072919.1:2001JAN12   2348125H1   701   777       2   LI:1072919.1:2001JAN12   2326913H1   707   781       2   LI:1072919.1:2001JAN12   6910068J1   1   480       2   LI:1072919.1:2001JAN12   2734509H1   1   269       2   LI:1072919.1:2001JAN12   2378578H1   41   261       2   LI:1072919.1:2001JAN12   2345378H1   17   272       2   LI:1072919.1:2001JAN12   2159523H1   19   299       2   LI:1072919.1:2001JAN12   2605621H1   29   261       2   LI:1072919.1:2001JAN12   2662581H1   39   288       2   LI:1072919.1:2001JAN12   2462466H1   48   286       2   LI:1072919.1:2001JAN12   2661835H1   49   323       2   LI:1072919.1:2001JAN12   221844H1   50   224       2   LI:1072919.1:2001JAN12   2444658H1   53   290       2   LI:1072919.1:2001JAN12   2399925H1   57   291       2   LI:1072919.1:2001JAN12   2590589H1   58   312       2   LI:1072919.1:2001JAN12   2606478H1   58   306       2   LI:1072919.1:2001JAN12   5728810H1   58   642       2   LI:1072919.1:2001JAN12   2655210H1   61   374       2   LI:1072919.1:2001JAN12   2482363H1   60   385       2   LI:1072919.1:2001JAN12   2661914H1   63   318       2   LI:1072919.1:2001JAN12   2445753H1   64   331       2   LI:1072919.1:2001JAN12   2259442H1   498   733       2   LI:1072919.1:2001JAN12   2422863H1   499   752       2   LI:1072919.1:2001JAN12   2444738H1   501   741       2   LI:1072919.1:2001JAN12   2634040H1   511   770       2   LI:1072919.1:2001JAN12   2510319H1   204   462       2   LI:1072919.1:2001JAN12   2398611H1   204   427       2   LI:1072919.1:2001JAN12   2641959H1   207   468       2   LI:1072919.1:2001JAN12   2391475H2   221   481       2   LI:1072919.1:2001JAN12   2344005H1   230   476       35   LI:230711.5:2001JAN12   71592819V1   1216   1876       35   LI:230711.5:2001JAN12   71593883V1   1215   1848       35   LI:230711.5:2001JAN12   71591755V1   1225   1904       35   LI:230711.5:2001JAN12   71597148V1   1227   1907       35   LI:230711.5:2001JAN12   70687607V1   1244   1649       35   LI:230711.5:2001JAN12   72157465V1   1257   1558       35   LI:230711.5:2001JAN12   71597474V1   1264   1980       35   LI:230711.5:2001JAN12   71593826V1   1276   1956       35   LI:230711.5:2001JAN12   70680047V1   1265   1894       35   LI:230711.5:2001JAN12   70679818V1   1292   1962       35   LI:230711.5:2001JAN12   6543969H1   1303   1861       35   LI:230711.5:2001JAN12   71595653V1   1303   1887       35   LI:230711.5:2001JAN12   5100839T6   1317   1904       35   LI:230711.5:2001JAN12   71805254V1   1348   1802       35   LI:230711.5:2001JAN12   4379312H1   1348   1625       35   LI:230711.5:2001JAN12   70682506V1   1366   1945       35   LI:230711.5:2001JAN12   55119937V1   1367   1535       35   LI:230711.5:2001JAN12   71595289V1   588   1253       35   LI:230711.5:2001JAN12   71593141V1   595   1192       35   LI:230711.5:2001JAN12   71594054V1   609   1171       35   LI:230711.5:2001JAN12   71597118V1   648   1370       35   LI:230711.5:2001JAN12   71592473V1   678   1387       35   LI:230711.5:2001JAN12   70681329V1   735   898       35   LI:230711.5:2001JAN12   71592682V1   747   1331       35   LI:230711.5:2001JAN12   71596835V1   765   1446       36   LI:199716.6:2001JAN12   4581943H1   235   500       36   LI:199716.6:2001JAN12   3601317F6   330   848       36   LI:199716.6:2001JAN12   6778060R8   470   1057       36   LI:199716.6:2001JAN12   6778060J1   470   1063       36   LI:199716.6:2001JAN12   8043250H1   571   1212       36   LI:199716.6:2001JAN12   6404959H1   584   878       36   LI:199716.6:2001JAN12   6718311H1   597   1086       36   LI:199716.6:2001JAN12   71364542V1   629   1404       36   LI:199716.6:2001JAN12   4918221H1   640   888       36   LI:199716.6:2001JAN12   7730017J1   1   573       36   LI:199716.6:2001JAN12   5666595H1   48   303       36   LI:199716.6:2001JAN12   1004218H1   214   461       36   LI:199716.6:2001JAN12   3162418H1   1   217       36   LI:199716.6:2001JAN12   5178208H1   649   933       36   LI:199716.6:2001JAN12   3138872H1   662   962       36   LI:199716.6:2001JAN12   6719332H1   833   1251       36   LI:199716.6:2001JAN12   2733376H1   838   1078       36   LI:199716.6:2001JAN12   2733128F6   838   1218       36   LI:199716.6:2001JAN12   2733128H1   838   1052       36   LI:199716.6:2001JAN12   3834703H1   872   1167       36   LI:199716.6:2001JAN12   2223246H1   1043   1121                    
     [0312]                       TABLE 6                       SEQ ID               NO:   Template ID   Tissue Distribution                                            1   LI:180252.16:2001JAN12   Exocrine Glands - 38%, Respiratory System - 23%, Nervous System - 23%       2   LI:1072919.1:2001JAN12   Endocrine System - 19%, Female Genitalia - 17%, Respiratory System - 13%       3   LI:477130.1:2001JAN12   Nervous System - 100%       4   LI:351355.1:2001JAN12   CardiovascularSystem - 52%, Unclassified/Mixed - 21%, Hemic and Immune System - 12%       5   LI:038285.2:2001JAN12   Digestive System - 30%, Liver - 20%, Pancreas - 18%       6   LI:1079031.1:2001JAN12   Stomatognathic System - 27%, Respiratory System - 16%, Female Genitalia - 12%       7   LI:306216.1:2001JAN12   Unclassified/Mixed - 30%, Liver - 20%, Cardiovascular System - 14%       8   LI:011799.1:2001JAN12   Female Genitalia - 42%, Endocrine System - 16%, Germ Cells - 11%       9   LI:109467.1:2001JAN12   Urinary Tract - 65%, Liver - 15%, Connective Tissue - 12%       10   LI:1175250.1:2001JAN12   Germ Cells - 74%       11   LI:2121744.1:2001JAN12   Nervous System - 60%, Urinary Tract - 40%       12   LI:1170908.1:2001JAN12   Unclassified/Mixed - 56%, Skin - 18%, Female Genitalia - 13%       13   LI:1173119.1:2001JAN12   Digestive System - 28%, Liver - 23%, Respiratory System - 11%, Endocrine System - 11%,               Nervous System - 11%       14   LI:1175131.1:2001JAN12   Liver - 35%, Hemic and Immune System - 20%, Germ Cells - 11%       15   LI:1174107.2:2001JAN12   Sense Organs - 51%, Unclassified/Mixed - 41%       16   LI:901832.1:2001JAN12   Cardiovascular System - 31%, Female Genitalia - 21%, Nervous System - 13%,               Digestive System - 13%       17   LI:1091903.1:2001JAN12   Germ Cells - 93%       18   LI:1089543.2:2001JAN12   Embryonic Structures - 56%, Unclassified/Mixed - 21%, Female Genitalia - 13%       19   LI:2049137.1:2001JAN12   Germ Cells - 51%, Unclassified/Mixed - 16%       20   LI:1171755.9:2001JAN12   Female Genitalia - 100%       21   LI:208529.12:2001JAN12   Nervous System - 100%       22   LI:024125.6:2001JAN12   Embryonic Structures - 20%, Connective Tissue - 13%       23   LI:235557.12:2001JAN12   Urinary Tract - 86%       24   LI:178860.1:2001JAN12   Respiratory System - 42%, Germ Cells - 27%, Unclassified/Mixed - 26%       25   LI:405798.1:2001JAN12   Endocrine System - 71%, Respiratory System - 18%, Nervous System - 12%       26   LI:1071427.101:2001JAN12   Liver - 68%       27   LI:1072276.1:2001JAN12   Urinary Tract - 51%, Germ Cells - 23%, Digestive System - 14%       28   LI:198296.1:2001JAN12   Embryonic Structures - 15%, Female Genitalia - 14%       29   LI:202943.4:2001JAN12   Embryonic Structures - 56%, Liver - 14%, Connective Tissue - 12%       30   LI:2121848.1:2001JAN12   Digestive System - 51%, Hemic and Immune System - 20%, Exocrine Glands - 14%       31   LI:796992.1:2001JAN12   Unclassified/Mixed - 32%, Skin - 18%, Nervous System - 12%       32   LI:1183014.7:2001JAN12   Urinary Tract - 88%, Endocrine System - 10%       33   LI:1171219.2:2001JAN12   Respiratory System - 36%, Digestive System - 22%, Musculoskeletal System - 12%       35   LI:230711.5:2001JAN12   Urinary Tract - 67%, Digestive System - 11%       36   LI:199716.6:2001JAN12   Female Genitalia - 61%, Connective Tissue - 13%                    
     [0313]                                           TABLE 7                       SEQ ID NO:   Frame   Length   Start   Stop   GI Number   Probability Score   Annotation                                                                37   2   117   149   499   g12060855   7.00E−45   serologically defined breast cancer antigen NY-BR-96       37   2   117   149   499   g12847582   1.00E−40   putative       37   2   117   149   499   g7959739   4.00E−17   PRO1038       39   2   153   164   622   g6650751   1.00E−49   ribosomal protein I       39   2   153   164   622   g6091722   3.00E−40   putative ribosomal protein L13       39   2   153   164   622   g2984157   1.00E−29   ribosomal protein L13       40   1   147   1   441   g14547146   7.00E−36   EGLN1 protein       40   1   147   1   441   g11345052   7.00E−36   SM-20       40   1   147   1   441   g11320938   7.00E−36   SM-20       41   1   166   1   498   g340446   2.00E−17   zinc finger protein 7 (ZFP7)       41   1   166   1   498   g14250235   2.00E−17   RIKEN cDNA 4633401C23 gene       41   1   166   1   498   g12852573   2.00E−17   putative       45   1   182   160   705   g9956035   9.00E−48   similar to Homo sapiens glyceraldehyde-3-phosphate dehydrogenase                                   (GAPDH) mRNA with GenBank Accession Number M33197.1       45   1   182   160   705   g9802302   9.00E−48   glyceraldehyde-3-phosphate dehydrogenase       45   1   182   160   705   g35053   9.00E−48   uracil DNA glycosylase       46   2   188   428   991   g15929781   6.00E−78   hypothetical protein FLJ12606       46   2   188   428   991   g10434195   8.00E−78   unnamed protein product       46   2   188   428   991   g13623354   6.00E−38   Similar to zinc finger protein 136 (clone pHZ-20)       47   2   160   2   481   g10435738   3.00E−70   unnamed protein product       47   2   160   2   481   g3342002   2.00E−57   hematopoietic cell derived zinc finger protein       47   2   160   2   481   g186774   6.00E−57   zinc finger protein       48   3   156   420   887   g12052983   3.00E−42   hypothetical protein       48   3   156   420   887   g5262560   6.00E−39   hypothetical protein       48   3   156   420   887   g10434856   2.00E−38   unnamed protein product       49   3   292   3   878   g16550444   1.00E−149   (AK055662) unnamed protein product       49   3   292   3   878   g16553223   1.00E−103   (AK057494) unnamed protein product       49   3   292   3   878   g488551   6.00E−99   zinc finger protein ZNF132       50   2   345   722   1756   g12052983   1.00E−116   hypothetical protein       50   2   345   722   1756   g14042293   1.00E−115   unnamed protein product       50   2   345   722   1756   g6467206   1.00E−109   gonadotropin inducible transcription repressor-4       51   3   132   48   443   g13623587   2.00E−45   Similar to zinc finger protein 254       51   3   132   48   443   g10435738   3.00E−35   unnamed protein product       51   3   132   48   443   g3342002   2.00E−34   hematopoietic cell derived zinc finger protein       52   1   193   1540   2118   g16198398   1.00E−105   Unknown (protein for MGC: 27353)       52   1   193   1540   2118   g8099348   2.00E−38   zinc finger protein       52   1   193   1540   2118   g5730196   3.00E−38   Kruppel-type zinc finger       53   2   101   131   433   g14042373   1.00E−24   unnamed protein product       53   2   101   131   433   g1389741   7.00E−24   KRAB/zinc finger suppressor protein 1       53   2   101   131   433   g16198398   2.00E−23   Unknown (protein for MGC: 27353)       54   2   346   92   1129   g14348588   0   KRAB zinc finger protein       54   2   346   92   1129   g10047297   0   KIAA1611 protein       54   2   346   92   1129   g10440398   1.00E−145   FLJ00032 protein       55   1   390   79   1248   g14042550   1.00E−108   unnamed protein product       55   1   390   79   1248   g13937909   1.00E−108   Similar to KIAA0961 protein       55   1   390   79   1248   g16552245   3.00E−95   (AK056753) unnamed protein product       56   3   125   3   377   g14249844   2.00E−64   Similar to hypothetical protein FLJ23233       56   3   125   3   377   g10439850   2.00E−64   unnamed protein product       56   3   125   3   377   g16552811   5.00E−60   (AK057209) unnamed protein product       57   3   310   3   932   g15430613   1.00E−177   clipin E/coronin 6 type B       57   3   310   3   932   g15430628   1.00E−176   coronin relative protein       57   3   310   3   932   g15430611   1.00E−169   clipin E/coronin 6 type A       58   1   271   682   1494   g12052959   1.00E−129   hypothetical protein       58   1   271   682   1494   g14336767   1.00E−128   similar to homoprotocatechuate catabolism bifunctional                                   isomerase/decarboxylase       58   1   271   682   1494   g7670464   1.00E−115   unnamed protein product       59   2   120   2   361   g13924750   9.00E−60   uridine kinase       59   2   120   2   361   g13506765   9.00E−60   uridine-cytidine kinase 1       59   2   120   2   361   g10433688   9.00E−60   unnamed protein product       60   1   91   211   483   g3513300   1.00E−29   F16601_1, partial CDS       60   1   91   211   483   g14133223   1.00E−29   KIAA0876 protein       60   1   91   211   483   g13938056   4.00E−29   Similar to KIAA0677 gene product       61   2   174   287   808   g15489391   1.00E−73   (BC013789) nescient helix loop helix 1       61   2   174   287   808   g183947   1.00E−73   helix-loop-helix protein       61   2   174   287   808   g200108   5.00E−65   NSCL       62   1   139   625   1041   g950002   9.00E−10   smooth muscle gamma-actin       63   1   136   250   657   g16306743   3.00E−23   (BC001555) Unknown (protein for MGC: 5054)       63   1   136   250   657   g2828710   3.00E−23   matrin cyclophilin       63   1   136   250   657   g1770526   3.00E−23   SRcyp protein       64   1   148   1   444   g7019911   2.00E−70   unnamed protein product       64   1   148   1   444   g12853497   8.00E−70   putative       64   1   148   1   444   g15990536   9.00E−25   Similar to hypothetical protein FLJ14106       65   2   256   2006   2773   g11177164   3.00E−90   polydom protein       65   2   256   2006   2773   g12060830   6.00E−76   serologically defined breast cancer antigen NY-BR-38       65   2   256   2006   2773   g14198157   5.00E−25   polydomain protein       66   3   53   384   542   g488557   4.00E−18   zinc finger protein ZNF137       66   3   53   384   542   g3135968   1.00E−14   b34l8.1 (zinc finger protein 184 (Kruppel-like))       66   3   53   384   542   g1769491   1.00E−14   kruppel-related zinc finger protein       67   3   292   3   878   g488551   3.00E−97   zinc finger protein ZNF132       67   3   292   3   878   g13543419   4.00E−97   Similar to zinc finger protein 304       67   3   292   3   878   g1199604   8.00E−97   zinc finger protein C2H2-25       68   2   136   26   433   g16198398   5.00E−39   Unknown (protein for MGC: 27353)       68   2   136   26   433   g7576272   1.00E−29   bA393J16.1 (zinc finger protein 33a (KOX 31))       68   2   136   26   433   g498152   1.00E−29   ha0946 protein is Kruppel-related.       69   3   247   3   743   g13121525   1.00E−111   Synthetic sequence       69   3   247   3   743   g413074   1.00E−105   chimeric monoclonal TSH antibody, kappa-chain       69   3   247   3   743   g16741061   1.00E−104   (BC016380) Similar to Immunoglobulin kappa constant       70   3   114   306   647   g12053161   5.00E−51   hypothetical protein       70   3   114   306   647   g16041104   5.00E−46   hypothetical protein       70   3   114   306   647   g15559639   2.00E−16   Unknown (protein for MGC: 20741)       71   2   519   2   1558   g15209684   1.00E−130   unnamed protein product       71   2   519   2   1558   g1002424   1.00E−126   YSPL-1 form 1       71   2   519   2   1558   g16550532   1.00E−107   (AK055730) unnamed protein product       72   2   408   179   1402   g14198276   0   hypothetical protein FLJ12496       72   2   408   179   1402   g10434017   0   unnamed protein product       72   2   408   179   1402   g10434437   0   unnamed protein product                    
     [0314]                           TABLE 8                       Program   Description   Reference   Parameter Threshold                  ABI   A program that removes vector sequences and masks   Applied Biosystems,           FACTURA   ambiguous bases in nucleic acid sequences.   Foster City, CA.       ABI/   A Fast Data Finder useful in   Applied Biosystems,   Mismatch &lt; 50%       PARACEL   comparing and annotating amino   Foster City, CA;       FDF   acid or nucleic acid sequences.   Paracel Inc., Pasadena, CA.       ABI   A program that assembles nucleic acid sequences.   Applied Biosystems,       AutoAssembler       Foster City, CA.       BLAST   A Basic Local Alignment Search Tool useful in   Altschul, S.F. et al. (1990)   ESTs: Probability           sequence similarity search for amino acid and nucleic   J. Mol. Biol. 215: 403-410;   value = 1.0E−8           acid sequences. BLAST includes five functions:   Altschul, S.F. et al. (1997)   or less;           blastp, blastn, blastx, tblastn, and tblastx.   Nucleic Acids Res. 25: 3389-3402.   Full Length sequences:                   Probability value =                   1.0E−10 or less       FASTA   A Pearson and Lipman algorithm that searches for   Pearson, W. R. and   ESTs: fasta E            similarity between a query sequence and a group of   D. J. Lipman (1988) Proc. Natl.   value = 1.06E−6;            sequences of the same type. FASTA comprises as   Acad Sci. USA 85: 2444-2448;   Assembled ESTs: fasta           least five functions: fasta, tfasta, fastx, tfastx, and   Pearson, W. R. (1990) Methods Enzymol. 183: 63-98;   Identity = 95% or           ssearch.   and Smith, T. F. and M. S. Waterman (1981)   greater and               Adv. Appl. Math. 2: 482-489.   Match length =                   200 bases or greater;                   fastx E value =                   1.0E−8 or less;                   Full Length sequences:                   fastx score =                   100 or greater       BLIMPS   A BLocks IMProved Searcher that matches a   Henikoff, S. and J. G. Henikoff (1991)   Probability value =           sequence against those in BLOCKS, PRINTS,   Nucleic Acids Res. 19: 6565-6572; Henikoff,   1.0E−3 or less           DOMO, PRODOM, and PFAM databases to search   J. G. and S. Henikoff (1996) Methods           for gene families, sequence homology, and structural   Enzymol. 266: 88-105; and Attwood, T. K. et           fingerprint regions.   al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.       HMMER   An algorithm for searching a query sequence against   Krogh, A. et al. (1994) J. Mol. Biol.   PFAM           hidden Markov model (HMM)-based databases of   235: 1501-1531; Sonnhammer, E. L. L. et al.   hits:           protein family consensus sequences, such as PFAM.   (1988) Nucleic Acids Res. 26: 320-322;   Probability value =               Durbin, R. et al. (1998) Our World View, in   1.0E−3 or less               a Nutshell, Cambridge Univ. Press, pp. 1-350.   Signal peptide hits:                   Score = 0 or greater       ProfileScan   An algorithm that searches for structural and   Gribskov, M. et al. (1988) CABIOS 4: 61-66;   Normalized quality           sequence motifs in protein sequences that match   Gribskov, M. et al. (1989) Methods   score ≧ GCG           sequence patterns defined in Prosite.   Enzymol. 183: 146-159; Bairoch, A. et al.   specified “HIGH”               (1997) Nucleic Acids Res. 25: 217-221.   value for that                   particular                   Prosite motif.                   Generally, score =                   1.4-2.1.       Phred   A base-calling algorithm that examines automated   Ewing, B. et al. (1998) Genome Res. 8: 175-185;           sequencer traces with high sensitivity and probability.   Ewing, B. and P. Green (1998) Genome               Res. 8: 186-194.       Phrap   A Phils Revised Assembly Program including   Smith, T. F. and M. S. Waterman (1981) Adv.   Score = 120 or greater;           SWAT and CrossMatch, programs based on efficient   Appl. Math. 2: 482-489; Smith, T. F. and   Match length =           implementation of the Smith-Waterman algorithm,   M. S. Waterman (1981) J. Mol. Biol. 147: 195-197;   56 or greater           useful in searching sequence homology and   and Green, P., University of           assembling DNA sequences.   Washington, Seattle, WA.       Consed   A graphical tool for viewing and editing Phrap   Gordon, D. et al. (1998) Genome Res. 8: 195-202.           assemblies.       SPScan   A weight matrix analysis program that scans protein   Nielson, H. et al. (1997) Protein Engineering   Score = 3.5 or greater           sequences for the presence of secretory signal    10: 1-6; Claverie, J. M. and S. Audic (1997)           peptides.   CABIOS 12: 431-439.       TMAP   A program that uses weight matrices to delineate   Persson, B. and P. Argos (1994) J. Mol. Biol.           transmembrane segments on protein sequences and   237: 182-192; Persson, B. and P. Argos           determine orientation.   (1996) Protein Sci. 5: 363-371.       TMHMMER   A program that uses a hidden Markov model (HMM)   Sonnhammer, E.L. et al. (1998) Proc. Sixth           to delineate transmembrane segments on protein   Intl. Conf. on Intelligent Systems for Mol.           sequences and determine orientation.   Biol., Glasgow et al., eds., The Am. Assoc.               for Artificial Intelligence Press,               Menlo Park, CA,               pp. 175-182.       Motifs   A program that searches amino acid sequences for   Bairoch, A. et al. (1997) Nucleic Acids Res.           patterns that matched those defined in Prosite.    25: 217-221; Wisconsin Package Program               Manual, version 9, page M51-59, Genetics               Computer Group, Madison, WI.                    
     [0315] 
    
     
       
         1 
         
           
             72  
           
           
             1  
             817  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI180252.162001JAN12  
             
           
            1 

aacatcccaa taaaagtggc tcgatatggc acgatattgg gatggttgaa gagtttggag     60 

acaatgagct gtgggttgtc acatcattca tggcatacgg ttctgcaaaa gatctcatct    120 

gtacacactt catggatggc atgaatgagc tggcgattgc ttacatcctg cagggggtgc    180 

tgaaggccct cgactacatc caccacatgg gatatgtaca cagaatctcc agggttatga    240 

tgccaagtct gacatctaca gtgtgggaat cacagcctgt gaactggcca acggccatgt    300 

cccctttaag gatatgcctg ccacccagat gctgctagag aaactgaacg gcacagtgcc    360 

ctgcctgttg gataccagca ccatccccgc tgaggagctg accatgagcc cttcgcgctc    420 

agtggccaac tctggcctga gtgacagcct gaccaccagc accccccggc cctccaacgg    480 

cccagtgcca gcaccctcct gaaccactct ttcttcaagc agatcaagcg acgtgcctca    540 

gaggctttgc ccgaattgct tcgtcctgtc acccccatca ccaattttga gggcagccag    600 

tctcaggacc acagtggaat ctttggcctg gtaacaaacc tggaagagct ggaggtggac    660 

gattgggagt tctgagcctc tgcaaactgt gcgcattctc cagccaggga tgcagaggcc    720 

acccagaggc ccttcctgag ggccggccac attcccgccc tcctgggcag attgggtaga    780 

aaggacattc ttccaggaaa gttgactgct gactgat                             817 

 
           
             2  
             781  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1072919.12001JAN12  
             
           
            2 

ggtttccgcc ctcctcctcg cgctgtttcc gcctcttgcc ttcggacgcc ggattttgac     60 

gtgctctcgc gagatttggg tctcttccta agccggcgct cggcgaagtt ctccccaggg    120 

gcaaagccca tgttcatggt cgagcgccaa gatcgtgaag ccccaatggg cgagaatgcc    180 

ggacgaattc cgagtccggg atcttcccag gctcttctgg aggctggagc atgaactcgg    240 

acctcacagg ctcagctcag gcagctgaat attacggctg ctaaggaaag tgganagttg    300 

gtggtggtcg gaaagctatc ataatctttg ttccacgttc ctcaactgaa atcctttcca    360 

ggaaaatcca agtccggcta gtacgcgaat tggagaaaaa gttcacatgg gaagcatgtc    420 

gtctttatcg ctcacgagga gaattctgcc taagcccaac tcgaaaaagc cgtaccccaa    480 

aataagccaa ggcgtccccg gagccctact ctgacagctg tgcccgatgc actcccttga    540 

ggacttggtc ttccccagcg aaattgtggg catagagaat ccgcgtcaaa ctagaatggc    600 

agccggctca taaagggttc attttggaca aaagcacagc agaacaatgt ggaacacaaa    660 

ggttgaaact ttttctggtg tctataagaa gctcacgggc acaggatgtt aattttgaat    720 

tccacagagt ttcaattgta aacaaaaatg actaaataaa aagtatatat tcacagtaaa    780 

a                                                                    781 

 
           
             3  
             773  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI477130.12001JAN12  
             
           
            3 

gaagtgctcc ggggaagcac cgtgacaccc ttgctcgccc gcatctctct aaccgccggc     60 

gccggcgccg gcgccggctc atcgttcaca tggctgcgat gccaccggcc ttcacgggca    120 

acctgaagaa agcacttgca ggtctgagaa gaatcacatt tagatgggct tcgatggacg    180 

cgtacttgat gctaagggtc aggtgctggg acgattggct tcccaaatag ccgttgtgct    240 

tcaaggcaag gataaaccga cctatgcgcc acatgtggaa aatggagaca tgtgcattgt    300 

acttaatgca caggatatca gtgttacagg aaggaaaatg acagataaga tttactactg    360 

gcatacaggg tatgttggcc atttgaagga aaggaggctc aaggaccaga tggagaaaga    420 

cccaactgaa gtgattcgca aagctgtgct gcgcatgctt ccccgcaaca aactgcgtga    480 

tgatagggat cgcaagctgc ggatattttc tggaattgag catccattcc atgaccgccc    540 

tcttgaagcc tttgtgatgc cacctacggc aagtacggga gatgcgaccc cgtgcaaggc    600 

gtgcaatgtt aagggcccag actaaagagc attcaaacag ggccaaggag gaagaagatg    660 

ctaagaatgc cacagctgag gtcactgaca taggctcctc atgtgaattt gcatgatgca    720 

aatttgctca gatgactgtt ttaggcctat catttatatt gacttggtag cct           773 

 
           
             4  
             442  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI351355.12001JAN12  
             
           
            4 

ggccgctacc cctcctgctc ggccgccgca gtcgcctcgc cccgcccgcc cgccgccatg     60 

gccaatgaca gcggcgggcc cggcgggccg agcccgagcg agcgagaccg gcagtactgc    120 

gagctgtgcg ggaagatgga gaacctgctg cgctgcagcc gctgccgcag ctccttctac    180 

tgctgcaagg agcaccagcg tcaggactgg aagaaagcac aagtctcgtg tgccacggca    240 

gcgagggcgc cctcggccac ggagtgggcc cacacccagc attccgggcc ccgcgccgcc    300 

ggttgcagtg ccgccgtgcc agggcccggg cccccgggag cccaggaagg cagcggcgcg    360 

cccggggaca acgcctcccg gggacgcggc caaaggggaa aagtaaaggc caaagccccc    420 

ggccgaccca gcggcggccg ct                                             442 

 
           
             5  
             1406  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI038285.22001JAN12  
             
           
            5 

aattcactgt ctgtagcatc tgctcctcca cagagggacc ctggaatggc gatggcactc     60 

ccgatgcctg gacctcagga ggcggttgtg ttcgaggatg tggctgtgta cttcacaagg    120 

atagagtgga gttgcctggc ccccgaccag caggcactct acagggacgt gatgctggag    180 

aactatggga acctggcctc actaggcttt cttgttgcca aaccagcact gatctcccta    240 

ttggagcaag gagaggagcc gggggccttg attctgcagg tggctgaaca gagcgtggcc    300 

aaagccagcc tgtgcacaga ggaccctaat acactgccca gcagaagcca gggaaggaag    360 

ccctgccagc ttcagaaggt gggccaggag agaagggtgt ggcctggaag ggtagccggt    420 

gggggtgctg catcctcttg gccccaccgg ggagcaccct gttcacccct aacagatgaa    480 

gagaaggtga ggggggattg agttacctgc ccactggtgt gtcaaactcc atgatggggg    540 

tgggaacatg cagacctggc ccctccaagg cccactgctc cccgggctgt gcgccccaca    600 

gtctgtgcca ggggctgcag aaagagccat gggaagcctg gccctgtgta gggcaccaag    660 

aatgggaggg gttggatcca ccctcctaga gaacaagaat cctgggcagt agccgggaca    720 

tggtggggga ggctgaaggg ttgtccctga gcatccccaa catggagctc ggaagtctgg    780 

gccatgggca tggaaagcac gaagtgtcag ggccagcctg gtggaaccga agagctgtgc    840 

cacgatccct tccacctggt ggcagctgcc cacatgtccc gccactgggt tccatcacct    900 

gagactcctg gcaggtgcct ctctgagtct tttgtcctgt gctggaaact gggatgtgca    960 

tgcacacatc ttcatcaccc acagcacgga cagcgggaat aacacttcct ttggggatcc   1020 

agggtttctg gtgtctccag atttttcagg cgcccaccat gttcctctca tcccagacgt   1080 

cggcaaccaa ggtggaagcc aggttcatgg catgcccggc ccagctgcag tccgagtgca   1140 

gatcccatgg cgagcgtggg atccagccca aagcacaagc cacgcacaag cccgccaagg   1200 

ttgagtgggc aggtacctcc aacagccagc ccaggttgag tgggcaggta cctccaacag   1260 

cctggagccg tgaggccttg cgcagggcgt tgccggccgt ggaggtctct ggctggcaaa   1320 

gtggcaccga aagagtcctg tgtcataacc agactcactt gtagcttctg ttgctctccc   1380 

tagctatttg caaagcatcc caggat                                        1406 

 
           
             6  
             2675  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1079031.12001JAN12  
             
           
            6 

cgagcgaggg aggggggagc aggcccggcg cgctgctgtg gtgggccctg ctgctctgct     60 

ggcgaggaca ggactcagtg ccaagcgcag gaggggaggg agccccggtg ggcccggggc    120 

ctgcggaggg agccgagctc ttggtgcttt tcccgaagga gcgcgggagg cgcgacgggt    180 

ccggcgagtg cccggcatgg cggcttttcc agcctgcttt gtgttaagcc gaggtcctgg    240 

cttctctgtg tctcccagct gggggccatg aggctccctg agatgactct tttccccttc    300 

tcccaactcc gtggcgtgac tctcagccca ggtattgctg gtccgctgct caggacagat    360 

tccgggggct ggtcctcctg cctcctgggg ttgaggtggc gtcccgttct tctccgtggc    420 

ttggaggaaa ctacatcagg atggtggctg ggaacgtgta ggggccctca gaggcccctg    480 

tgtagttggt tgtcccctgt ctgctttctg gctttcagag atgagcggca tagaatcagg    540 

cgaggggttt ctgcttctga gccttagagt cttgtgagga gacccctccc tgatgtggtg    600 

gcacaggagc ctgggtgggg gcgggggtga ctgggagggc acacctgggg gacagcagcg    660 

gcgggagtgt ggtccgactg gcctggaaga tcttgggcag agctgacctc agagaacagt    720 

gcgggtctct cgccctcctg gggcagtccc caggacgagg tgccaggtgc ctggcccatg    780 

ttgcagcgcg gccgtgcgag cccatgcagg atcgacgtgg acccccagga agacccgcag    840 

aatgcacctg tacgtcaact acgtggtgga gaaccccagc ctggatctgg aacagtacgc    900 

ggccagctac agcggcctga ctgcgcatcg aacggctgca gttcattgct gatcactgcc    960 

ccacgctgcg ggtggaggcc ctgaagatgg ccctctcctt cgtgcagaga acctttaacg   1020 

tggacatgta cgaggagatc caccgcaagc tctcagaggc caccagggca ggctgcacga   1080 

acgcacccga cgccatcccg tgagagcggc gtggagcccc cagccctgga cacggcctgg   1140 

gtggaggcca cgcggaacga aggcgctgct tgaagctgga gaagctggac acagacctga   1200 

agaactacag agggcaacct ccagccgaag agagcatccg gcgcggccac gacgacctgg   1260 

gcgaccacta cctggactgt ggggacctca gcaacgccct tcaagtgcta ttcccggtgc   1320 

ccgggactac tgcaccagcg ccataacacg tcatcaacat gtgcctcaag tgtcatcaag   1380 

gtcatgcgtc taccttgcag aattggtctc atgtgctcag cctacgtcaa gcaaggctga   1440 

cgtccacccc agtagattgc cgagcagcag aggacgagcg tgatagccag accccaggcc   1500 

aatcctcagc aacgctcaat gtgtgccgcg ggcttggcag agctggccgc ctcgaggtcc   1560 

aagtcgaggc tgccaaggtg cctcctgcga ggctcccttt gatcactgtt gcacttccct   1620 

gtagctgctg tcccccatgc aggtggtcat ctacgtgtgg cctgtgcgcc ttggctacct   1680 

ttgaccggca ggagctgcag cagcaatgtc atctccagca gctccttcaa gttgttcttg   1740 

gagctggagc cacagtgtcc tgagacatca atcttcaaat tctacgagtc caagtacgcc   1800 

tcatggtctc aagatgctgg acgagatgaa ggacaacctg ctcctggaca tgtatctggc   1860 

cccccatgtc aggaccctgt acacccagat tcgcaaccgt gccctcatcc agtatttcag   1920 

cccctacgtg tcagccgaca tgcataggat ggcggcagcc ttcaatacca cggtggccgc   1980 

cctggaggac gagctgacgc agctaatcct ggaggggctg atcagttgcc cgtgtggact   2040 

cacacagcaa gatcctatac gcccgggaac gtggatcagc gcagcaccac ctttgagaag   2100 

tctctgttga tgggcaagga gttccagcgc cgcgcccagg cccatgatgc tgcgggcaac   2160 

tgtgctccgc aaacccagat cccaagtcaa gtccccccgc cccagagaag ggagcccggg   2220 

ggagactgac tcccagcgcc acagcccagt ccccggatga gccacccaca tagtgagggg   2280 

gtgtacctct ggcctccaac aggacatctt gcacacccct ccccaccctc caccggagcc   2340 

tcggaacctc cacggcggct cacagtgctg cctgacggcc cacgctaaag gggcctcggc   2400 

cacactgggt gcacaaccca gcccgttgtg cccctcccct ggggcctgaa ggaaggcaca   2460 

ggccggctgt ctatagtata gtggccacct tccctgtgaa aggaagaagg ccctgcacag   2520 

ggctctgaga cccctgtggg gtttcttgtc tcccacaggg agagcaagaa ctgttgccgg   2580 

cacacccaca ggcccacagt ggcacacata ttcccagaca ccctcctgtt cccgcctccg   2640 

gtcaggtgca gacaaatggg cggtgtccca tttaa                              2675 

 
           
             7  
             2370  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI306216.12001JAN12  
             
           
            7 

ggggggtcgc cgcggtgcta gctgctcagt gggagcgggt cttcgcaact gtctccgcgt     60 

ggcgcgcgcc tctagccgcc cttcccctgg cggctaacgg ccggagggag cggaggcaga    120 

gcgggagtcg ggctcccatg gagaagcggc ggacaactgg gcagaggcgg agcttttcaa    180 

tctcggcacc ctggtcccag tgacccgcgc tagctgtccc gtcccgcccg cgtcggagcg    240 

gccgccggcc ccgggactga ccggcctcgc cgcacctccc gcaccgacta gcgctcccgg    300 

gcgctcctgc gcccgactac gccctcgccc ccactccccg gcgggatggc ggcggccggg    360 

cccccacggc ggcggccgga gcagcagcag cagcagcagg agcccgcctc tatgatgaag    420 

ttcaagccca accagacgcg gacctacgac cgcgaggggc ttcaagaagc gggcggcgtg    480 

cctgtgcttc cggagcgagc aggaggacga ggtgctgctg gtgagtagca gccggtaccc    540 

agaccagtgg attgtcccag gaggaggaat gaaacccgag gaggaacctg gcggtgctgc    600 

cgtgagggaa gtttatgagg aggctggagt caaaggaaaa ctaggccaga cttctgggca    660 

ttaatttgag cagaaccaag gcccgaaagc acagaacata tgttcagtgt cctaacagtc    720 

actgaaatat tagaagattg ggaagattct gttaatattg gaaggaagag agagtggttc    780 

aaagtagaag atgctatcaa agttctccag tgtcataaac ctgtacatgc agagtatctg    840 

gaaaagctaa aagctggggt tggtccccca gccaactgga aattctacag tacccttccc    900 

ttccggataa taatgccttg tatgtaaccg ctgcacagac ctctgggtat gccatctagt    960 

gtaagatagc agagaactgg gtaggcctct cccaccatgt gcagtctcat ggggagaggc   1020 

ttctattcgt ttcctcgtca aacatctgat tgacgcttgc aaactgtctg aatttgccat   1080 

gcaaggtttt caaacaattt gcatgttgtg ctcagatgct ttcaaagtct ttttgttcaa   1140 

gaaaaatagt gtaaacatat tttcaataag ccaagagcca tgtggaattt tcgttctaga   1200 

tgccttaact gtgccatagc ccagaatccc ctatattatt ttggttgtct atttctcaca   1260 

gcatattttc agttttttgt ccatttgaca tcagtctgtg gtttattttg tcatcagatt   1320 

acttgtgggt atacctaccc caaaattgtt ttctcattca cagcattagc atattcagca   1380 

aatccatctg tggtgggaat taaaaatatt attcggtatt taaagaaatc cattcacccc   1440 

aaaacttgtt ttacaggatt acaattttaa ttcaaacact ttccagattg gggctatttc   1500 

tgtatgatcc aataacttca tttggtcaca gggtctgtaa ttgtgccagt ttatcgggga   1560 

tttgtcgact catttggtct gaattatgtc acaactggta ttatgtcact agctacctga   1620 

tacggctatt tcccttataa ctcaatagta ccttaagcac aagagtataa ctctgtatca   1680 

gttggtgaat attttaggga aatattagca aaactgcatg tagtaaagag catcttatga   1740 

aaactgtatt catggaattt gatttatgca tgctcagtgt gccagttccc attatcgata   1800 

ctcgtttctt tgcagaatac cgttagaacc gttatttccc tcagtgtaga ttgcgtctta   1860 

agaattattc agttatttag tggcccccac aggagtggag tcttgcaaat ctaattctaa   1920 

agtgccagtc agtgatgatc gccatcacca gattgagatg aaatggcctt ctctgttcca   1980 

gctgttagca ggactggaag attgttaggg ccacccttag aaatgtctca tctttttcta   2040 

ggttgtcaca caggtactaa tttgtcacag taactaactt tcgaggcacc tgggacatag   2100 

cctgaactaa gaattaaaat ctttttactt taataactca ctgtaaaatc cagaatcccc   2160 

atctaagaca cattaggtac cttattcttg aaactccttg cacttccccc acccgggcag   2220 

aaaatgaggt gggagaaagt ttgactaaaa tggagaggat gggggaaagt aaaagatgtt   2280 

attttatttt ttgaaactcg cttggctcac ccaggctgga gatgcaagag gccacaatca   2340 

tcaacatcac cgcaacctcc gcctcccggg                                    2370 

 
           
             8  
             4119  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI011799.12001JAN12  
             
           
            8 

gctacatttg aaagaaccag gtaggaggaa gatcccatcg gccttgcagt ccaccagacc     60 

aggtggttgg ttctctggcc tcatgggcac ctttgttact ggggactact gtcctataaa    120 

cggtattaga gagtggcttg caaggattgt ttgtcaagcc ctgcgagttg gtgccgagga    180 

cggagatttg atcatcaggt ttccccttcc tgaagctcga tgaagggtga tggtggcggt    240 

ggtgggttgt gcatgtgtgt ggcagatgga aaaacttccc gtgtgtgttt gtctatgtta    300 

ggtagtctct ggctgtgtcc acatgtctgt ctgtgcatca ctggtcagat gtctctgtgg    360 

atgtgtctat ttcgggggcg gcggcagggt gatgtgtaag ttatgcttcc atgtgcaagt    420 

gggtgtatat gttatatttg aaagtacctg tgaccaggtc tgcgtgcatc acacccacat    480 

aagttgtttt catgaggtta aactatatga taatacctcc ccccagcaaa gctggctatt    540 

gagttagcag gtcacgagct gagtctgtgt actgtagata aactgggtaa ttggactctc    600 

cgacctcttc atccaaaaca aacacaaaag cccgccccca caccggaggg agtctgtgcc    660 

cgtcatctgg gtgcttggtt ctagtgccct gctttccttg accccctgta gacaaggtga    720 

gcgcttccgc ggaggggctt ctgtacagag gtcacagcac gctgtgtccc gggacgcacg    780 

cggattcctg cacaggtgtg gtggctgcgg atggggacgg agcggagcag gctcgccggc    840 

ctcctccccg gcggcggctc cgcttctcct tcctgctgtt cacttcatct cctcatctgc    900 

atgtgtgaca gcggcgcgcg gactggggaa ggacagagcg ccctctcccc ggctcccgtg    960 

cagcggggcg ggggctccgg gctccccagt gatgcgtcgt ctgcgcctcg ccgccgcgct   1020 

ccccgggcct ggcagcgtaa gtgatgcggg ggcgggggcg ccgagactgc ggggaggggg   1080 

cgcggggaaa gagaggcgtc gacgccgaga gacgctaact ccttcctccg cccggggact   1140 

gcccggcacc ccgaacccct gaaagccccg gctgcggctt gcttcggcag tgtccgagca   1200 

gcgggtgggg agggggcggg gaccaagcag tgcagggtgt ggtgctgccc ccggggggcg   1260 

ccctccgccg ccgcgtcttc ccagtgaagt tgaccagggg ctgcggagcc catccgctgc   1320 

ccgccggagg gcgcgtggcc ccagctgccc ttgattcacc gcgttccccc cgcagggcca   1380 

ggcgtggacg ccgccggacc gctgagactc ggggcacggt gaagcactgg ccggggtctg   1440 

gctgggtccg gcgctcggga gccagatgga ggtggcgata ggggccgtgg gagccggcgc   1500 

caagtagccg gtggaccccc gcgctcgcac ctctcccggc gcccgggcgc tccccaaggc   1560 

tgccatggag gtgcctaacg tcaaggactt ccagtggaag cgcctggcgc cactgcccag   1620 

gcgccgggtc tactgctccc tgctggagac cgggggccag gtctatgcca tcgggggatg   1680 

tgacgacaac ggcgtcccca tggactgctt cgaggtctac tccccggagg ccgaccagtg   1740 

gaccgccttg ccccggctgc ccacagcccg ggcgggggtg tccgtcaccg ccctggggaa   1800 

gcggatcatg ggtgattggg ggcgtgggcg accaatcagc tggcccctgg agggtcgtgg   1860 

agatgtacaa catcgatgag ggcaagtgga agaagaggag catgctgcgt gaggccgcca   1920 

tgggcatttc tgtcacggcc taagattgac cgagtatatg cggcaggcgg gatgggcctg   1980 

gacctacgtc cacacaacca cctccaacac tatgacatgc tgaaggacat gtgggtgggc   2040 

ggtagcaccc atgccccacc ccgagatatg ctgccacctc cttcctgtcg aggctccaaa   2100 

gatctacgtg gctgggggga cgacagtcca agttacgcgg tgcaacgctt tcgaggtctt   2160 

tgacatcgag actcgctcct ggaccaagtt tccccaaatt tccctataag cgggccttct   2220 

ccagctttgt gaccctggac aaccacttgt acagcctagg aggcctgcgg caaggtcgcc   2280 

tctaacgggc aggcccaagt tccctgcgga cgaatggacc gttgttcgac aatggaacag   2340 

ggggggttgg ctgaagatgg aacgatcgtt ctttcctcaa gaaagcgggc gggcagcaat   2400 

ttgtgtgcgc tggctctctg agtggcacgg gtcatagtcg gctgggcgga cattgggaat   2460 

caacccactg tcctggagac gccggaagca tttccaccca gtggaagaac aaatgggaga   2520 

tcctccctgg ccatgcccac accccggctg tgcctgctac cagcatagtc gtcaagaact   2580 

gcctcctcgc ccgtgggacg gtcgtcaacc agggtctgag cgacgcacgt ggatggccct   2640 

gtgtgtctct gactccatta gctgtcttct gggctcagta ccttatgccc tgtgaccata   2700 

tcacttcaac tcttaacatg aggaatgatc ttgtcgcaag cagtcggggg ctacttccaa   2760 

gaatgtcagc tcctgtttag caaccaggag gaggtctggc ccttggggcc tctaagttga   2820 

ccgtctcgta tagctccaaa tccgtaccaa tctcagaaga actgtaagga ggcacaagat   2880 

gacgtccacc agcgtgcaga gcttgactct gaagagagtc ttcagcttac tgcagcaggc   2940 

aaaagaaagg cacaggaata tgttcctgac ctcgccctcc tgttgagtcc cacctgcccc   3000 

ccacccccat ctccaggagg ctaggtagag cagttctgat ccgagaggat agacgtgctg   3060 

ttgctgtctt tccccagctc tgaactagtt ttaaggtagc ttaggatgac acaatggacg   3120 

gatgattggg gggttccaaa ccactttctt ctcccttggc ttatatctct tcaccatttg   3180 

gctggtcaac tgtgggccta ccctggacct catctactca gcgagaattg gacatgaagc   3240 

tagaggcagc tgccttggaa agggagtcaa ggctccattt gtcaagccca ggccatggca   3300 

ggaagaatcc ctccctcctt ggggggtcct tgatggggca tgtagtgatg gggaaggagc   3360 

agtctcccag gcgcgcgtgg gtctgctctc gcgcacatct ctcctatagt tccagcgttc   3420 

agccgttttg ccatcccctg tccccacgca gatggcctag cccttgttgt caccgaaggc   3480 

ccccatgatg tgtttctggt gtgaaacacc tacttcattt acggctgttg gcactcgaga   3540 

gaagtccaca aaagatggat taattgcagc tctgtgttga atagcagcag caacaaatgg   3600 

attaaaatct atagttccta tcttctctag caccctggtg tgggggatgg ggcggaaggg   3660 

tgtcttgagg gggcacggga gggagcccca cttaaaccat ccctcctgca ttttcacggc   3720 

tataataggg cccccagtga ctacactgtt ctataggcat gtccccacta ctgaagaagg   3780 

ctctagccat tactacacag ccaccaccca gttggcccca ctccccagga aaacagcaca   3840 

tgttcgttct tctcctgcca ttgagactgc cgtgttagtc ttccaattca taactcatca   3900 

gcagctcagt gccttcatta tgtctagtct ccctccattc agccaaagct catttttgtc   3960 

ctatccaaag tacgaaaggg tttttttagg aaacttgtaa gaatgtgcct cctcgttagc   4020 

atctgtttct gactcccagt tatttttaca cataacatga tgaatacaat gcctgccctg   4080 

aagggttctg gaggagtcag tgtatcactc atcaaaaaa                          4119 

 
           
             9  
             1349  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI109467.12001JAN12  
             
           
            9 

aaataaaata aaataaaatg agacagcaac cacacacaaa aaaatactta taaaacagat     60 

tttaaaaaat attaatcaca taatgtctac tctcagacct cagtggaatt aaactgaaaa    120 

tcaatagaga aagataggct ctctgttcct tctgtgtgat aaaggacaca gcagcagcca    180 

tgcagcagca gccatgcagc agcagccatg tccctgagac agttggtgaa attgaaggtt    240 

gtagtaaaca catttggctg tactgggcat ctggtcaact gggctgcttt taactctggc    300 

aaagtggata ttgtcatcat cagtgacccc ttcactgact ccagctacat ggtctacatg    360 

ttccagtatg attccaccag tggcaagctc cacagcactg tcaaggctga gaatcacaag    420 

tttgtcatca gtggaaatcc tatctccatc ttccaggagc aagataccac caaaatcaaa    480 

tgcagtgatg ctggcactgg ttgtgttgtg gagtcaactg gtgtcttcac tatcttgtat    540 

atggctgggg cacacttaga ggagagagcc aaagagtcat catctctgct gcctttgacc    600 

ccctgtttga tgggcatgaa ccatgagaag tacgaaagca acctcacaat catcagcatt    660 

gcctcctgca ccaccaactg cttagcattc tctgaccaag atcatccatg atagctctgg    720 

catcatggag ggactcctga ccacagtccc tgctatcact gccacccagg agacctatgg    780 

atggcttttc tgggaaactg tgacgtcatg gttgtggagc tctgcagaac attattcctg    840 

catctactgg aacttccatg gctgtgggca aggacatccc tgagctgaat ggggagatca    900 

ctggcatggc cttcctcgtc cctaccacca atgtgtcagt tgtggacctg acctgctgtc    960 

tggagtaacc tgccaaatat gatggcttca agaagatggt gaagcaggca tcggaaggcc   1020 

cttcgagggc acactgggct acactgaaca ccaagttgtc ccctgtgact ttaacggtga   1080 

cactccctct tccactttta attctggggc tagcattgcc ctcagcaacc attttgtgaa   1140 

gttaatttcc tggtatgaca attagttttg ctacagcaac ggggtggtgg acctcatggt   1200 

ccacatggcc tccaaggaat aacagccctc cggactacca gccactagtg agagcacgag   1260 

agaaaaagag aggctctcag ctgctgagga gtaccctgcc tcactccgtc ccctcaccac   1320 

acccaacgaa gctcccctcc atccacagt                                     1349 

 
           
             10  
             1261  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1175250.12001JAN12  
             
           
            10 

cgacttcgcc ggagccggct cttcctgtta gtctccgctg ctagttcttg gctctgggag     60 

gcccaggtgg ctctgcagca gcctctgcca ccctgtgacc tgcatgtact gggggattcg    120 

cagggaggat gtcgggacac ccgggaagcc gaggaatgga ctcggtggct tttgaggatg    180 

tggctgtgaa ctttacccag gaggaatggg ctttgctaga ttcttctcag aagaatctct    240 

acagagaagt gatgcaggaa acctgcagga acctggcttc tgtaggaagc caatggaaag    300 

accagaatat tgaagatcac ttcgaaaaac ctgggaaaga tataagaaat catatcgtac    360 

agagactgtg tgaaagtaaa gaagatggtc agtatggaga agttgtcagc caaattccaa    420 

atcttgatct gaacgagaac atttctactg gattaataac catgtgaatg cagtatgttg    480 

tggaaaagtc tttgtacgtc atgccctccg taataggcat atcctagctg cactcaggat    540 

acaaaccata tggagagaag caatgataaa tgtgaacacg tgtgggaaat tcttcgtttc    600 

tgttccaggt gttagaagac acatgataat gcacagtgga aatccagctt ataaatgtac    660 

gatatgtggg aaagcttttt attttctcaa ttcagttgaa agacatcaga gaactcacac    720 

aggagaaaaa ccctataaat gtaaacaatg tggtaaagca ttcactgttt ccggttcttg    780 

tctaatacat gagacgaact cacactgtga gatggaaccc tacgtatgta aggaatgtgg    840 

gaataccatt agattctctt gttcttttaa gacgcatgaa aggactcaca ctggagaaag    900 

accctataaa tgtaccaaat gtgataaagc cttcagctgt tccacttccc ttcgttacca    960 

tggaagcatt cagtactgga gagagaccct atgagtgtaa acaatgtggc aaagccttta   1020 

gtcgtcttga gttccctttg taaccataga agtactcata ccggagagaa accctatgaa   1080 

gtgtaaacaa tgtgatcaag ccttcagtcg cctcaagttc ctttcacctc ccacgaaaga   1140 

attcatactg ggagaaaacc cctatgaatg taagaaatgc ggtaaagcct acactcgtta   1200 

ccagtcacct tacttcgcca tgaaagaagt catgatatag aggctgggtg tagtgactca   1260 

g                                                                   1261 

 
           
             11  
             481  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2121744.12001JAN12  
             
           
            11 

aatgtggact atcaagggag caagtggatg ccctggggct gagaggagtc ttctggtgca     60 

gtcttatttt gaaaaggggc cattgacgtt tagggatgtg gccatagaat tctctctgga    120 

ggagtggcaa tgcctggaca gtgctcagca gggtttgtat aggaaagtga tgttagagaa    180 

ctacagaaac ctggtcttct tggcaggtat tgctctcact aagccagacc tgatcacctg    240 

tctggagcaa ggaaaagagc cctggaatat aaagagacat gagatggtag ccaaaccccc    300 

agttatatgt tctcattttc cccaagacct ttgggcagag caggacatta aagattcttt    360 

tcaagaagcg attctgaaaa aatatggaaa atatggacat gacaatttac agttacaaaa    420 

aggctgtaaa agtgtggatg agtgtaaagt gcacaaagaa catgataaca aattaaacca    480 

g                                                                    481 

 
           
             12  
             1260  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1170908.12001JAN12  
             
           
            12 

gggaatgcat ggaagcactc acacttggca gaaactctat gaatgtagca atgtgggaaa     60 

gccttcagat ctgccccaaa tcttcaattg catggtagga ctcacactgg agagaaaccg    120 

tatcaatgta aggaatgtgg gaaagctttc ggatctgcct cacaacttcg aatccatcgt    180 

aggattcaca ctggagagaa accctatgaa tgtaagaaat gtgggaaagc cttcagatat    240 

gtccagaact ttcgatttca tgaaaggaca caaacacata agaatgcact ctggagaaag    300 

accttataaa tataagatat atgggaaaca cttttattct gccaagttat ttcaaacaca    360 

tgaaaaaatt cacactggag agaaacccta taaatgcaag caatgtggta aagccttaat    420 

tgttccagtt cctttcgata tctaaaagga ctcacagtgg agaaaaactc tatgagtgta    480 

agcaatgtgg gaaagtcttc agatctgtca agaacctttc aatttatgaa aggacacaca    540 

ctggagagaa accctatgaa tgtaagaaat gtggaaaagc gttccataat ttctcttctt    600 

ttcaaataca tgaaagttgc acagaggaga ggcgccctaa gaatgtaagc attgtgggaa    660 

agcattcata tctgccaaga tcgtttgaat acatgcaaaa cacacactgg agagaaacct    720 

atgaatgtaa ggaatgcaaa caagcattca attatttttc ttccttgcat atacatgaaa    780 

ggactcatac gagagagaat ccgtatgaat gtaaggattg tgggaaagca ttcagcttgc    840 

ttaattgctt tcatagacat gtaaagacac accagaagga aaccctatga atgtaagcaa    900 

tgtggcaaaa gctttcactt cttccagttc ttttcaatat catgaaagga ctcacactgg    960 

ggagaaaccg tatcaatgta agcaatgtgg gaaagccgtc agatcagcct caagacttca   1020 

aatgcatgga agcactcaca cttggcagaa actctatgaa tgtaagcagt atgggaaagc   1080 

cttcagatcg gctaggattc tttgaataca aataatgaat gtaaacaatt aactgtttat   1140 

aataactgta tactaacaaa tgttattctt tttaaataat taagaagcta taataaaata   1200 

tccattggtg tcatgtatta gatcaagctt ataatgttac attgttatta tttggatatt   1260 

 
           
             13  
             1551  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1173119.12001JAN12  
             
           
            13 

ccgagcaggg actgtacacg tgtccagcac atcttcacca gcaccaaaag gagcagatta     60 

gagagaaact ttctagaggg gatggaggaa gaccgacatt tgtgaagaac cacagagttc    120 

acatggcagg gaagaccttc ttgtgcagtg aatgtgggaa agcctttagc cacaaacata    180 

aactttctga ccatcagaaa atccacactg gagaaagaac ttataagtgc agcaaatgtg    240 

ggatattgtt tatggaaagg tccacactca atagacatca gagaactcac actggagaaa    300 

ggccttatga gtgcaatgaa tgtgggaaag cctttctttg taagtctcac cttgttcgtc    360 

accagacaat ccactctgga gaaaggcctt atgagtgcag tgaatgtggg aaattgttta    420 

tgtggagttc cacactcatt acacatcaga gggttcacac tggaaagagg ccttatggtt    480 

gcagtgaatg tgggaagttc tttaagtgca actcaaacct ctttaggcat tacagaattc    540 

atacaggaaa aaggtcttat ggttgcagtg aatgtgggaa attctttatg gaaaggtcta    600 

cactcagtag acatcagaga gttcacactg gagaaaggcc ttatgagtgc aatgaatgtg    660 

ggaaattctt cagcttgaaa tccgtcctca ttcaacacca aagagttcac actggagaac    720 

ggccttatga atgcagtgag tgtgggaagg ccttccttac aaagtcccac ctcatttgtc    780 

atcagacagt tcacactgca gcaaagcagt gcagtgaatg tgggaaattc tttaggtata    840 

actctacact tctcagacat cagaaagtcc acactggata aggcccttat gaatgcagtg    900 

gatatgggaa agccttcagt caccaacata ttgtggctgg acagcaggca gtacacactg    960 

gagaaagact gaatgccgtg aacgtgggta attatgtagg tacagctctc cagtcgctat   1020 

gtatcagaga attcacactg cagaaatgtg tgttcagcaa actcgggaca ttattttggt   1080 

ttgactctca tctcattaga cattggagag tttacactga agaagagtct tttcaataaa   1140 

gtagaaagtg gtaaagattc aacatgcaag attgtactta ttgggcttca gaatatccac   1200 

actagtgaaa gtcttctgag tacagcaaat gtgtgacatt attttgctac tactccacac   1260 

tacttagaca tcatgtagtt cacactggaa aaaggccacg tatgtgcctt gaatgtagcc   1320 

aaaatgatga acaacaccca gaaatctgtg atttagcact gagaactagt attatatggt   1380 

ttttaaaaaa caatggtgaa gtacatgcca cataaaattt gccatcttaa ctattgtaat   1440 

gtcttgttta atacttgaag tacattaaca ttgttgagca aagaatatcc tgaactcttt   1500 

atcttgtaaa atgaaactct ataaccacca ttaaaaaaac aactcattcc c            1551 

 
           
             14  
             2192  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1175131.12001JAN12  
             
           
            14 

tgcgaaggcc ctggctctcc tcggttcccg gctccaggcg gcgagctgag gttgggagcc     60 

tggntttccc ctccgagagg nttcaggtgc ctctgccata gcttctgtcg cctgtgctgt    120 

gacccgcact ggtcgtggga gtcacctgaa aggcaagaaa tggattcagt ggcctttgag    180 

gatgtggctg tgaccttcac ccaagaggag tgggctttgc tggatccttc ccagaaaaat    240 

ctctgtagag atgtgatgca agaaaccttc aggaacctgg cctctatagg gaaaaaatgg    300 

aaaccccaga acatatatgt agagtacgaa aatctaagga gaaacctaag aattgtggga    360 

gagagactct ttgaaagtaa agaaggtcat cagcatggag aaattttgac ccaggttcca    420 

gatgacatgc tgaagaaaac aactactgga gtaaaatcat gcgaaagcag tgtgtatgga    480 

gaagtaggca gtgctcattc atctcttaat aggcacatca gagatgacac tggacacaag    540 

gcatatgagt atcaagaata tggacagaaa ccatataaat gtaaatactg taaaaaacct    600 

ttcaactgtc tctcctctgt tcagacacat gaaagggctc atagtggaag gaaactctat    660 

gtttgtgagg aatgcggaaa aacatttatt tcccattcaa accttcaaag acacaggata    720 

atgcaccgtg gagatggacc ttataagtgt aaattttgtg gggaaagcct tgatgtttct    780 

cagtttggta tcttatccac aaacgaactc acgactggag agaaaccata tcaatgtaaa    840 

cgagtgtggt aaagccttta gtcattctag tagccttcga atacatgaaa gaactcacac    900 

tggggagaag ccttataaat gtaatgaatg tgggaaagca ttccatagtt ccacatgcct    960 

tcatgctcat aaaagaactc acactgggga gaagccatat gaatgtaaac agtgtgggaa   1020 

agccttcagc tcttcccatt cctttcaaat acatgaaaga actcacacgg gggagaaacc   1080 

atatgaatgt aaggaatgtg gaaaagcatt caagtgtccc agttctgttc gcagacatga   1140 

aagaacccac tctaggaaaa aaccctatga atgtaaacat tgtgggaaag tattatctta   1200 

tcttaccagc tttcaaaacc acttgggaat gcacactgga gagatatctc ataaatgtaa   1260 

gatatgtggg aaagcctttt attctcccag ttcacttcaa acacatgaaa aaactcacac   1320 

tggagagaaa ccctataaat gcaaccaatg tggtaaagcc tttaattctt ccagttcctt   1380 

ccgatatcat gaaagaactc acactggaga gaaaccttac gagtgtaagc aatgtgggaa   1440 

agccttcaga tctgcctcac tccttcaaac acatggtagg actcacacgg gagagaaacc   1500 

ctatgcatgt aaggaatgtg gaaaaccatt tagtaatttc tctttctttc aaatacatga   1560 

aaggatgcac agagaagaga agccgtatga atgtaagggt tatgggaaaa cattcagttt   1620 

gcccagttta tttcatagac atgaaaggac tcacactgga ggaaaaacct atgaatgcaa   1680 

gcagtgtggc atgatccttc aactgttcga gctcctttcg atatcatgga aggactcaca   1740 

ctggagagaa accctatgaa tgcaagcaat gtggaaaagc cttcagatct gcctcacagc   1800 

ttcaaattca tggaaggact cacactggag agaaacctta tgaatgtaag cagtgtggga   1860 

aagcctttgg atctgcctca caccttcaaa tgcatggaag gactcacact ggagagaaac   1920 

cctatgaatg taagcagtgt gggaagtctt ttggatgtgc ctcgcgactt caaatgcatg   1980 

gaaggactca cactggagag aaaccgtata aatgtaagca atgtgggaaa gcttttggat   2040 

gtccctcaaa ccttcgaagg catggaagga ctcacactgg agagaaaccc tataaatgta   2100 

accaatgtgg taaagtcttt agatgttctt cacaacttca agtgcatgga agggctcact   2160 

gcatagacac cccataaccc caggctttag ga                                 2192 

 
           
             15  
             584  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1174107.22001JAN12  
             
           
            15 

gggcgggtct tcactgctct gtgtcctcag cgtgtgtggc ttcgtgacct gaagatactg     60 

ggaaatccat agctaagatg ccaggacccc ctgaaagcct agacatgggg ccgttgacat    120 

ttagggatgt ggccatagaa ttctctctgg aggagtggca atgcctggac actgctcagc    180 

aggatttgta taggaaagtg atgttagaga actacagaaa cctggtcttc ttggcaggta    240 

ttgctgtctc taagccagat ctggtcacct gtctggagca aggaaaagat ccctggaata    300 

tgaagggaca cagtacggta gtcaaacccc caggttttct taccgccatc tgtgacagct    360 

tcttgatctg tcccaagtta tatgttctca ttttgctgaa gacttttgcc cagggccagg    420 

cattaaagat tcttttcaaa aagtgatact gagagaatat gtaaaatgtg gacataagga    480 

tttacagtta agaaaaggat gtaaaagtat gaatgagtgt aatgtgcaca aagaaggtta    540 

taatgaacta aaccagtatt tgacaactac ccagagcatt gcgg                     584 

 
           
             16  
             3152  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI901832.12001JAN12  
             
           
            16 

gggagggctg gagcgagggt ggactggagg tgccgcttgt cctggaggtg ggagagaggg     60 

agcggctttg ccgcctggcc tgcgtcctaa tcctgtcctg gttcttctgc tcccgaaggg    120 

aacgtaggtc ccgcgcctgt gataagtaag gttggatttt ctcttccctg aggtgaagga    180 

tgcccggagg cctcggcagg accgcgcgga aacgggcctt ctgcccaaaa gatgctgctt    240 

ctctccttat tctttcccct cagaatctcg ctgtctcctt ccaaccacct gtggtcggca    300 

tccccgcgtt gtcactgcga cgcagaggcg agcgaggtgg cgggaagcac ccgcggggcg    360 

gggagggacc ctgcgggcgc ggactccaca ccaagcctct gctcagcgtc accccgcttg    420 

ctgtgtcctc gcaggtcgca gcttcatggc ctgatgcctt caggaagtat tttgaagtca    480 

tcgtggctgt ggattggggg atttcttgtt tccactgacc tgtgaggccg cgcacgtgga    540 

gggaggcacc ccgggtcctc cggcactgtc cggcctcgcc tgtgtcccta gtagcagtgg    600 

gcatttccag acggtgcagc ttgtggctaa agtgacagga agatgtagga gctttcagtc    660 

ttggatgagg attcgaactg aagggcttag gcccagctgt cttggagcaa aacatctgtt    720 

gtgggatgtg gcggcagagg agggcaaggc cgaaggagca gacagcaccg cttcttgggg    780 

agttgtgaag gcatcatgcg gagggccgag cttagcagcc aagtggagga cagcaccctc    840 

catgcctgga ttcgttactc gctcgttctc gatgttgagc tgctggcata ttgcagcaca    900 

actagagatg tacggatgcc cccatcttga tcttacagaa tcagaggtgc agccgcaaga    960 

aagagtcaag aacagacact gagtcgcttg aggactcagg caggtgtttg ctgcattgac   1020 

aacagactac accctctcgg ttttctctgc tctgccaaca ctagtggaat atgatcacat   1080 

cccagagttt cacatctttt atgcccatgg ctggagatac agaggtgcga tcttggctca   1140 

ctgcaacatc tgcctcctgg atattacaag atgattctcc tgtcttagac ctcctgagat   1200 

agcatgggat tacagggatc agtgtcattt agggatgtga ctatgggctt cactcaagag   1260 

gagtggcatc atcttgaccc tgctcagagg accctgtaga ggaatgtgat gctggagaac   1320 

tacagccacc ttgtctcagt agggtattgc attcctaaac cagaagtgat cctcaaattg   1380 

gagacaggca aggagccatg gatattagag gaaaaatttc gaagccagag tcatctgggt   1440 

gagttagtgc cagatggaat ttaaagaatt aattaatacc agtagaaact attcaagaat   1500 

gaagttcaat gagtttaaca aaggtggaaa atgtttctgt gatgaaagca tgaaataatt   1560 

cattttgaag aggaaccttc tgaatataat aacaatggga acagcttctg gctgaatgaa   1620 

gacctcattt ggcatcagaa gattaaaaat tgggagcaac cttttgaata caatgaatgt   1680 

gggaaagctt tccctgagaa ttcactcttc cttgtacata agagagctta cacaggacag   1740 

aaaacatgca aatatactga acatgggaaa acctgttata tgtcattttt tattactcat   1800 

cagcaaacac atccaagaga gaaccactat gaatgtaatg aatgtggaga aagtatcttt   1860 

gaggaatcca ttctctttga acatcagaat gtttacccat tcagccagaa tttaaatccc   1920 

actctaattc agagaaccca ctcaattagc aatattattg aatataatga atgtggaacc   1980 

tttttcagtg aaaaattagc ccttcattta caacagagaa cacatccagg ggaaaaacct   2040 

tatgaatgtc atgaatgtgg aaaaaccttc acccagaagt cagcccacac aagacatcag   2100 

agaacacaca cagggaaaac cctatgaatg tcacggatgt gggaagacct tctataagaa   2160 

ttcagacctc attagaaatc aaagaattca cacaggggag agaccttaca gatgtcatga   2220 

atggagaaat ccttcagtga aaagtcatcc cttactcaaa atcagagaac acacgtgggg   2280 

agaaatcatg aatgtcatga atgtgggaaa acctcgttta agtcagttct aactgtgcat   2340 

cagaaaacac acaggggaga agccctatga atgctatgca tgtggcaaca cctttctcag   2400 

aaaatccgac ctcattaaac atcagagaat tcacacagga gaaaaacctt atgaatgtaa   2460 

tgaatgtggg aagtcattct ccgagaagtc aacccttact aaacatctaa gaacacacag   2520 

atgggaaatc ttatgcatgt attcaatgtg gaaaattttt ctgctgctac tacagtttca   2580 

cagaacatct gagaagacac acaggggaga aaccttttgg atgtaatgaa tgtgggaaaa   2640 

ccttccatca gaagttggcc ctaattgttc accagagaac tcatataaga cagaaaccct   2700 

atggatgtaa tgaatgtgga aaatcattct gtgtgaagtc aaaactcatt gcacatcata   2760 

gaacatacac aggggagaaa ccctatgaat gtaatgtttg tggaaaatta ttattaagtc   2820 

aaaactaact gtacatcaca gaacacactt gaggtgaaac cctataaatg tagtaagtga   2880 

gggaaattac tctgggtgaa gtcagaactt tgtagagcag agaacataaa gggtgagaga   2940 

aatctgttaa tataatgata atgagaacac ctttgccctg aagtcagttc tcacagtaga   3000 

gaagagaact taaagaggga aaaaacaata tgaagatatg gaatgcagga aaacattatt   3060 

ctgggatttg ggccatagat tatgtttaag aactaaaagt gaaaaaacac ttattggtga   3120 

atgaatatgg acacattttg ctcaatgcac ac                                 3152 

 
           
             17  
             631  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1091903.12001JAN12  
             
           
            17 

ggcaaccgaa ggcagtcttt agctctcatg gattgggagc tgggaaagga atgagaagac     60 

agaagtcaga gacaagaaga ggctaacatg actgatacca ctataattta gtgaactgcc    120 

tcttttctaa agaggactcc aaaggaagga ctggtcatct ctttcatatc tcaaaaccat    180 

ggctcaggga tcagtgtctt tcaatgatgt gactgtggac ttcactcagg aggagtggca    240 

gcacctggat catgctcaga agactctata tatggatgtg atgttggaaa actattgcca    300 

cctcatctct gtggggtgtc acatgaccaa acctgatgtg atcctcaagt tggaacgagg    360 

agaagagcca tggacatcat ttgcaggtca tacctgcttg ggtggagagg atggcctaac    420 

tggatgttta tcctagcgtc aacccaccaa agatttgggg aacatgtgag tcacattctc    480 

tgggacattc tactcccctt tgattttgca tttccagaca tttcagtggc taccacaaaa    540 

aataaaaagt atctgtggca tcactgaaaa aaaaaaaaac aacacaaccc ccaccacgca    600 

aacaacaaaa acacacaaaa cacaacaaaa c                                   631 

 
           
             18  
             1129  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1089543.22001JAN12  
             
           
            18 

ttcggctcga gcatttttct cctcttctcc ttttatgtga aattttgaac tctcccctta     60 

gccacttggt gaaatgtgtt tttcatttta ggtacggttg acatttaggg atgtggccat    120 

agaattctct ctggaggagt ggcaatgcct ggacatggct cagcagaatt tatataggga    180 

cgtgatgttg gagaactaca gaaaccttgt ttctctggga ctgtgtcatt ttgatatgaa    240 

tattatctcc atgttggagg aagggaaaga gccctggact gtgaagagct gtgtgaaaat    300 

agcaagaaaa ccaagaacgc gggaatgtgt caaaggcgtg gtcacagata tccctcctaa    360 

atgtacaatc aaggatttgc taccaaaaga gaagagcagt acagaagcag tattccacac    420 

agtggtgttg gaaagacacg aaagccctga cattgaagac ttttccttca aggaacccca    480 

gaaaaatgtg catgattttg agtgtcaatg gagagatgac acaggaaatt acaagggagt    540 

gcttatggcc cagaaagaag gtaaaagaga tcaacgcgac agaagagaca tagaaaacaa    600 

gcttatgaac aatcagcttg gagtaagctt tcattctcat ctgcctgaac tgcagctatt    660 

tcaaggtgag gggaaaatgt atgaatgtaa tcaagttgag aagtctacca acaatggttc    720 

ctcagtgtca ccacttcaac aaattccttc tagtgtccaa acccacaggt ctaaaaaata    780 

tcatgaactt aaccattttt cattactcac acaaagacga aaagcaaaca gttgtggaaa    840 

accttataaa tgtaatgaat gtggcaaggc gttcactcag aattcgaacc ttacaagtca    900 

taggagaatt catagtggag agaagcctta caaatgcagt gagtgcggca aaacctttac    960 

tgttcgttca aatctaacta ttcatcaggt catccatact ggagaaaaac cttacaaatg   1020 

tcatgagtgt ggcaaggtct tcaggcacaa ttcatacctt gcaactcatc ggcgaattca   1080 

tactggagag aaaccttaca agtgtaatga gtgtggaaaa gcctttaga               1129 

 
           
             19  
             1250  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2049137.12001JAN12  
             
           
            19 

ggaggtgaga tattttggtc cccaggagaa ctggctcagg tctncaagtt cccatccggg     60 

atgactggaa agggttagga aacctctctg aggtctggtc agattccaac cctggacagc    120 

agtgaacaca acctttcccc tgagccactg gaattggaca gaatgcccca ttctcctctg    180 

atctccattc ctcatgtgtg gtgtcaccca gaagaggagg aaagaatgca tgatgaactt    240 

ctacaagcag tatccaaggg gccggtgatg ttcagggatg tttccataga cttctctcaa    300 

gaggaatggg aatgcctgga cgctgatcag atgaatttat acaaagaagt gatgttggag    360 

aatttcagca acctggtttc agtgggactt tccaattcta agccagctgt gatctcctta    420 

ttggaacaag gaaaagagcc ctggatggtt gatagagagc tgactagagg cctgtgttca    480 

gatctggaat caatgtgtga gaccaaaata ttatctctaa agaagagaca tttcagtcaa    540 

gtaataatta cccgtgaaga catgtctact tttattcagc ccacatttct tattccacct    600 

caaaaaacta tgagtgaaga gaaaccatgg gaatgtaaga tatgtggaaa gacctttaat    660 

caaaactcac aatttatcca acatcagaga attcattttg gtgaaaaaca ctatgaatct    720 

aaggagtatg ggaagtcctt tagtcgtggc tcactcgtta ctcgacatca gaggattcac    780 

actggtaaaa aaccctatga atgtaaggaa tgtggcaagg cttttagttg tagttcatat    840 

ttttctcaac atcagaggat tcacactggt gagaaaccct atgaatgtaa ggaatgtgga    900 

aaagccttta agtattgctc aaaccttaat gatcatcaga gaattcacac tggtgagaaa    960 

ccctatgaat gtaaagtatg tggaaaagcc tttactaaaa gttcacaact ttttctacat   1020 

ctgagaattc atactggtga gaaaccttat gaatgtaaag aatgtgggaa agcctttact   1080 

caacactcaa ggcttattca gcatcagaga atgcatactg gtgagaaacc ttatgaatgt   1140 

aagcagtgtg ggaaggcttt aatagtgcct caacacttac taaccatcac agaattcatg   1200 

ctggtgagaa gctctatgaa tgtgaagaat gtggaaaggg ctttattcag              1250 

 
           
             20  
             379  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1171755.92001JAN12  
             
           
            20 

gtgaatgtgg gaagttattt agagatatgt ccaacctttt tatacaccaa atagttcaca     60 

ctggagaaag gccttacggg tgtagtaact gtggaaaatc ctttagccgt aatgctcacc    120 

tcattgaaca ccagagagtt cacactggag aaaagccttt tacatgcagt gaatgtggaa    180 

aagctttcag gcataattcc acacttgttc agcatcacaa aatccacact ggagtaaggc    240 

cttatgagtg cagtgaatgt ggaaaattgt ttagtttcaa ctccagcctc atgaaacatc    300 

agagagttca cactggagaa agaccttata aggttggact tgtggctata gaattttcca    360 

cattcactgc acttataag                                                 379 

 
           
             21  
             934  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI208529.122001JAN12  
             
           
            21 

ccgtccgtag tggggcggct ggaggcgggg gtgccttcat cgtcctgcct ctggccaaga     60 

cagggcgagt ggataagaac tacccactgg tcactgggca cactgcccct gtgctggata    120 

ttgactggtg tccacacaat gacaacgtta tcgccagtgc ctcagacgac accaccatca    180 

tggtgtggca gattccagac tataccccca tgcgcaacat tacggaacct atcatcacac    240 

ttgagggcca ctccaagcgt gtgggcatcc tctcctggca ccctactgcc aggaatgtcc    300 

tgctcagtgc aggtggtgac aatgtgatca tcatctggaa tgtgggcacc ggggaggtgc    360 

tgctgagcct ggatgatatg cacccagacg tcatccacag tgtgtgctgg aacagcaacg    420 

gtagcctgct agccaccacc tgcaaggaca agaccttgcg catcgttgac cccagaaaag    480 

gccaagtggt ggcggagagg tttgcggccc acgaggggat gaggcccatg cgggccgtct    540 

tcacgcgcca gggccatatc ttcaccacgg gcttcacccg catgagccag cgagagctgg    600 

gcctgtggga cccgaacaac ttcgaggagc cagtggcact gcaggagatg gacacaagca    660 

acggggtcct attgcccttt tacgatcccg actccagcat cgtctacctg tgtggcaagg    720 

gcgacagcag cattcggtac tttgagatta ccgacgagcc gcctttcgtg cactacctga    780 

acacgttcag cagcaaagag ccgcagcggg gcatgggttt catgcccaaa aggggactgg    840 

atgtcagcaa gtgtgagatc gcccggttct acaagctaca cgaaagaaag tgtgaaccta    900 

tcatcatgac tgtgccctcc tcattacggt cgaa                                934 

 
           
             22  
             2509  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI024125.62001JAN12  
             
           
            22 

tcacctctga caccaaagcg aactcctgca acagaagaac tggtcttagg gctcaaatca     60 

gtggccagta ttagactaac agatgagggg aagtggggac cctacagaaa gcaaacacag    120 

cttcctggaa acaccaaggg cctcctccat ccaaaaacaa ctttcttctc aactgtctcc    180 

aaaagcctag atgttttttg acattgtggc acctggcaca gccagcccac gggactggga    240 

agacccatgt tcccagctcc ctggcgacaa cggcgacaag gccatgcacc cggtgcttac    300 

tggatgccag cccctgtgct aattgctctt tatgtccagg tcaaatggaa atctcctaac    360 

aaccttttgg tggaagagtc agaagacttc tgaggacatt aatattcaat gactattaat    420 

gaagagaccc taaagatcat cttcttaagc cctcagacga cagaaaggga aactgaggcc    480 

tgggacttgt atacttttcc aaagcctctt ctttgccagg ttttgcacct tcctctaaga    540 

catcttttct tttccatctc ataattctgg atgcaaatga actcatagct catggaaact    600 

ataaacccat aaaaatgcac aaaaggacat taacaaaata ttacctaaaa gtttccagaa    660 

cttcatcaac cttcttcctg atccataagt gcatccacag atcccaggtt gagcaggcct    720 

gcttccaaca atacccacat tgttggatgt aaattcttac acaaagactc actcggggaa    780 

cttcgtccct ttctagttct agatcgcgag ctagaactag tcatgggaat catggcagca    840 

tccaggccat tgtcccgctt ctgggagtgg ggaaagaaca tcgtctgcgt ggggaggaac    900 

tacgcggacc acgtcaggga gatgcgcagc gcggtgttga gcgagcccgt gctgttcctg    960 

aagccgtcca cggcctacgc gcccgagggc tcgcccatcc tcatgcccgc gtacactcgc   1020 

aacctgcacc acgagctgga gctgggcgtg gtgatgggca agcgctgccg cgcagtcccc   1080 

gaggctgcgg ccatggacta cgtgggcggc tatgccctgt gcctggatat gaccgcccgg   1140 

gacgtgcagg acgagtgcaa gaagaagggg ctgccctgga ctctggcgaa gagcttcacg   1200 

gcgtcctgcc cggtcagcgc gttcgtgccc aaggagaaga tccctgaccc tcacaagctg   1260 

aagctctggc tcaaggtcaa cggcgaactg agacaggagg gtgagacatc ctccatgatt   1320 

ttttccatcc cctacatcat cagctatgtt tctaagatca taaccttgga agaaggagat   1380 

attatcttga ctgggacgcc aaagggagtt ggaccggtta aagaaaacga tgagatcgag   1440 

gctggcatac acgggctggt cagtatgaca tttaaagtgg aaaagccaga atattgagtt   1500 

atttcttaac aagtttcgag agagaaggga gcaagacaag agcaagcaac ggctattaaa   1560 

tgtcacaatc ctttaattag aaaccattta ttggccggac gcggtggctc acgcctgtaa   1620 

tcgcagcact ttgggaggcc gaggcgggcg gctcacgacg tcaggagatc cagaccatct   1680 

tggctaacag ggtgaaaccc cgtctctact aaaaatacaa aaaattagcc gggcgtggtg   1740 

gcgggcgcct gtagtcccag ctactctgga ggctgaggca ggagaatcaa ttgaacccgg   1800 

gaggcggagc ttacagtgag ctgagattgc gccactgtac tcctgggcaa cagcgagact   1860 

ccgtctcaaa aaaaaaaata aaaaaaagga acccttttat tttaaaaatg attagattgc   1920 

tatgcctcaa ctcatagaag atgaaccctt caagaaaacg tgaagtagaa cgggtgggcc   1980 

agaaatgaaa acaggcaagt aaagtatttc ttcggaaaac attttatcaa accaaatgtt   2040 

aaaaagactt tccttttgta aaactggatt agagaagact tttcagtggg ttatctctag   2100 

gatgatcagt agttcagcac ttaaaaactg cagagaaaac tgaaagttat gttccagata   2160 

actttccgtt gtttaccaaa ttttcttaga tttggtcatc atcaggaagc atttgtaaaa   2220 

ataaaaatct ccacaaatta ctggcccatc tcggacttgc tgaatcaatt tgataggatt   2280 

aatctccagt gaagctgtgt ttacagggca ttccaagtga ttcttatcag gaaatgtgaa   2340 

aaacactcct gtacataatc ggttaattta aaattttact taataagtga acaagtaatg   2400 

aagatttcac ctgtttactt agggtatcta cccagaccca tcgattctga gttcgggaga   2460 

tgattttgaa attactgttt tccaaataaa ggtgctccct tctaagtgg               2509 

 
           
             23  
             734  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI235557.122001JAN12  
             
           
            23 

ctccaaccct gcagatgcct ttgataatga tttgatgcac aggactctga agaacatcgt     60 

ggagggcaaa acggtggagg tgccgaccta tgattttgtg acacactcaa ggttaccaga    120 

gaccacggtg gtctaccctg cggacgtggt tctgtttgag ggcatcttgg tgttctacag    180 

ccaggagatc cgggacatgt tccacctgcg cctcttcgtg gacaccgact ccgacgtcag    240 

gctgtctcga agagttctcc gggacgtgcg ccgagggagg gacctggagc agattctgac    300 

gcagtacacc accttcgtga agccggcctt cgaggagttc tgcctgccgc agcagagcat    360 

ctgacaggga atgagagtca gcattgagcc aatgagtggt tggatgaggg aacaaagaag    420 

tatgccgatg tgatcatccc acgaggagtg gacaatatgg ttgccatcaa cctgatcgtg    480 

cagcacatcc aggacattct gaatggtgac atctgcaaat ggcaccgagg agggtccaat    540 

gggcggagct acaagcggac nttttctgag ccaggggacc accctgggat gctgacntct    600 

ggcaaacggt nacatttgga gnccagcnnc cgtccgtcca ggntcaccca cagtagtgat    660 

gcagacgtga cgtgggggaa gggggctgag ccctgtggct gggttctgac aactgtaacg    720 

gttttgtcga gctt                                                      734 

 
           
             24  
             484  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI178860.12001JAN12  
             
           
            24 

cctggcaaag ctgctgccca gagtggaatc tcactagtga ataaacaagc ccaagaaaga     60 

ttatcatctc atttgcaaaa aaaaaaagta cgctggtaga tcctgctacc tcatagataa    120 

caccagtcaa attttttttt aaagtagcat tttcctacat tgtcaactat ctagaacata    180 

cctaaaaact aagagtttac tgcttattaa atggaaacta tgaagtctaa ggccaactgt    240 

gcccagaatc caaattgtaa cataatgata tttcatccaa ccaaagaaga gtttaatgat    300 

ttggataaat atattgctta catggaatcc caaggtgcac acagagctgg cttggctaag    360 

ataattccac ccaaagaatg gaaagccaga gagacctatg ataatatcag tgaaatctta    420 

atagccactc ccctccagca ggtggcctct gggcgggcag gggtgtttac tcaataccat    480 

aaaa                                                                 484 

 
           
             25  
             2537  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI405798.12001JAN12  
             
           
            25 

gctggcccag tacctgccaa gcccaccact tccacctggg ccctacaccc ccacaatgtg     60 

tacccctctt atctgccctg gagcctgtac agccatgcca cgctacccct gagagtctag    120 

aaagctggtc actaactttg cagacggatg agccttgagc acccagagga gactggggct    180 

gtcaacgctg ccccttgtcc tgccggcttg gatcccctga cagggtcctt ctaggcttca    240 

gactggcacc ctgaccatgg aaccctgaag tggcagtgac ttctagagct cagtggcaga    300 

ccccacgacc cttcctcccc cttcctcccc ctcccaccac cagctttcaa gctcccagag    360 

ggaggggtgg ggaggggatc ctgatctcac agggcagggg gcttccatca tgatgctcaa    420 

ctcagacacc atggagctgg acctgccgcc cacccactca gagactgagt cgggcttcag    480 

tgactgtggg ggcggggcgg gccctgatgg tgccgggcct gggggtccgg gagggggcca    540 

ggcccgaggc ccagagccgg gagagcctgg ccggaaagac ctgcagcatc tgagccgcga    600 

ggagcgccgg cgccggcgcc gcgccacagc caagtaccgc acggcccacg ccacgcgaga    660 

acgcatccgc gtggaagcct tcaacctggc cttcgccgag ctgcgcaagc tgctgcctac    720 

gctgcccccc gacaagaagc tctccaagat tgagattctg cgcctggcca tctgctatat    780 

ctcctacctg aaccacgtgc tggacgtctg aactcagcct gtctcccacc tcccgggcct    840 

ctctggggcc cctttccacc gctcactgct tagaaaggcc gcatcctccc cgagccctta    900 

taccttggca tggagtccca aaggccctgg gcacaggcag agagcccacc ggctggtcat    960 

gagggcctct tcctttctct gacccaggca tcctcgaggg ctattctcct gggttccttc   1020 

cggggtttat tgctgaggcc cagctgtgca gaattgtttg ctagtgtggt tggtatggaa   1080 

tccttgctgg ctttactaag ccagccacac ttggagtctg cccccaagct ctctcactga   1140 

atgctgcctc ttctacccct atgtccaaat tttcagccac cacagacctc agctgtgtat   1200 

cctatctgtt ctagcttctc ctgcccctgg tggggatggg ctgtcagaat tgcaagggag   1260 

gaaggctggg gttagagtgg ggagtgggct tcttcctcca agatctcagt ctctcagtgc   1320 

ttggcagagg ggtgaggccc tggggaggca ggggttggtg ccctgactcc tgtgagggga   1380 

atctcagtag ctgggaatta tggaaaaact cttcctgttt ctgtccatct tgttcctgtg   1440 

gcttagcaca tacagacctc agatcttact tggtagtgag tgccttgccc tctttgagct   1500 

atttggctac ttccctgtcc ctctgactcc tactgtccca attttctccc tccctgtgtg   1560 

tcactagaga aaaaaaaaaa caaaaaccta gattccggat taggggatga catcccaaac   1620 

agcccggagt atttgcagaa ggctcaggca acgagtgggc cacatctcac ttctgcttcc   1680 

tcatctcagc ccactctgaa aatgtgcagc accctcactg gttcctcccc ccaacgcaag   1740 

gaggatgccc aattgttgcc ctctaaaaat gcacagttct cctggcccta ggacttactt   1800 

attacatttt tttctctttc cttgagctgc ctttggcaag ggaagagacc cccaactctg   1860 

cgcccctact ccatgctgct gatccccacc tgcgcactat agcgcagggt cagcagtgga   1920 

atgaagggcc ttagaacctg catagaagaa atgaactcac tgcatttctg tgctccctcc   1980 

tccctcgcac caaactccta gctctacaag tatatttatt tatttattta tttattcatc   2040 

tatttattta cttattnatt tatttataaa tattgctatt tattgccgag ttgtgcactt   2100 

tggggtagag tgaggggctc ccagcagctc tagctgggtc tctcttgctt cctccctgct   2160 

tacgcctttc cttttcttgc tcccttcttc aactcctggt gtgtgtgagc atgccctttg   2220 

cttgccacac catatccttt ccccagatcc acctgtcctg acactctagt cctccaggat   2280 

agtgctcctc ccccagctcc agggctcctg gatgtccttc ctcaactccc tccaccccta   2340 

gacaatccta cctggtccca tctgcctctt ttctctcccc agcctgccct gtgacccttg   2400 

cctcttcctg atactcccaa gagcaggccc caggggtctg tgtcacatat ctctgtgtga   2460 

ttccttctgg ttgcatcccc aatttcatac aaaaagaaaa ataaaagtga cctcgttcta   2520 

gcaccaaaaa aaaaaaa                                                  2537 

 
           
             26  
             1041  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1071427.1012001JAN12  
             
           
            26 

gggcataccc ctcgtagatg ggcacagtgt gggtgacccc gtcaccggag tccatcacga     60 

tgccagtggt acggccagag gcgtacaggg atagcacagc ctggacctga ctgactacct    120 

catgaagatc ctcaccgagc gcggctacag cttcaccacc acggccgagc gggaaatcgt    180 

gcgtgacatt aaggagaagc tgtgctacgt cgccctggac ttcgagcaag agatggccac    240 

ggctgcttcc agctcctccc tggagaagag ctacgagctg cctggccggg acctgactga    300 

ctacctcatg aagatcctca ccgagcgcgg ctacagcttc accaccacgg ccgagcggga    360 

aatcgtgcgt gacattaagg agaagctgtg ctacgtcgcc ctggacttcg agcaagagat    420 

ggccacggct gcttccagcc ttccttcctg ggcatggagt cctgtggcat ccacgaaact    480 

accttcaact ccatcatgaa gtgtgacgtg gacatccgca aagacctgta cgccaacaca    540 

gtgctgtctg gcggcaccac catgtaccct ggcatgccga caggatgcag aaggagatca    600 

ctgccctggc acccagcaca atgaagatca agatcattgc tcctcctgag cgcaagtact    660 

ccgtgtggat cggcggctcc atcctggcct cgctgtccac cttccagcag atgtggatca    720 

gcaagcagga gtatgacgag tccggcccct ccatcgtcca ccgcaaatgc ttctagcgcg    780 

gactatgact tagttgcgtt acaccctttc ttgacaaaac ctaacttgcg cagaaaacaa    840 

gatgagatgg catggcttta tttgtttttt tggtttggtt tgggtttttt tttttttttg    900 

ggggtggact caggatttaa aacacgggaa cgggtgaagg gtgacagcag tcggtgggag    960 

cgagcatccc ccaaagttca caaggtggcc gaggacttgg atggcccatg gtgggtttta   1020 

aatagtcatt ccaaatttga g                                             1041 

 
           
             27  
             950  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1072276.12001JAN12  
             
           
            27 

ggcagcgact gcgcgcctga actctagcgg agccgggttg attttctaaa cgcttcaaaa     60 

tcctaagact cagcactgtt gcggggagca cagggcatca cgttgtcctt gttttttttt    120 

ggtcttttct tcatttgaag attaagtatt ggagccatgg gaataaaggt tcaacgtcct    180 

cgatgttttt ttgacattgc cattaacaat caacctgctg gaagagttgt ctttgaactt    240 

attttctgac tgtgtgcccc aaaacatgcg agaactttcg ttgtctttgt acaggtgaaa    300 

aggggaccgg gaaatcaact cagaaaccat tacattcata agagttgtct ctttcacaga    360 

gttgtcaagg attttatggt tcaaggtggt gacttcagtg aacggaaatg gacgaggcag    420 

gggaatctat ctatggagga ttttttgaag acgagagttt cgctgttaaa cacaacaaca    480 

gaatttctct tgtcaatggc caacagaggg aaggatacaa atggttcaca gttcttcata    540 

acaacgaaac caactcctca ctttagcatg ggcactcatg ttgctttttg gacaagtaac    600 

tctctggtca acgaagcttg taagagcaga ttgaaaacca ggaaaacagg atgcagctag    660 

gcaaaccgtt tgcggaggta cggatactca gttgctggac gagctgattc ccaaactcta    720 

aagttaagaa agaagaaaag aaaaggcata aatcatcatc atcttcctcc tcctcatcta    780 

gtgactcaga tagctcaagt gattctcagt cctcttctga ttcctctgat tccgaaagtg    840 

ctactgtaga tccatcaaag ataagtccga agcaacatcg gaaaaattcc cgaaaacaca    900 

agacagaaaa gctaaagcga aagtcagcga gatgagtgca tctagtgaga               950 

 
           
             28  
             4230  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI198296.12001JAN12  
             
           
            28 

aaaacactct tcacaaaatg caaaaatttt gcgttacaga cttttgagga tgtatcccag     60 

cacgaagaat ttcttgagct tgacaaagat gaacttattg attatatttg tagtgatgaa    120 

cttgttattg gtaaagagga gatggttttt gaagccgtca tgcgttgggt ctatcgtgcc    180 

gttgatctga gaagaccact gttacacgag ctcctgacac atgtgagact ccctcttgtt    240 

gcatcccaac tactttgttc aaacagtgtg aaaggtggga cattgatcca gaattctcct    300 

gagtgttatc agttgttgca tgaagcaaga cggtaccaca tacttgggaa tgaaatgatg    360 

tccccaagga ctaggccacg caggtccact ggctattctg aggtgatagt tgtcgttgga    420 

ggatgtgagc gagttggaag gatttaatct tccatacact gagtgctacg atcctgtaac    480 

aggagaatgg aagtctttgg ctaagcttcc agaatttacc aaatcagagt atgcagtctg    540 

tgctctaagg aatgacattc ttgtttcagg tggaagaatc aacagccgtg atgtctggat    600 

ttataactca cagttaacat attcggctca ggagtttgcc tctctcaata aaggcagatg    660 

gcgtcacaaa atggctgtcc tccttggtaa agtatatgtt gtcggtggct atgatgggca    720 

aaacagactt agcagcgtag aatgttatga ttccttttca aatcgatgga ctgaagttgc    780 

tccccttaag gaagccgtga gttctcctgg cagtggataa gctggggtag gcaaacggtt    840 

tgtgattggt ggaggacctg atgataatac ttgttctgat aaggttcaat cttatgatcc    900 

agaaaccaat tcttggctac ttcgtgcagc tatcccaatt gccaaaaggt gtataacagc    960 

tgtatcccct aaacaaccct gatcctatgt tgcccggtgg acctgaccca aggcaatata   1020 

cctgttacga tcccagttga aggattactg ggatgcacgt acagaataca ttcagccgtc   1080 

agggaaaact gtggtatgtc tgtgtgtaat gggtaaaata tatatccctg ggcggaagac   1140 

gggaaaatgg agaagccaca gacactattc tctgttatga tcctgcaaca agtatcatca   1200 

caggggctat gctgcagatg cgccaggcca gttgtcccta tcatggttgt gtgtactatt   1260 

catagataca ttgagaaatg ctttaaactc tggaagacag gatacctcac cgaagaagcc   1320 

acactgatcc aagatgggag ggttttaaag attctagcag tgcgaacttc acatatttcc   1380 

tttgtgccat atgcaaaaat agggaaagaa taataatttg gtgcctttct cctcaaaata   1440 

tcaatctttc aaactataat aaagcctttc ctataattga aaaaaaaaac ttttttgtta   1500 

aaggtaatgg tggttgttac ttggcctttg aagagtgtac ctttgtaagt atttgtaaga   1560 

agtctatgtg aattaggaaa tgtctgtctg catacctttt aggagcgtgt gaatggtgtc   1620 

ttcacttatt atgtatgttt atctgtatgt atattcctta ttttgtcata tatgtagaga   1680 

aaattgcatg acttgaggca tcatttaggt tgaagaagtt aatgcttaga atgcattcta   1740 

ggagaaaaaa tcagttttaa aaacctttgt tgttaacaaa gtatatccag attggttaat   1800 

tttattgaag ggtttttttc tgtaattgat aaaaatgtaa tgacaacaat tcaggcatca   1860 

taaaatactg aactattgtg actttattct tagaattgct gtcttacatt aaacatgttt   1920 

ttagggggaa gttaggtagg agatagaaaa ataagtgccc ctacaagggg gattaaaatt   1980 

acaagggtta attcctaaga gaaaaatgga atggcctttg aaggaaaaat gacccactat   2040 

ggctctcaaa gtttttatgc atcatctctt caatcctcta agaaagcctc ttttcttaac   2100 

ttgataaagc agtggaaacc cattntgcaa tattgttttg tgaaaaacag ggacagacag   2160 

ccaggtacag agactcacac ctgtactccc aactactcag caggctgggg caggaggatt   2220 

gcttgagccc aggagtctga ggctacagtg agctatgaac gcacacggca ccctagcctg   2280 

ggcaacaggt tgcgacactg tctcaagaga aaagaaaaag aaaaataggg ataggttttc   2340 

cttcctagcc cagtagagtt tgacctcatt agtatggtgc tttgggtgag gacctcttcc   2400 

ttgattatcc cactttctag tgaacagcta aaattcctga gagtctctac tgttaaggta   2460 

cctttaatag gataaagcag ggaccaccta tctcagtggg tccatttttc ttttaaaatt   2520 

agttatctga aaaaacttag cagtagttcc catctttaag gtaagtcttt catttggtcc   2580 

ccattgtgta aaatactaat caacattttc aagcttctgt acaacagact gcttttgtct   2640 

agatttctca actccacttt ataaagctta tcagttttca gagaggaatg tgaatttttt   2700 

tttctaatgc aaataaatgg atatggcagg aactaccagc ataagtgatt attgtgattc   2760 

tgggtggacg gatataattt acaacattta gggatgttct aggtagcctg ctgtagtttg   2820 

acttccagtc actgttgtct ttcacattat aatttgtata tttcttgtga tagaagggat   2880 

gatgcaaata tgtaattaaa gtgtcaccag atttctgtta aaaccaaggt tgaaataaaa   2940 

agcctaacat tggtaagcta cattgttttc tcattttaga atgattcaga gatttcagat   3000 

agacattttt taaactttaa tgcttagcta gaatctacat tctgaggaaa actctaaaaa   3060 

acttaaaaat ttttagggaa tttttatgtt gttgcaaaat cagtagatgt ttaaaatgga   3120 

tagataccat tttgtgataa caacaattca gaagacgaat tttctatcct cttagttgaa   3180 

agaatgtagg tacagtttgg atacttgtac tttaatttta gagtaaacat ctgcattata   3240 

ctcttataga taatagaatt atttagttaa gaaattcttt acagtaaatg agataatgtg   3300 

tgaaaaagta ttttgtaaat gctgaggatt ctacaaatga tagttgttat tttcatgtgt   3360 

atttgtaaga tcatgtccat ttcatgaata taggacttca cataaaaaaa gactttctca   3420 

agacaacttt atattctagt atttttctgt tgtaaaaagt attaactatt tacttttatt   3480 

ttgttataca tttattttaa tatccatgtg tttattatag taaatttgaa atgaaatcct   3540 

gaaaaacaga atttttttaa acacagacct cacaccaata ttaatttttt ctctacataa   3600 

tttaaaacta cataaattaa gtacttaaaa tttatattga aggccaccaa gaacttaggt   3660 

tgaatcttag aaaatttaaa taactatttt taaagttacc caacttaata ttttactttt   3720 

ttaatattta tcttccttta ctaattcttg actaaataat agcattagac ttgataacaa   3780 

taaaaaaacg aattttagag tagaattact atatcaaaag gggtatatta aacaaattgg   3840 

tgtcagattg tattcattct ctcatcacat aaagattttt cttttgatag gtgatgctca   3900 

tatgaacctt tggtttagaa tctatntatg gacatgtgta tgtatgnaga tagtatggtt   3960 

gtatacacac atatatacca aacaccatga attttagcag gtctgtgatg atcagcaaaa   4020 

aagcacataa agtaaacaat tagttgacca tgctaaattc aattctggaa tttttttttt   4080 

atttgggcat ttctagaact ttttacattt gaaagtacat gatgagtatt agtaaccgat   4140 

gacttatgta taatccagaa tctttatgac aatttagttt tacaaggtcc gaagagatga   4200 

gtttgctaaa ccccagctgt gatacctcag                                    4230 

 
           
             29  
             3262  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI202943.42001JAN12  
             
           
            29 

cgcgtccgca aaccacatgg ctttacatag ggaattctag gtgtaggatt ccaaaatttc     60 

aggcaacaac gagtctagtg ggagaagtag ctgggagagg gaatgataga gctgggagag    120 

agggaaacag aagagaatct cctgctgccc ctgaaatcat acctgctccc ctccaccccc    180 

atctctaaaa aatctgtgaa tgttttcaat aggactaaat taatgtgtaa taactccatc    240 

ttaatggaac aagtagggct tatctaaagt gttattaaac tttcaggtga gtcactggct    300 

acctcctgcc cagaggaact cagtaaagga aacgtgttag catggcctga tttcttgtca    360 

ggaattgtgg ggaaagtgaa gatcgattct aagagcatat tttgttctgg ttgcccacgc    420 

ttaggagggt cagtgcctca tctgagaact gcatctgaag atttaaagcc aggttccaaa    480 

gtcaatctgt tctgtgatcc aggcttccag ctggtcggga accctgtgca gtactgtctg    540 

aatcaaggac agtggacaca accacttcct cactgtgaac gcattagctg tggggtgcca    600 

cctcctttgg agaatggctt ccattcagcc gatgacttct atgctggcag cacagtaaac    660 

taccagtgca acaatggcta ctatctattg ggtgactcag ggatgttctg tacagataat    720 

gggagctagg aacggcgttt caccatcctg ccgtgatgtc gatgagtgtg cagttggatc    780 

agattgtagt gagcatgctt cttgcctgaa acgtagatgg atcctacata tgttcatgtg    840 

tcccaccgta cacaggagat gggaaaaact gtgcagaacc tataaaatgc taaggctcca    900 

gcgcagaatc cggaaaatgg ccactcctca ggtgagattt atacacgtag gtgcccgaag    960 

tcacattatt acgtgtcagg aaggataccc agttgatggg agtaaccaaa atcacatgtt   1020 

tggagtactg gagaatggaa tcatctaata ccaatattgt aaagctgttt catgtggtaa   1080 

accggactat tccagaaaat ggttgcattg acggagttag ccacttttac ctatttgggc   1140 

agcaaagtga catataggtg taataaagga tatactctgg ccggtgataa agaatcatcc   1200 

tgtcttgcta acagttcttg gagtcattcc cctcctgtgt gtgaaccagt gaagtgttct   1260 

agtccggaca atataactaa tggacaacta tatatagagt gggcttacct acctttctac   1320 

tgcatcataa ttcatgcgat acaggataca gcttacaggg cccttcccat tattgaatgc   1380 

acggcttctg gcatctggga cagagcggca ccctgcctgt cacctcgtct tctgtggaga   1440 

accacctgcc atcaaagatg ctgtcattac ggggaataac ttcactttca ggaacaccgt   1500 

cacttacact tgcaaagaag gctatactct tgctggtctt gacaccattg aatgcctggc   1560 

cgacggcaag tggagtagaa gtgaccagca gtgcctggct gtctcctgtg atgagccacc   1620 

cattgtggac cacgcctctc cagagactgc ccatcggctc ttcggagaca ttgcattcta   1680 

ctactgctct gatggttaca gcctagcaga caattcccag cttctctgca atgcccaggg   1740 

caagtggggt acccccagaa ggtcaagaca tgccccgttg tatagctcat ttctgtgaaa   1800 

aaacctccat cggtttccta tagcatcttg gaatctgtga gcaaagcaaa atttgcagct   1860 

ggctcagttg tgagctttaa atgcatggaa ggctttgtac tgaacacctc agcaaagatt   1920 

gaatgtatga gaggtgggca gtggaaccct tcccccatgt ccatccagtg catccctgtg   1980 

cggtgtggag agccaccaag catcatgaat ggctatgcaa gtggatcaaa ctacagtttt   2040 

ggagccatgg tggcttacag ctgcaacaag gggttctaca tcaaagggga aaagaagagc   2100 

acctgcgaag ccacagggca gtggagtagt cctataccga cgtgccaccc ggtatcttgt   2160 

ggtgaaccac ctaaggttga gaatggcttt ctggagcata caactggcag gatctttgag   2220 

agtgaagttg aggtatcagt gtaacccggg ctataagtca gtcggaagtc ctgtatttgt   2280 

ctgccaagcc aatcgccact ggcacagtga atcccctctg atgtgtgttc ctctcgactg   2340 

tggaaaacct cccccgatcc agaatggctt catgaaagga gaaaactttg aagtagggtc   2400 

caaggttcag tttttctgta atgagggtta tgagcttgtt ggtgacagtt cttggacatg   2460 

tcagaaatct ggcaaatgga ataagaagtc aaatccaaag tgcatgcctg ccaagtgccc   2520 

agagccgccc ctcttggaaa accagctagt attaaaggag ttgaccaccg aggtaggagt   2580 

tgtgacattt tcctgtaaag aagggcatgt cctgcaaggc ccctctgtcc tgaaatgctt   2640 

gccatcccag caatggaatg actctttccc tgtttgtaag attgttcttt gtaccccacc   2700 

tcccctaatt tcctttggtg tccccattcc ttcttctgct cttcattttg gaagtactgt   2760 

caaggtattc ttgatgtagg tgggtttttc ctaagcagga aattctacca ccctctgcca   2820 

acctgatggc acctggaggc tctccactga cagaatgtgt tccagtagaa tgtccccaac   2880 

ctgaggaaat ccccaatgga atcattgatg tgcaaggcct tgcctatctc agcacagctc   2940 

tctatacctg caagccaggc tttgaattgg tgggaaatac taccaccctt tgtggagaaa   3000 

atggtcactg gcttggagga aaaccaagat gtaaagccat tgagtgccgt gaaacccaag   3060 

gagattttga atggcaaatt ctcttacacg gacctacact atggacagac cgttacctac   3120 

tcttgcaacc agaggctttc ggctcgaagg tcccagtgcc ttgacctgtt tagagacagg   3180 

tgattgggat gtagattgcc ccatcttgca atagcatcca ctgtgattcc ccacaaccat   3240 

tgaaatggtt ttgtaaaggt gc                                            3262 

 
           
             30  
             975  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2121848.12001JAN12  
             
           
            30 

gaatcttggg cgtgattcac acctggccca acaaactaga agtcacactg gagagaaacc     60 

ttacaagtgt actgagtgtg gcaaagcttt agtgggcagt caacacttat tcaccatcag    120 

gcaatccatg gtatagggta actttataaa tgtaatgatt gtcacaaagt cttcagtaac    180 

actacaaccg tttcaaatca ttggagaatc cataatgaga gattttgaac agtgtaataa    240 

atgtggcaaa tttttcagac attgttcata ccttgcaggt catcggtgaa ctcatgctgg    300 

agagaaacct tacaaatgtc atgattgtgg caaggtcttc agtctagctt catcgtatgc    360 

aaaacaggag acgtcataca ggagactaac ttcacaagta tgatgattgc agcaaagcct    420 

ttacttcacg ttcacaccta attagacatc agagaatcca tactggacag aaatcttaca    480 

aatgtcatca gtgtggcaag gtcttcagtc tgagatcacc ccttaaggaa catcagaaaa    540 

ttcatttttg agatgattgt tccaaatgca atgagtatag caaaccatca agcattaatt    600 

ggcattagag tcaattcagc attgacttga gtttgaattg acttaacatt gagttcaagc    660 

attaattgac attaaagtgt ttatgttata gaagattggg cctaggcggg gtggctctac    720 

gcctgtaatc cctagctact ttgggtaggc catagtacct aattagtatc tacttgaggt    780 

caggtagttt gtagtaccta gtactggcct tactagtact atgtagtcta cttttcccac    840 

cctgtatttt gtttctttat ataaaaactg ttacgggttt ttatgggtat ctgttgtata    900 

tctataatca ctatttgttt gtataatcta ttcaacaata ttatagactt cctaatccta    960 

tcatatatgg gttgt                                                     975 

 
           
             31  
             2641  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI796992.12001JAN12  
             
           
            31 

gtgtgctgga aaggaaattc ttcagccgaa gctccaacct cattcagcat aagagggttc     60 

acactggtga aaagcaatat gagtgcagcg actgtgggaa gttcttcagc cagcgttcca    120 

acctcattca tcataagagg gttcatacgg gcagaagtgc ccatgagtgc agtgaatgtg    180 

ggaaatcttt caactgcaac tccagcctaa ttaaacattg gagagttcac actggagaaa    240 

gaccttacaa gtgtaacgaa tgtgggaaat tcttcagcca cattgccagc ctcattcaac    300 

atcagatagt tcacactggc gagcggcctc acgggtgtgg tgagtgtggg aaagccttca    360 

gccgaagctc tgacctcatg aaacatcagc gagttcacac tggtgagcgg ccttatgaat    420 

gcaatgaatg tgggaagtta tttagccaga gctccagcct caatagccat cggagacttc    480 

acactggtga acggccttac cagtgcagtg aatgtgggaa attctttaac caaagctcca    540 

gcctcaataa ccaccggaga cttcacaccg gcgagcggcc ttatgagtgc agcgaatgtg    600 

ggaaaacctt caggcagagg tccaatctga ggcagcacct gaaagttcac aaaccagaca    660 

ggccttacga atgcagcgaa tgtgggaaag ccttcaacca aaggcctacc ctcattcggc    720 

atcagaagat tcacatcaga gaaaggagca tggagaatgt gctccttccc tgttcacagc    780 

acacaccaga gataagctct gagaacagac cttatcaggg cgctgtcaac tacaagttga    840 

aacttgttca tccaagtacc caccctgggg aggttcccta ggaatgctag ctgtgttgga    900 

agctttctgg agacaagtta cattctctta ctgtagagtt tatcagcgtt ttttcactgc    960 

tggggttgtg atagaagcca tgtcagcacc acacactgca gctctccaaa gagtgtgtcc   1020 

accactccac tgtgctcagg gaaggcagac ctctcctctc tctttccaat ccctaaaggg   1080 

aattaggagt agtctgaagc cttgggaaga tgtcattccc gccctgtatg gctggtttag   1140 

ccatggacat gaccagcttt tggctgtgaa gacctgagca gggttttgcc aacagcttgt   1200 

tctagagaag gtttcccttt ttctgggaca ttgttggtct catgttatgc ctgtgaagga   1260 

tttgtccagc cttcatgtta ctctacacaa caacttatct cctgtgtatt gccctggttc   1320 

atgtgatgat aatggcctta tgataaagcc gcctttagtc ttccatgttc tgatcactgt   1380 

gtggggtggt tcaagagcag agttaagatc taccaaactg aaggggtctc cagattatct   1440 

tggaggggac aggaggatgg cagagaaaca actgtcaatc cagatttgac ctcatttgca   1500 

ttgccaccaa ggcctcctag gaaaaattgt aggaatttat gggtataata ttgtggtctg   1560 

aatggcgtga atttttatcc cgaggagggg gcagttgtga caacctccag tgcatgtggg   1620 

aacagcatga attgggtccc ttattcccag ggggtgcccc atattcccca atactgtaaa   1680 

gcagatgctg tttagcacct gccaaggagc catatgccct gaagttcagc attaggcagg   1740 

tatctcttaa ctgtaagaca taccaggccc agctgggacc ataatttgta cagaaacact   1800 

ggatgtgatt aatagggagt aggcgagatt atagcaaacc agcagaaatg gaactctgct   1860 

aaatgtgcat ccgtgaatgc tcccttgaat gtggctgtgc aggattcagg gtttgcagaa   1920 

attctcagga cctcagacct ctgtcctatg actaatgtta ctggcagagc aaataatcct   1980 

aaaggttttg gttttgtgga ttaccatcct ccgtgctgtg catctgaagg ccagtgctgt   2040 

gctgggcagg aaaataggga ctgagaaaaa gcagatccta tactataggg actgtagtat   2100 

ctatgacgta gccagccatt ctttgctccc aaggcaagaa gaaagagatg acagagtcaa   2160 

tatagggttg ccaaatcgga ttttctaaaa tgagtaggaa gttggatttt tatgtgcaac   2220 

agtttctttt aatgctttgt tgatatgtga ttgtcatgca ataattattc atatttggta   2280 

agttttgtac atatattatg tacactcagg gaaccaatac cataatcatg ataatgaacg   2340 

tatccatcac ctgcaaagct acctcatgcc cctttacatt ccctccttgc cttccctagg   2400 

aaaccgttga tttacatttt ttactttaga tttgtttgcc ttttctagaa ttaacacaat   2460 

tggaatcata aagtatttat actctctttt ggtctggttt ctttcatgca gcataattat   2520 

cttgagaatc atccatgctg tgtgtatata tagttcattc cttttactac tgagtagtgc   2580 

tatactgggt gagtgcacca tagtttttta tggttcattt aaaaatgtta aaaaaatctg   2640 

a                                                                   2641 

 
           
             32  
             604  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1183014.72001JAN12  
             
           
            32 

aaagatggta agaattagtc cctaaacatc ttttttcacg tcaactgatt cttatcactt     60 

cagactgagc aaaattgtga ttttccaggg atcagtgtcg tttagggatg tgactgtggg    120 

cttcactcaa gaggagtggc agcatctgga ccctgctcag aggaccctgt acagggatgt    180 

gatgctggag aactacagcc accttgtctc agtagggtat tgcattccta aaccagaagt    240 

gattctcaag ttggagaaag gcgaggagcc atggatatta gaggaaaaat ttccaagcca    300 

gagtcatctg ggtgagttag tatgtgccag atggaattta aaggaaggta gatcacaaag    360 

ggtaagtttg gataataaga ccattgaaat gttctttagg aatcatgttt tagaggctcc    420 

agacctttgg aagtaacatg ttgacgtgac ccaaatatgc agtgactctg aatcacccag    480 

catctcccag tatcactttc atacacacat cttgttgttt tttttaaaat tgtgatataa    540 

actatatagt ttagccagag attaataaaa ttttatatat atatgtaaca ctcatgtacc    600 

catc                                                                 604 

 
           
             33  
             1081  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1171219.22001JAN12  
             
           
            33 

aaaaaacctc agttcacctt ctcacaatga ggctccctgc tcagctcctg gggctgctaa     60 

tgctctgggt ctctggatcc agtggggata ttgtgatgac tcagtctcca ctctccctgt    120 

ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtcagagc ctcctgcata    180 

gtaatggaaa caactatttg gattggttcc tgcagaagcc agggcagcct ccacagctcc    240 

tgatctattt gggttctagt cgggcctccg gggtccctga caggttcagt ggcggtggat    300 

caggcacaga ttttacactg aaaatcagca gagtggaggc tgaggatgtt ggggtttatt    360 

actgcatgca agtagtacaa ataccttcca ctttcggcgg agggaccaag gtggagatca    420 

aacgaactgt ggctgcacca tctgtcttca tcttcccgcc atctgatgag cagttgaaat    480 

ctggaactgc ctctgttgtg tgcctgctga ataacttcta tcccagagag gccaaagtac    540 

agtggaaggt ggataacgcc ctccaatcgg gtaactccca ggagagtgtc acagagcagg    600 

acagcaagga cagcacctac agcctcagca gcaccctgac gctgagcaaa gcagactacg    660 

agaaacacaa agtctacgcc tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa    720 

agagcttcaa caggggagag tgttagaggg agaagtgccc ccacctgctc ctcagttcca    780 

gcctgacccc ctcccatcct ttggcctctg accctttttc cacaggggac ctacccctat    840 

tgcggtcctc cagctcatct ttcagctcac ccccctcctc ctccttggct ttaattatgg    900 

ctaatgttgg aggagaatga ataaatacag tgaatctttg gcagaagaaa aaaaaaaaag    960 

agggggcccc aattatgggc ctctcgaccg ggatttatcc ggaccggtac ttgagggggg   1020 

gtgcagattc cgattcaagt tatgtacgca cctcgagggg gccggaccca ttccctttgg   1080 

t                                                                   1081 

 
           
             34  
             647  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI428428.42001JAN12  
             
           
            34 

ggccgccccg gctcggcctg ttttcagatg cttcaagtgt tgtgaacaga gacttgttgg     60 

attatgcatt tctcagctag actaaataaa tgctagcaat ggatacgtgc aaacatgttg    120 

ggcagctgca gcttgctcaa gaccattcca gcctcaaccc tcagaaatgg cactgtgtgg    180 

actgcaacac gaccgagtcc atttgggctt gccttagctg ctcccatgtt gcctgtggaa    240 

gatatattga agagcatgca ctcaagcact ttcaagaaag cagtcatcct gttgcatgga    300 

ggtgaatgag atgtacgttt ttgttacctt gtgatgatta tgttctgaat gataacgcaa    360 

ctggagacct gaagttacta cgacgtacat taagtgccat caaaagtcaa aattatcact    420 

gcacaactcg tagtgggagg tttttacggt ccatgggtac aggtgatgat tcttatttct    480 

tacatgacgg tgcccaatct ctgcttcaaa gtgaagatca actgtatact gctctttggc    540 

acaggagaag gatactaatg ggtaaaatct ttcgaacatg gtttgaacaa tcacccattg    600 

gaagaaaaaa agcaagaaga accatttcag gaaaaaatag tagtaac                  647 

 
           
             35  
             2014  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI230711.52001JAN12  
             
           
            35 

cgggcagaca agacaaagcg aaaggcaagg cagcatgagc cgatcacccc tcaatcccag     60 

ccaactccga tcagtgggct cccaggatgc cctggccccc ttgcctccac ctgctcccca    120 

gaatccctcc acccactctt gggacccttt gtgtggatct ctgccttggg gcctcagctg    180 

tcttctggct ctgcagcatg tcttggtcat ggcttctctg ctctgtgtct cccacctgct    240 

cctgctttgc agtctctccc caggaggact ctcttactcc ccttctcagc tcctggcctc    300 

cagcttcttt tcatgtggta tgtctaccat cctgcaaact tggatgggca gcaggctgcc    360 

tcttgtccag gctccatcct tagagttcct tatccctgct ctggtgctga ccagccagaa    420 

gctaccccgg gccatccaga cacctggaaa ctcctccctc atgctgcacc tttgtagggg    480 

acctagctgc catggcctgg ggcactggaa cacttctctc caggaggtgt ccggggcagt    540 

ggtagtatct gggctgctgc agggcatgat ggggctgctg gggagtcccg gccacgtgtt    600 

cccccactgt gggcccctgg tgctggctcc cagcctggtt gtggcagggc tctctgccca    660 

cagggaggta gcccagttct gcttcacaca ctgggggttg gccttgctgg ttatcctgct    720 

catggtggtc tgttctcagc acctgggctc ctgccagttt catgtgtgcc cctggaggcg    780 

agcttcaacg tcatcaactc acactcctct ccctgtcttc cggctccttt cggtgctgat    840 

cccagtggcc tgtgtgtgga ttgtttctgc ctttgtggga ttcagtgtta tcccccagga    900 

actgtctgcc cccaccaagg caccatggat ttggctgcct cacccaggct ggatctcagc    960 

aagtggctca cttagtgggg ctactctgcg tggggcttgg actctccccc aggttggctc   1020 

agctcctcac caccatccca ctgcctgttg ttgcttctac ctggctgaca tagactctgg   1080 

gcgaaatatc ttcattgtgg gcttctccat cttcatggcc ttgctgctgc caagatggtt   1140 

tcgggaagcc ccagtcctgt tcagcacagg ctggagcccc ttggatgtat tactgcactc   1200 

actgctgaca cagcccatct tcctggctgg actctcaggc ttcctactag agaacacgat   1260 

tcctggcaca cagcttgagc gaggcctagg tcaagggcta ccatctcctt tcactgccca   1320 

agaggctcga atgcctcaga agcccaggga gaaggctgct caagtgtaca gacttccttt   1380 

ccccatccaa aacctctgtc cctgcatccc ccagcctctc cactgcctct gcccactgcc   1440 

tgaagaccct ggggatgagg aaggaggctc ctctgagcca gaagagatgg cagacttgct   1500 

gcctggctca ggggagccat gccctgaatc tagcagagaa gggtttaggt cccagaaatg   1560 

accagaacgc ctacttctgc cctggttaat ttagccctaa ctctcatctg ctggagagtc   1620 

agctcccaaa ctgttctttc ttgtaggcag aggatatgtg tgtgtgtatt acatgggact   1680 

gtctagaggt tccatttccc aatagggtgg gttgcctttc cttgtcttaa ttaggcctaa   1740 

ctgttccaga gcagaggcca tgatttagtg gaccatgaat gattgagatt ttgcctgtgt   1800 

actatcaatg ccacttgaac ccaagcattc actttaatac ttactgagca tctcccatgt   1860 

gcaaggtcct ggaactacag ggataagaca gggtccatgc cgtctcaagg catttacggt   1920 

ttaaaaagac ctttgtaatt actaacgaaa atgcaaagca gaaagcagtc tgtaataaag   1980 

attaaaataa tgccgtggga gcaaagagga aaag                               2014 

 
           
             36  
             1404  
             DNA  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI199716.62001JAN12  
             
           
            36 

gtgctatatt cttcattttg tgtaagcatt tccccccttt ttttgtatgt ttaacaaatt     60 

tctatttatg gattttgatg gtcacatcat ttacttattt tgggaaattc ttcagtgctt    120 

gcatttagtg ccgacagtta ctgtgttggt tttggtagct taaacttcga aaatttaaac    180 

aatattgttt tttctctttg tagctgccaa tatcttatca tctccctcta agagaggaca    240 

aaaaggtacc cttattggat attctcctga aggaacacct ctttataact tcatgggtga    300 

tgcttttcag catagctctc aatcgatccc taggtttatt aaggaatcac taaaacaaat    360 

tcttgaggag agtgactcta ggcagatctt ttacttcttg tgcttgaatc tgctttttac    420 

ctttgtggaa ttattctatg gcgtgctgac caatagtctg ggcctgatct cggatggatt    480 

ccacatgctt tttgactgct ctgctttagt catgggactt tttgctgccc tgatgagtag    540 

gtggaaagcc actcggattt tctcctatgg gtacggccga atagaaattc tgtctggatt    600 

tattaatgga ctttttctaa tagtaatagc gttttttgtg tttatggagt cagtggctag    660 

attgattgat cctccagaat tagacactca catgttaaca ccagtctcag ttggagggct    720 

gatagtaaac cttattggta tctgtgcctt tagccatgcc catagccatg cccatggagc    780 

ttctcaagga agctgtcact catctgatca cagccattca catcatatgc atggacacag    840 

tgaccatggg catggtcaca gccacggatc tgcgggtgga ggcatgaatg ctaacatgag    900 

gggtgtattt ctacatgttt tggcagatac tcttggcagc attggtgtga tcgtatccac    960 

agttcttata gagcagtttg gatggttcat cgctgaccca ctctgttctc tttttattgc   1020 

tatattaata tttctcagtg ttgttccact gattaaagat gcctgccagg ttctactcct   1080 

gagattgcca ccagaatatg aaaaagaact acatattgct ttagaaaaga tacagaaaat   1140 

tgaaggatta atatcatacc gagaccctca tttttggcgt cattctgcta gtattgtggc   1200 

aggaacaatt catatacagg tgacatctga tgtgctagaa caaagaatag tacggcaggt   1260 

tacaggaata cttaaagatg ctggagtaaa caatttaaca attcaagtgg aaaaggaggc   1320 

atactttcaa catatgtctg gcctaagtac tggatttcat gatgttctgg ctatgaccaa   1380 

aacaaatgga atccataaaa tact                                          1404 

 
           
             37  
             117  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI180252.16.orf22001JAN12  
             
           
            37 

Ala Gly Asp Cys Leu His Pro Ala Gly Gly Ala Glu Gly Pro Arg 
  1               5                  10                  15 

Leu His Pro Pro His Gly Ile Cys Thr Gln Asn Leu Gln Gly Tyr 
                 20                  25                  30 

Asp Ala Lys Ser Asp Ile Tyr Ser Val Gly Ile Thr Ala Cys Glu 
                 35                  40                  45 

Leu Ala Asn Gly His Val Pro Phe Lys Asp Met Pro Ala Thr Gln 
                 50                  55                  60 

Met Leu Leu Glu Lys Leu Asn Gly Thr Val Pro Cys Leu Leu Asp 
                 65                  70                  75 

Thr Ser Thr Ile Pro Ala Glu Glu Leu Thr Met Ser Pro Ser Arg 
                 80                  85                  90 

Ser Val Ala Asn Ser Gly Leu Ser Asp Ser Leu Thr Thr Ser Thr 
                 95                 100                 105 

Pro Arg Pro Ser Asn Gly Pro Val Pro Ala Pro Ser 
                110                 115 

 
           
             38  
             77  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1072919.1.orf12001JAN12  
             
           
            38 

Gly Phe Arg Pro Pro Pro Arg Ala Val Ser Ala Ser Cys Leu Arg 
  1               5                  10                  15 

Thr Pro Asp Phe Asp Val Leu Ser Arg Asp Leu Gly Leu Phe Leu 
                 20                  25                  30 

Ser Arg Arg Ser Ala Lys Phe Ser Pro Gly Ala Lys Pro Met Phe 
                 35                  40                  45 

Met Val Glu Arg Gln Asp Arg Glu Ala Pro Met Gly Glu Asn Ala 
                 50                  55                  60 

Gly Arg Ile Pro Ser Pro Gly Ser Ser Gln Ala Leu Leu Glu Ala 
                 65                  70                  75 

Gly Ala 

 
           
             39  
             153  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI477130.1.orf22001JAN12  
             
           
            39 

Met Gly Phe Asp Gly Arg Val Leu Asp Ala Lys Gly Gln Val Leu 
  1               5                  10                  15 

Gly Arg Leu Ala Ser Gln Ile Ala Val Val Leu Gln Gly Lys Asp 
                 20                  25                  30 

Lys Pro Thr Tyr Ala Pro His Val Glu Asn Gly Asp Met Cys Ile 
                 35                  40                  45 

Val Leu Asn Ala Gln Asp Ile Ser Val Thr Gly Arg Lys Met Thr 
                 50                  55                  60 

Asp Lys Ile Tyr Tyr Trp His Thr Gly Tyr Val Gly His Leu Lys 
                 65                  70                  75 

Glu Arg Arg Leu Lys Asp Gln Met Glu Lys Asp Pro Thr Glu Val 
                 80                  85                  90 

Ile Arg Lys Ala Val Leu Arg Met Leu Pro Arg Asn Lys Leu Arg 
                 95                 100                 105 

Asp Asp Arg Asp Arg Lys Leu Arg Ile Phe Ser Gly Ile Glu His 
                110                 115                 120 

Pro Phe His Asp Arg Pro Leu Glu Ala Phe Val Met Pro Pro Thr 
                125                 130                 135 

Ala Ser Thr Gly Asp Ala Thr Pro Cys Lys Ala Cys Asn Val Lys 
                140                 145                 150 

Gly Pro Asp 

 
           
             40  
             147  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI351355.1.orf12001JAN12  
             
           
            40 

Gly Arg Tyr Pro Ser Cys Ser Ala Ala Ala Val Ala Ser Pro Arg 
  1               5                  10                  15 

Pro Pro Ala Ala Met Ala Asn Asp Ser Gly Gly Pro Gly Gly Pro 
                 20                  25                  30 

Ser Pro Ser Glu Arg Asp Arg Gln Tyr Cys Glu Leu Cys Gly Lys 
                 35                  40                  45 

Met Glu Asn Leu Leu Arg Cys Ser Arg Cys Arg Ser Ser Phe Tyr 
                 50                  55                  60 

Cys Cys Lys Glu His Gln Arg Gln Asp Trp Lys Lys Ala Gln Val 
                 65                  70                  75 

Ser Cys Ala Thr Ala Ala Arg Ala Pro Ser Ala Thr Glu Trp Ala 
                 80                  85                  90 

His Thr Gln His Ser Gly Pro Arg Ala Ala Gly Cys Ser Ala Ala 
                 95                 100                 105 

Val Pro Gly Pro Gly Pro Pro Gly Ala Gln Glu Gly Ser Gly Ala 
                110                 115                 120 

Pro Gly Asp Asn Ala Ser Arg Gly Arg Gly Gln Arg Gly Lys Val 
                125                 130                 135 

Lys Ala Lys Ala Pro Gly Arg Pro Ser Gly Gly Arg 
                140                 145 

 
           
             41  
             166  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI038285.2.orf12001JAN12  
             
           
            41 

Asn Ser Leu Ser Val Ala Ser Ala Pro Pro Gln Arg Asp Pro Gly 
  1               5                  10                  15 

Met Ala Met Ala Leu Pro Met Pro Gly Pro Gln Glu Ala Val Val 
                 20                  25                  30 

Phe Glu Asp Val Ala Val Tyr Phe Thr Arg Ile Glu Trp Ser Cys 
                 35                  40                  45 

Leu Ala Pro Asp Gln Gln Ala Leu Tyr Arg Asp Val Met Leu Glu 
                 50                  55                  60 

Asn Tyr Gly Asn Leu Ala Ser Leu Gly Phe Leu Val Ala Lys Pro 
                 65                  70                  75 

Ala Leu Ile Ser Leu Leu Glu Gln Gly Glu Glu Pro Gly Ala Leu 
                 80                  85                  90 

Ile Leu Gln Val Ala Glu Gln Ser Val Ala Lys Ala Ser Leu Cys 
                 95                 100                 105 

Thr Glu Asp Pro Asn Thr Leu Pro Ser Arg Ser Gln Gly Arg Lys 
                110                 115                 120 

Pro Cys Gln Leu Gln Lys Val Gly Gln Glu Arg Arg Val Trp Pro 
                125                 130                 135 

Gly Arg Val Ala Gly Gly Gly Ala Ala Ser Ser Trp Pro His Arg 
                140                 145                 150 

Gly Ala Pro Cys Ser Pro Leu Thr Asp Glu Glu Lys Val Arg Gly 
                155                 160                 165 

Asp 

 
           
             42  
             188  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1079031.1.orf12001JAN12  
             
           
            42 

Arg Ala Arg Glu Gly Gly Ala Gly Pro Ala Arg Cys Cys Gly Gly 
  1               5                  10                  15 

Pro Cys Cys Ser Ala Gly Glu Asp Arg Thr Gln Cys Gln Ala Gln 
                 20                  25                  30 

Glu Gly Arg Glu Pro Arg Trp Ala Arg Gly Leu Arg Arg Glu Pro 
                 35                  40                  45 

Ser Ser Trp Cys Phe Ser Arg Arg Ser Ala Gly Gly Ala Thr Gly 
                 50                  55                  60 

Pro Ala Ser Ala Arg His Gly Gly Phe Ser Ser Leu Leu Cys Val 
                 65                  70                  75 

Lys Pro Arg Ser Trp Leu Leu Cys Val Ser Gln Leu Gly Ala Met 
                 80                  85                  90 

Arg Leu Pro Glu Met Thr Leu Phe Pro Phe Ser Gln Leu Arg Gly 
                 95                 100                 105 

Val Thr Leu Ser Pro Gly Ile Ala Gly Pro Leu Leu Arg Thr Asp 
                110                 115                 120 

Ser Gly Gly Trp Ser Ser Cys Leu Leu Gly Leu Arg Trp Arg Pro 
                125                 130                 135 

Val Leu Leu Arg Gly Leu Glu Glu Thr Thr Ser Gly Trp Trp Leu 
                140                 145                 150 

Gly Thr Cys Arg Gly Pro Gln Arg Pro Leu Cys Ser Trp Leu Ser 
                155                 160                 165 

Pro Val Cys Phe Leu Ala Phe Arg Asp Glu Arg His Arg Ile Arg 
                170                 175                 180 

Arg Gly Val Ser Ala Ser Glu Pro 
                185 

 
           
             43  
             106  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI306216.1.orf12001JAN12  
             
           
            43 

Cys Lys His Ile Phe Asn Lys Pro Arg Ala Met Trp Asn Phe Arg 
  1               5                  10                  15 

Ser Arg Cys Leu Asn Cys Ala Ile Ala Gln Asn Pro Leu Tyr Tyr 
                 20                  25                  30 

Phe Gly Cys Leu Phe Leu Thr Ala Tyr Phe Gln Phe Phe Val His 
                 35                  40                  45 

Leu Thr Ser Val Cys Gly Leu Phe Cys His Gln Ile Thr Cys Gly 
                 50                  55                  60 

Tyr Thr Tyr Pro Lys Ile Val Phe Ser Phe Thr Ala Leu Ala Tyr 
                 65                  70                  75 

Ser Ala Asn Pro Ser Val Val Gly Ile Lys Asn Ile Ile Arg Tyr 
                 80                  85                  90 

Leu Lys Lys Ser Ile His Pro Lys Thr Cys Phe Thr Gly Leu Gln 
                 95                 100                 105 

Phe 

 
           
             44  
             194  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI011799.1.orf22001JAN12  
             
           
            44 

Ile Asn Trp Val Ile Gly Leu Ser Asp Leu Phe Ile Gln Asn Lys 
  1               5                  10                  15 

His Lys Ser Pro Pro Pro His Arg Arg Glu Ser Val Pro Val Ile 
                 20                  25                  30 

Trp Val Leu Gly Ser Ser Ala Leu Leu Ser Leu Thr Pro Cys Arg 
                 35                  40                  45 

Gln Gly Glu Arg Phe Arg Gly Gly Ala Ser Val Gln Arg Ser Gln 
                 50                  55                  60 

His Ala Val Ser Arg Asp Ala Arg Gly Phe Leu His Arg Cys Gly 
                 65                  70                  75 

Gly Cys Gly Trp Gly Arg Ser Gly Ala Gly Ser Pro Ala Ser Ser 
                 80                  85                  90 

Pro Ala Ala Ala Pro Leu Leu Leu Pro Ala Val His Phe Ile Ser 
                 95                 100                 105 

Ser Ser Ala Cys Val Thr Ala Ala Arg Gly Leu Gly Lys Asp Arg 
                110                 115                 120 

Ala Pro Ser Pro Arg Leu Pro Cys Ser Gly Ala Gly Ala Pro Gly 
                125                 130                 135 

Ser Pro Val Met Arg Arg Leu Arg Leu Ala Ala Ala Leu Pro Gly 
                140                 145                 150 

Pro Gly Ser Val Ser Asp Ala Gly Ala Gly Ala Pro Arg Leu Arg 
                155                 160                 165 

Gly Gly Gly Ala Gly Lys Glu Arg Arg Arg Arg Arg Glu Thr Leu 
                170                 175                 180 

Thr Pro Ser Ser Ala Arg Gly Leu Pro Gly Thr Pro Asn Pro 
                185                 190 

 
           
             45  
             182  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI109467.1.orf12001JAN12  
             
           
            45 

Arg Thr Gln Gln Gln Pro Cys Ser Ser Ser His Ala Ala Ala Ala 
  1               5                  10                  15 

Met Ser Leu Arg Gln Leu Val Lys Leu Lys Val Val Val Asn Thr 
                 20                  25                  30 

Phe Gly Cys Thr Gly His Leu Val Asn Trp Ala Ala Phe Asn Ser 
                 35                  40                  45 

Gly Lys Val Asp Ile Val Ile Ile Ser Asp Pro Phe Thr Asp Ser 
                 50                  55                  60 

Ser Tyr Met Val Tyr Met Phe Gln Tyr Asp Ser Thr Ser Gly Lys 
                 65                  70                  75 

Leu His Ser Thr Val Lys Ala Glu Asn His Lys Phe Val Ile Ser 
                 80                  85                  90 

Gly Asn Pro Ile Ser Ile Phe Gln Glu Gln Asp Thr Thr Lys Ile 
                 95                 100                 105 

Lys Cys Ser Asp Ala Gly Thr Gly Cys Val Val Glu Ser Thr Gly 
                110                 115                 120 

Val Phe Thr Ile Leu Tyr Met Ala Gly Ala His Leu Glu Glu Arg 
                125                 130                 135 

Ala Lys Glu Ser Ser Ser Leu Leu Pro Leu Thr Pro Cys Leu Met 
                140                 145                 150 

Gly Met Asn His Glu Lys Tyr Glu Ser Asn Leu Thr Ile Ile Ser 
                155                 160                 165 

Ile Ala Ser Cys Thr Thr Asn Cys Leu Ala Phe Ser Asp Gln Asp 
                170                 175                 180 

His Pro 

 
           
             46  
             188  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1175250.1.orf22001JAN12  
             
           
            46 

Ser Glu Arg Glu His Phe Tyr Trp Ile Asn Asn His Val Asn Ala 
  1               5                  10                  15 

Val Cys Cys Gly Lys Val Phe Val Arg His Ala Leu Arg Asn Arg 
                 20                  25                  30 

His Ile Leu Ala Ala Leu Arg Ile Gln Thr Ile Trp Arg Glu Ala 
                 35                  40                  45 

Met Ile Asn Val Asn Thr Cys Gly Lys Phe Phe Val Ser Val Pro 
                 50                  55                  60 

Gly Val Arg Arg His Met Ile Met His Ser Gly Asn Pro Ala Tyr 
                 65                  70                  75 

Lys Cys Thr Ile Cys Gly Lys Ala Phe Tyr Phe Leu Asn Ser Val 
                 80                  85                  90 

Glu Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys 
                 95                 100                 105 

Lys Gln Cys Gly Lys Ala Phe Thr Val Ser Gly Ser Cys Leu Ile 
                110                 115                 120 

His Glu Thr Asn Ser His Cys Glu Met Glu Pro Tyr Val Cys Lys 
                125                 130                 135 

Glu Cys Gly Asn Thr Ile Arg Phe Ser Cys Ser Phe Lys Thr His 
                140                 145                 150 

Glu Arg Thr His Thr Gly Glu Arg Pro Tyr Lys Cys Thr Lys Cys 
                155                 160                 165 

Asp Lys Ala Phe Ser Cys Ser Thr Ser Leu Arg Tyr His Gly Ser 
                170                 175                 180 

Ile Gln Tyr Trp Arg Glu Thr Leu 
                185 

 
           
             47  
             160  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2121744.1.orf22001JAN12  
             
           
            47 

Met Trp Thr Ile Lys Gly Ala Ser Gly Cys Pro Gly Ala Glu Arg 
  1               5                  10                  15 

Ser Leu Leu Val Gln Ser Tyr Phe Glu Lys Gly Pro Leu Thr Phe 
                 20                  25                  30 

Arg Asp Val Ala Ile Glu Phe Ser Leu Glu Glu Trp Gln Cys Leu 
                 35                  40                  45 

Asp Ser Ala Gln Gln Gly Leu Tyr Arg Lys Val Met Leu Glu Asn 
                 50                  55                  60 

Tyr Arg Asn Leu Val Phe Leu Ala Gly Ile Ala Leu Thr Lys Pro 
                 65                  70                  75 

Asp Leu Ile Thr Cys Leu Glu Gln Gly Lys Glu Pro Trp Asn Ile 
                 80                  85                  90 

Lys Arg His Glu Met Val Ala Lys Pro Pro Val Ile Cys Ser His 
                 95                 100                 105 

Phe Pro Gln Asp Leu Trp Ala Glu Gln Asp Ile Lys Asp Ser Phe 
                110                 115                 120 

Gln Glu Ala Ile Leu Lys Lys Tyr Gly Lys Tyr Gly His Asp Asn 
                125                 130                 135 

Leu Gln Leu Gln Lys Gly Cys Lys Ser Val Asp Glu Cys Lys Val 
                140                 145                 150 

His Lys Glu His Asp Asn Lys Leu Asn Gln 
                155                 160 

 
           
             48  
             156  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1170908.1.orf32001JAN12  
             
           
            48 

Leu Phe Gln Phe Leu Ser Ile Ser Lys Arg Thr His Ser Gly Glu 
  1               5                  10                  15 

Lys Leu Tyr Glu Cys Lys Gln Cys Gly Lys Val Phe Arg Ser Val 
                 20                  25                  30 

Lys Asn Leu Ser Ile Tyr Glu Arg Thr His Thr Gly Glu Lys Pro 
                 35                  40                  45 

Tyr Glu Cys Lys Lys Cys Gly Lys Ala Phe His Asn Phe Ser Ser 
                 50                  55                  60 

Phe Gln Ile His Glu Ser Cys Thr Glu Glu Arg Arg Pro Lys Asn 
                 65                  70                  75 

Val Ser Ile Val Gly Lys His Ser Tyr Leu Pro Arg Ser Phe Glu 
                 80                  85                  90 

Tyr Met Gln Asn Thr His Trp Arg Glu Thr Tyr Glu Cys Lys Glu 
                 95                 100                 105 

Cys Lys Gln Ala Phe Asn Tyr Phe Ser Ser Leu His Ile His Glu 
                110                 115                 120 

Arg Thr His Thr Arg Glu Asn Pro Tyr Glu Cys Lys Asp Cys Gly 
                125                 130                 135 

Lys Ala Phe Ser Leu Leu Asn Cys Phe His Arg His Val Lys Thr 
                140                 145                 150 

His Gln Lys Glu Thr Leu 
                155 

 
           
             49  
             292  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1173119.1.orf32001JAN12  
             
           
            49 

Glu Gln Gly Leu Tyr Thr Cys Pro Ala His Leu His Gln His Gln 
  1               5                  10                  15 

Lys Glu Gln Ile Arg Glu Lys Leu Ser Arg Gly Asp Gly Gly Arg 
                 20                  25                  30 

Pro Thr Phe Val Lys Asn His Arg Val His Met Ala Gly Lys Thr 
                 35                  40                  45 

Phe Leu Cys Ser Glu Cys Gly Lys Ala Phe Ser His Lys His Lys 
                 50                  55                  60 

Leu Ser Asp His Gln Lys Ile His Thr Gly Glu Arg Thr Tyr Lys 
                 65                  70                  75 

Cys Ser Lys Cys Gly Ile Leu Phe Met Glu Arg Ser Thr Leu Asn 
                 80                  85                  90 

Arg His Gln Arg Thr His Thr Gly Glu Arg Pro Tyr Glu Cys Asn 
                 95                 100                 105 

Glu Cys Gly Lys Ala Phe Leu Cys Lys Ser His Leu Val Arg His 
                110                 115                 120 

Gln Thr Ile His Ser Gly Glu Arg Pro Tyr Glu Cys Ser Glu Cys 
                125                 130                 135 

Gly Lys Leu Phe Met Trp Ser Ser Thr Leu Ile Thr His Gln Arg 
                140                 145                 150 

Val His Thr Gly Lys Arg Pro Tyr Gly Cys Ser Glu Cys Gly Lys 
                155                 160                 165 

Phe Phe Lys Cys Asn Ser Asn Leu Phe Arg His Tyr Arg Ile His 
                170                 175                 180 

Thr Gly Lys Arg Ser Tyr Gly Cys Ser Glu Cys Gly Lys Phe Phe 
                185                 190                 195 

Met Glu Arg Ser Thr Leu Ser Arg His Gln Arg Val His Thr Gly 
                200                 205                 210 

Glu Arg Pro Tyr Glu Cys Asn Glu Cys Gly Lys Phe Phe Ser Leu 
                215                 220                 225 

Lys Ser Val Leu Ile Gln His Gln Arg Val His Thr Gly Glu Arg 
                230                 235                 240 

Pro Tyr Glu Cys Ser Glu Cys Gly Lys Ala Phe Leu Thr Lys Ser 
                245                 250                 255 

His Leu Ile Cys His Gln Thr Val His Thr Ala Ala Lys Gln Cys 
                260                 265                 270 

Ser Glu Cys Gly Lys Phe Phe Arg Tyr Asn Ser Thr Leu Leu Arg 
                275                 280                 285 

His Gln Lys Val His Thr Gly 
                290 

 
           
             50  
             345  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1175131.1.orf22001JAN12  
             
           
            50 

Cys Thr Val Glu Met Asp Leu Ile Ser Val Asn Phe Val Gly Lys 
  1               5                  10                  15 

Ala Leu Met Phe Leu Ser Leu Val Ser Tyr Pro Gln Thr Asn Ser 
                 20                  25                  30 

Arg Leu Glu Arg Asn His Ile Asn Val Asn Glu Cys Gly Lys Ala 
                 35                  40                  45 

Phe Ser His Ser Ser Ser Leu Arg Ile His Glu Arg Thr His Thr 
                 50                  55                  60 

Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe His 
                 65                  70                  75 

Ser Ser Thr Cys Leu His Ala His Lys Arg Thr His Thr Gly Glu 
                 80                  85                  90 

Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys Ala Phe Ser Ser Ser 
                 95                 100                 105 

His Ser Phe Gln Ile His Glu Arg Thr His Thr Gly Glu Lys Pro 
                110                 115                 120 

Tyr Glu Cys Lys Glu Cys Gly Lys Ala Phe Lys Cys Pro Ser Ser 
                125                 130                 135 

Val Arg Arg His Glu Arg Thr His Ser Arg Lys Lys Pro Tyr Glu 
                140                 145                 150 

Cys Lys His Cys Gly Lys Val Leu Ser Tyr Leu Thr Ser Phe Gln 
                155                 160                 165 

Asn His Leu Gly Met His Thr Gly Glu Ile Ser His Lys Cys Lys 
                170                 175                 180 

Ile Cys Gly Lys Ala Phe Tyr Ser Pro Ser Ser Leu Gln Thr His 
                185                 190                 195 

Glu Lys Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Gln Cys 
                200                 205                 210 

Gly Lys Ala Phe Asn Ser Ser Ser Ser Phe Arg Tyr His Glu Arg 
                215                 220                 225 

Thr His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys 
                230                 235                 240 

Ala Phe Arg Ser Ala Ser Leu Leu Gln Thr His Gly Arg Thr His 
                245                 250                 255 

Thr Gly Glu Lys Pro Tyr Ala Cys Lys Glu Cys Gly Lys Pro Phe 
                260                 265                 270 

Ser Asn Phe Ser Phe Phe Gln Ile His Glu Arg Met His Arg Glu 
                275                 280                 285 

Glu Lys Pro Tyr Glu Cys Lys Gly Tyr Gly Lys Thr Phe Ser Leu 
                290                 295                 300 

Pro Ser Leu Phe His Arg His Glu Arg Thr His Thr Gly Gly Lys 
                305                 310                 315 

Thr Tyr Glu Cys Lys Gln Cys Gly Met Ile Leu Gln Leu Phe Glu 
                320                 325                 330 

Leu Leu Ser Ile Ser Trp Lys Asp Ser His Trp Arg Glu Thr Leu 
                335                 340                 345 

 
           
             51  
             132  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1174107.2.orf32001JAN12  
             
           
            51 

Pro Glu Asp Thr Gly Lys Ser Ile Ala Lys Met Pro Gly Pro Pro 
  1               5                  10                  15 

Glu Ser Leu Asp Met Gly Pro Leu Thr Phe Arg Asp Val Ala Ile 
                 20                  25                  30 

Glu Phe Ser Leu Glu Glu Trp Gln Cys Leu Asp Thr Ala Gln Gln 
                 35                  40                  45 

Asp Leu Tyr Arg Lys Val Met Leu Glu Asn Tyr Arg Asn Leu Val 
                 50                  55                  60 

Phe Leu Ala Gly Ile Ala Val Ser Lys Pro Asp Leu Val Thr Cys 
                 65                  70                  75 

Leu Glu Gln Gly Lys Asp Pro Trp Asn Met Lys Gly His Ser Thr 
                 80                  85                  90 

Val Val Lys Pro Pro Gly Phe Leu Thr Ala Ile Cys Asp Ser Phe 
                 95                 100                 105 

Leu Ile Cys Pro Lys Leu Tyr Val Leu Ile Leu Leu Lys Thr Phe 
                110                 115                 120 

Ala Gln Gly Gln Ala Leu Lys Ile Leu Phe Lys Lys 
                125                 130 

 
           
             52  
             193  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI901832.1.orf12001JAN12  
             
           
            52 

Lys His Glu Ile Ile His Phe Glu Glu Glu Pro Ser Glu Tyr Asn 
  1               5                  10                  15 

Asn Asn Gly Asn Ser Phe Trp Leu Asn Glu Asp Leu Ile Trp His 
                 20                  25                  30 

Gln Lys Ile Lys Asn Trp Glu Gln Pro Phe Glu Tyr Asn Glu Cys 
                 35                  40                  45 

Gly Lys Ala Phe Pro Glu Asn Ser Leu Phe Leu Val His Lys Arg 
                 50                  55                  60 

Ala Tyr Thr Gly Gln Lys Thr Cys Lys Tyr Thr Glu His Gly Lys 
                 65                  70                  75 

Thr Cys Tyr Met Ser Phe Phe Ile Thr His Gln Gln Thr His Pro 
                 80                  85                  90 

Arg Glu Asn His Tyr Glu Cys Asn Glu Cys Gly Glu Ser Ile Phe 
                 95                 100                 105 

Glu Glu Ser Ile Leu Phe Glu His Gln Asn Val Tyr Pro Phe Ser 
                110                 115                 120 

Gln Asn Leu Asn Pro Thr Leu Ile Gln Arg Thr His Ser Ile Ser 
                125                 130                 135 

Asn Ile Ile Glu Tyr Asn Glu Cys Gly Thr Phe Phe Ser Glu Lys 
                140                 145                 150 

Leu Ala Leu His Leu Gln Gln Arg Thr His Pro Gly Glu Lys Pro 
                155                 160                 165 

Tyr Glu Cys His Glu Cys Gly Lys Thr Phe Thr Gln Lys Ser Ala 
                170                 175                 180 

His Thr Arg His Gln Arg Thr His Thr Gly Lys Thr Leu 
                185                 190 

 
           
             53  
             101  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1091903.1.orf22001JAN12  
             
           
            53 

Arg Gly Leu Gln Arg Lys Asp Trp Ser Ser Leu Ser Tyr Leu Lys 
  1               5                  10                  15 

Thr Met Ala Gln Gly Ser Val Ser Phe Asn Asp Val Thr Val Asp 
                 20                  25                  30 

Phe Thr Gln Glu Glu Trp Gln His Leu Asp His Ala Gln Lys Thr 
                 35                  40                  45 

Leu Tyr Met Asp Val Met Leu Glu Asn Tyr Cys His Leu Ile Ser 
                 50                  55                  60 

Val Gly Cys His Met Thr Lys Pro Asp Val Ile Leu Lys Leu Glu 
                 65                  70                  75 

Arg Gly Glu Glu Pro Trp Thr Ser Phe Ala Gly His Thr Cys Leu 
                 80                  85                  90 

Gly Gly Glu Asp Gly Leu Thr Gly Cys Leu Ser 
                 95                 100 

 
           
             54  
             346  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1089543.2.orf22001JAN12  
             
           
            54 

Val Arg Leu Thr Phe Arg Asp Val Ala Ile Glu Phe Ser Leu Glu 
  1               5                  10                  15 

Glu Trp Gln Cys Leu Asp Met Ala Gln Gln Asn Leu Tyr Arg Asp 
                 20                  25                  30 

Val Met Leu Glu Asn Tyr Arg Asn Leu Val Ser Leu Gly Leu Cys 
                 35                  40                  45 

His Phe Asp Met Asn Ile Ile Ser Met Leu Glu Glu Gly Lys Glu 
                 50                  55                  60 

Pro Trp Thr Val Lys Ser Cys Val Lys Ile Ala Arg Lys Pro Arg 
                 65                  70                  75 

Thr Arg Glu Cys Val Lys Gly Val Val Thr Asp Ile Pro Pro Lys 
                 80                  85                  90 

Cys Thr Ile Lys Asp Leu Leu Pro Lys Glu Lys Ser Ser Thr Glu 
                 95                 100                 105 

Ala Val Phe His Thr Val Val Leu Glu Arg His Glu Ser Pro Asp 
                110                 115                 120 

Ile Glu Asp Phe Ser Phe Lys Glu Pro Gln Lys Asn Val His Asp 
                125                 130                 135 

Phe Glu Cys Gln Trp Arg Asp Asp Thr Gly Asn Tyr Lys Gly Val 
                140                 145                 150 

Leu Met Ala Gln Lys Glu Gly Lys Arg Asp Gln Arg Asp Arg Arg 
                155                 160                 165 

Asp Ile Glu Asn Lys Leu Met Asn Asn Gln Leu Gly Val Ser Phe 
                170                 175                 180 

His Ser His Leu Pro Glu Leu Gln Leu Phe Gln Gly Glu Gly Lys 
                185                 190                 195 

Met Tyr Glu Cys Asn Gln Val Glu Lys Ser Thr Asn Asn Gly Ser 
                200                 205                 210 

Ser Val Ser Pro Leu Gln Gln Ile Pro Ser Ser Val Gln Thr His 
                215                 220                 225 

Arg Ser Lys Lys Tyr His Glu Leu Asn His Phe Ser Leu Leu Thr 
                230                 235                 240 

Gln Arg Arg Lys Ala Asn Ser Cys Gly Lys Pro Tyr Lys Cys Asn 
                245                 250                 255 

Glu Cys Gly Lys Ala Phe Thr Gln Asn Ser Asn Leu Thr Ser His 
                260                 265                 270 

Arg Arg Ile His Ser Gly Glu Lys Pro Tyr Lys Cys Ser Glu Cys 
                275                 280                 285 

Gly Lys Thr Phe Thr Val Arg Ser Asn Leu Thr Ile His Gln Val 
                290                 295                 300 

Ile His Thr Gly Glu Lys Pro Tyr Lys Cys His Glu Cys Gly Lys 
                305                 310                 315 

Val Phe Arg His Asn Ser Tyr Leu Ala Thr His Arg Arg Ile His 
                320                 325                 330 

Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe 
                335                 340                 345 

Arg 

 
           
             55  
             390  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2049137.1.orf12001JAN12  
             
           
            55 

Glu Thr Ser Leu Arg Ser Gly Gln Ile Pro Thr Leu Asp Ser Ser 
  1               5                  10                  15 

Glu His Asn Leu Ser Pro Glu Pro Leu Glu Leu Asp Arg Met Pro 
                 20                  25                  30 

His Ser Pro Leu Ile Ser Ile Pro His Val Trp Cys His Pro Glu 
                 35                  40                  45 

Glu Glu Glu Arg Met His Asp Glu Leu Leu Gln Ala Val Ser Lys 
                 50                  55                  60 

Gly Pro Val Met Phe Arg Asp Val Ser Ile Asp Phe Ser Gln Glu 
                 65                  70                  75 

Glu Trp Glu Cys Leu Asp Ala Asp Gln Met Asn Leu Tyr Lys Glu 
                 80                  85                  90 

Val Met Leu Glu Asn Phe Ser Asn Leu Val Ser Val Gly Leu Ser 
                 95                 100                 105 

Asn Ser Lys Pro Ala Val Ile Ser Leu Leu Glu Gln Gly Lys Glu 
                110                 115                 120 

Pro Trp Met Val Asp Arg Glu Leu Thr Arg Gly Leu Cys Ser Asp 
                125                 130                 135 

Leu Glu Ser Met Cys Glu Thr Lys Ile Leu Ser Leu Lys Lys Arg 
                140                 145                 150 

His Phe Ser Gln Val Ile Ile Thr Arg Glu Asp Met Ser Thr Phe 
                155                 160                 165 

Ile Gln Pro Thr Phe Leu Ile Pro Pro Gln Lys Thr Met Ser Glu 
                170                 175                 180 

Glu Lys Pro Trp Glu Cys Lys Ile Cys Gly Lys Thr Phe Asn Gln 
                185                 190                 195 

Asn Ser Gln Phe Ile Gln His Gln Arg Ile His Phe Gly Glu Lys 
                200                 205                 210 

His Tyr Glu Ser Lys Glu Tyr Gly Lys Ser Phe Ser Arg Gly Ser 
                215                 220                 225 

Leu Val Thr Arg His Gln Arg Ile His Thr Gly Lys Lys Pro Tyr 
                230                 235                 240 

Glu Cys Lys Glu Cys Gly Lys Ala Phe Ser Cys Ser Ser Tyr Phe 
                245                 250                 255 

Ser Gln His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys 
                260                 265                 270 

Lys Glu Cys Gly Lys Ala Phe Lys Tyr Cys Ser Asn Leu Asn Asp 
                275                 280                 285 

His Gln Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Val 
                290                 295                 300 

Cys Gly Lys Ala Phe Thr Lys Ser Ser Gln Leu Phe Leu His Leu 
                305                 310                 315 

Arg Ile His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Glu Cys Gly 
                320                 325                 330 

Lys Ala Phe Thr Gln His Ser Arg Leu Ile Gln His Gln Arg Met 
                335                 340                 345 

His Thr Gly Glu Lys Pro Tyr Glu Cys Lys Gln Cys Gly Lys Ala 
                350                 355                 360 

Leu Ile Val Pro Gln His Leu Leu Thr Ile Thr Glu Phe Met Leu 
                365                 370                 375 

Val Arg Ser Ser Met Asn Val Lys Asn Val Glu Arg Ala Leu Phe 
                380                 385                 390 

 
           
             56  
             125  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1171755.9.orf32001JAN12  
             
           
            56 

Glu Cys Gly Lys Leu Phe Arg Asp Met Ser Asn Leu Phe Ile His 
  1               5                  10                  15 

Gln Ile Val His Thr Gly Glu Arg Pro Tyr Gly Cys Ser Asn Cys 
                 20                  25                  30 

Gly Lys Ser Phe Ser Arg Asn Ala His Leu Ile Glu His Gln Arg 
                 35                  40                  45 

Val His Thr Gly Glu Lys Pro Phe Thr Cys Ser Glu Cys Gly Lys 
                 50                  55                  60 

Ala Phe Arg His Asn Ser Thr Leu Val Gln His His Lys Ile His 
                 65                  70                  75 

Thr Gly Val Arg Pro Tyr Glu Cys Ser Glu Cys Gly Lys Leu Phe 
                 80                  85                  90 

Ser Phe Asn Ser Ser Leu Met Lys His Gln Arg Val His Thr Gly 
                 95                 100                 105 

Glu Arg Pro Tyr Lys Val Gly Leu Val Ala Ile Glu Phe Ser Thr 
                110                 115                 120 

Phe Thr Ala Leu Ile 
                125 

 
           
             57  
             310  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI208529.12.orf32001JAN12  
             
           
            57 

Val Arg Ser Gly Ala Ala Gly Gly Gly Gly Ala Phe Ile Val Leu 
  1               5                  10                  15 

Pro Leu Ala Lys Thr Gly Arg Val Asp Lys Asn Tyr Pro Leu Val 
                 20                  25                  30 

Thr Gly His Thr Ala Pro Val Leu Asp Ile Asp Trp Cys Pro His 
                 35                  40                  45 

Asn Asp Asn Val Ile Ala Ser Ala Ser Asp Asp Thr Thr Ile Met 
                 50                  55                  60 

Val Trp Gln Ile Pro Asp Tyr Thr Pro Met Arg Asn Ile Thr Glu 
                 65                  70                  75 

Pro Ile Ile Thr Leu Glu Gly His Ser Lys Arg Val Gly Ile Leu 
                 80                  85                  90 

Ser Trp His Pro Thr Ala Arg Asn Val Leu Leu Ser Ala Gly Gly 
                 95                 100                 105 

Asp Asn Val Ile Ile Ile Trp Asn Val Gly Thr Gly Glu Val Leu 
                110                 115                 120 

Leu Ser Leu Asp Asp Met His Pro Asp Val Ile His Ser Val Cys 
                125                 130                 135 

Trp Asn Ser Asn Gly Ser Leu Leu Ala Thr Thr Cys Lys Asp Lys 
                140                 145                 150 

Thr Leu Arg Ile Val Asp Pro Arg Lys Gly Gln Val Val Ala Glu 
                155                 160                 165 

Arg Phe Ala Ala His Glu Gly Met Arg Pro Met Arg Ala Val Phe 
                170                 175                 180 

Thr Arg Gln Gly His Ile Phe Thr Thr Gly Phe Thr Arg Met Ser 
                185                 190                 195 

Gln Arg Glu Leu Gly Leu Trp Asp Pro Asn Asn Phe Glu Glu Pro 
                200                 205                 210 

Val Ala Leu Gln Glu Met Asp Thr Ser Asn Gly Val Leu Leu Pro 
                215                 220                 225 

Phe Tyr Asp Pro Asp Ser Ser Ile Val Tyr Leu Cys Gly Lys Gly 
                230                 235                 240 

Asp Ser Ser Ile Arg Tyr Phe Glu Ile Thr Asp Glu Pro Pro Phe 
                245                 250                 255 

Val His Tyr Leu Asn Thr Phe Ser Ser Lys Glu Pro Gln Arg Gly 
                260                 265                 270 

Met Gly Phe Met Pro Lys Arg Gly Leu Asp Val Ser Lys Cys Glu 
                275                 280                 285 

Ile Ala Arg Phe Tyr Lys Leu His Glu Arg Lys Cys Glu Pro Ile 
                290                 295                 300 

Ile Met Thr Val Pro Ser Ser Leu Arg Ser 
                305                 310 

 
           
             58  
             271  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI024125.6.orf12001JAN12  
             
           
            58 

Ser Ile Ser Ala Ser Thr Asp Pro Arg Leu Ser Arg Pro Ala Ser 
  1               5                  10                  15 

Asn Asn Thr His Ile Val Gly Cys Lys Phe Leu His Lys Asp Ser 
                 20                  25                  30 

Leu Gly Glu Leu Arg Pro Phe Leu Val Leu Asp Arg Glu Leu Glu 
                 35                  40                  45 

Leu Val Met Gly Ile Met Ala Ala Ser Arg Pro Leu Ser Arg Phe 
                 50                  55                  60 

Trp Glu Trp Gly Lys Asn Ile Val Cys Val Gly Arg Asn Tyr Ala 
                 65                  70                  75 

Asp His Val Arg Glu Met Arg Ser Ala Val Leu Ser Glu Pro Val 
                 80                  85                  90 

Leu Phe Leu Lys Pro Ser Thr Ala Tyr Ala Pro Glu Gly Ser Pro 
                 95                 100                 105 

Ile Leu Met Pro Ala Tyr Thr Arg Asn Leu His His Glu Leu Glu 
                110                 115                 120 

Leu Gly Val Val Met Gly Lys Arg Cys Arg Ala Val Pro Glu Ala 
                125                 130                 135 

Ala Ala Met Asp Tyr Val Gly Gly Tyr Ala Leu Cys Leu Asp Met 
                140                 145                 150 

Thr Ala Arg Asp Val Gln Asp Glu Cys Lys Lys Lys Gly Leu Pro 
                155                 160                 165 

Trp Thr Leu Ala Lys Ser Phe Thr Ala Ser Cys Pro Val Ser Ala 
                170                 175                 180 

Phe Val Pro Lys Glu Lys Ile Pro Asp Pro His Lys Leu Lys Leu 
                185                 190                 195 

Trp Leu Lys Val Asn Gly Glu Leu Arg Gln Glu Gly Glu Thr Ser 
                200                 205                 210 

Ser Met Ile Phe Ser Ile Pro Tyr Ile Ile Ser Tyr Val Ser Lys 
                215                 220                 225 

Ile Ile Thr Leu Glu Glu Gly Asp Ile Ile Leu Thr Gly Thr Pro 
                230                 235                 240 

Lys Gly Val Gly Pro Val Lys Glu Asn Asp Glu Ile Glu Ala Gly 
                245                 250                 255 

Ile His Gly Leu Val Ser Met Thr Phe Lys Val Glu Lys Pro Glu 
                260                 265                 270 

Tyr 

 
           
             59  
             120  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI235557.12.orf22001JAN12  
             
           
            59 

Ser Asn Pro Ala Asp Ala Phe Asp Asn Asp Leu Met His Arg Thr 
  1               5                  10                  15 

Leu Lys Asn Ile Val Glu Gly Lys Thr Val Glu Val Pro Thr Tyr 
                 20                  25                  30 

Asp Phe Val Thr His Ser Arg Leu Pro Glu Thr Thr Val Val Tyr 
                 35                  40                  45 

Pro Ala Asp Val Val Leu Phe Glu Gly Ile Leu Val Phe Tyr Ser 
                 50                  55                  60 

Gln Glu Ile Arg Asp Met Phe His Leu Arg Leu Phe Val Asp Thr 
                 65                  70                  75 

Asp Ser Asp Val Arg Leu Ser Arg Arg Val Leu Arg Asp Val Arg 
                 80                  85                  90 

Arg Gly Arg Asp Leu Glu Gln Ile Leu Thr Gln Tyr Thr Thr Phe 
                 95                 100                 105 

Val Lys Pro Ala Phe Glu Glu Phe Cys Leu Pro Gln Gln Ser Ile 
                110                 115                 120 

 
           
             60  
             91  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI178860.1.orf12001JAN12  
             
           
            60 

Met Glu Thr Met Lys Ser Lys Ala Asn Cys Ala Gln Asn Pro Asn 
  1               5                  10                  15 

Cys Asn Ile Met Ile Phe His Pro Thr Lys Glu Glu Phe Asn Asp 
                 20                  25                  30 

Leu Asp Lys Tyr Ile Ala Tyr Met Glu Ser Gln Gly Ala His Arg 
                 35                  40                  45 

Ala Gly Leu Ala Lys Ile Ile Pro Pro Lys Glu Trp Lys Ala Arg 
                 50                  55                  60 

Glu Thr Tyr Asp Asn Ile Ser Glu Ile Leu Ile Ala Thr Pro Leu 
                 65                  70                  75 

Gln Gln Val Ala Ser Gly Arg Ala Gly Val Phe Thr Gln Tyr His 
                 80                  85                  90 

Lys 

 
           
             61  
             174  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI405798.1.orf22001JAN12  
             
           
            61 

Ser Ser Val Ala Asp Pro Thr Thr Leu Pro Pro Pro Ser Ser Pro 
  1               5                  10                  15 

Ser His His Gln Leu Ser Ser Ser Gln Arg Glu Gly Trp Gly Gly 
                 20                  25                  30 

Asp Pro Asp Leu Thr Gly Gln Gly Ala Ser Ile Met Met Leu Asn 
                 35                  40                  45 

Ser Asp Thr Met Glu Leu Asp Leu Pro Pro Thr His Ser Glu Thr 
                 50                  55                  60 

Glu Ser Gly Phe Ser Asp Cys Gly Gly Gly Ala Gly Pro Asp Gly 
                 65                  70                  75 

Ala Gly Pro Gly Gly Pro Gly Gly Gly Gln Ala Arg Gly Pro Glu 
                 80                  85                  90 

Pro Gly Glu Pro Gly Arg Lys Asp Leu Gln His Leu Ser Arg Glu 
                 95                 100                 105 

Glu Arg Arg Arg Arg Arg Arg Ala Thr Ala Lys Tyr Arg Thr Ala 
                110                 115                 120 

His Ala Thr Arg Glu Arg Ile Arg Val Glu Ala Phe Asn Leu Ala 
                125                 130                 135 

Phe Ala Glu Leu Arg Lys Leu Leu Pro Thr Leu Pro Pro Asp Lys 
                140                 145                 150 

Lys Leu Ser Lys Ile Glu Ile Leu Arg Leu Ala Ile Cys Tyr Ile 
                155                 160                 165 

Ser Tyr Leu Asn His Val Leu Asp Val 
                170 

 
           
             62  
             139  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1071427.101.orf12001JAN12  
             
           
            62 

Arg Ser Arg Ser Leu Leu Leu Leu Ser Ala Ser Thr Pro Cys Gly 
  1               5                  10                  15 

Ser Ala Ala Pro Ser Trp Pro Arg Cys Pro Pro Ser Ser Arg Cys 
                 20                  25                  30 

Gly Ser Ala Ser Arg Ser Met Thr Ser Pro Ala Pro Pro Ser Ser 
                 35                  40                  45 

Thr Ala Asn Ala Ser Ser Ala Asp Tyr Asp Leu Val Ala Leu His 
                 50                  55                  60 

Pro Phe Leu Thr Lys Pro Asn Leu Arg Arg Lys Gln Asp Glu Met 
                 65                  70                  75 

Ala Trp Leu Tyr Leu Phe Phe Trp Phe Gly Leu Gly Phe Phe Phe 
                 80                  85                  90 

Phe Leu Gly Val Asp Ser Gly Phe Lys Thr Arg Glu Arg Val Lys 
                 95                 100                 105 

Gly Asp Ser Ser Arg Trp Glu Arg Ala Ser Pro Lys Val His Lys 
                110                 115                 120 

Val Ala Glu Asp Leu Asp Gly Pro Trp Trp Val Leu Asn Ser His 
                125                 130                 135 

Ser Lys Phe Glu 

 
           
             63  
             136  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1072276.1.orf12001JAN12  
             
           
            63 

Leu Cys Ala Pro Lys His Ala Arg Thr Phe Val Val Phe Val Gln 
  1               5                  10                  15 

Val Lys Arg Gly Pro Gly Asn Gln Leu Arg Asn His Tyr Ile His 
                 20                  25                  30 

Lys Ser Cys Leu Phe His Arg Val Val Lys Asp Phe Met Val Gln 
                 35                  40                  45 

Gly Gly Asp Phe Ser Glu Arg Lys Trp Thr Arg Gln Gly Asn Leu 
                 50                  55                  60 

Ser Met Glu Asp Phe Leu Lys Thr Arg Val Ser Leu Leu Asn Thr 
                 65                  70                  75 

Thr Thr Glu Phe Leu Leu Ser Met Ala Asn Arg Gly Lys Asp Thr 
                 80                  85                  90 

Asn Gly Ser Gln Phe Phe Ile Thr Thr Lys Pro Thr Pro His Phe 
                 95                 100                 105 

Ser Met Gly Thr His Val Ala Phe Trp Thr Ser Asn Ser Leu Val 
                110                 115                 120 

Asn Glu Ala Cys Lys Ser Arg Leu Lys Thr Arg Lys Thr Gly Cys 
                125                 130                 135 

Ser 

 
           
             64  
             148  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI198296.1.orf12001JAN12  
             
           
            64 

Lys Thr Leu Phe Thr Lys Cys Lys Asn Phe Ala Leu Gln Thr Phe 
  1               5                  10                  15 

Glu Asp Val Ser Gln His Glu Glu Phe Leu Glu Leu Asp Lys Asp 
                 20                  25                  30 

Glu Leu Ile Asp Tyr Ile Cys Ser Asp Glu Leu Val Ile Gly Lys 
                 35                  40                  45 

Glu Glu Met Val Phe Glu Ala Val Met Arg Trp Val Tyr Arg Ala 
                 50                  55                  60 

Val Asp Leu Arg Arg Pro Leu Leu His Glu Leu Leu Thr His Val 
                 65                  70                  75 

Arg Leu Pro Leu Val Ala Ser Gln Leu Leu Cys Ser Asn Ser Val 
                 80                  85                  90 

Lys Gly Gly Thr Leu Ile Gln Asn Ser Pro Glu Cys Tyr Gln Leu 
                 95                 100                 105 

Leu His Glu Ala Arg Arg Tyr His Ile Leu Gly Asn Glu Met Met 
                110                 115                 120 

Ser Pro Arg Thr Arg Pro Arg Arg Ser Thr Gly Tyr Ser Glu Val 
                125                 130                 135 

Ile Val Val Val Gly Gly Cys Glu Arg Val Gly Arg Ile 
                140                 145 

 
           
             65  
             256  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI202943.4.orf22001JAN12  
             
           
            65 

Met Ala Met Gln Val Asp Gln Thr Thr Val Leu Glu Pro Trp Trp 
  1               5                  10                  15 

Leu Thr Ala Ala Thr Arg Gly Ser Thr Ser Lys Gly Lys Arg Arg 
                 20                  25                  30 

Ala Pro Ala Lys Pro Gln Gly Ser Gly Val Val Leu Tyr Arg Arg 
                 35                  40                  45 

Ala Thr Arg Tyr Leu Val Val Asn His Leu Arg Leu Arg Met Ala 
                 50                  55                  60 

Phe Trp Ser Ile Gln Leu Ala Gly Ser Leu Arg Val Lys Leu Arg 
                 65                  70                  75 

Tyr Gln Cys Asn Pro Gly Tyr Lys Ser Val Gly Ser Pro Val Phe 
                 80                  85                  90 

Val Cys Gln Ala Asn Arg His Trp His Ser Glu Ser Pro Leu Met 
                 95                 100                 105 

Cys Val Pro Leu Asp Cys Gly Lys Pro Pro Pro Ile Gln Asn Gly 
                110                 115                 120 

Phe Met Lys Gly Glu Asn Phe Glu Val Gly Ser Lys Val Gln Phe 
                125                 130                 135 

Phe Cys Asn Glu Gly Tyr Glu Leu Val Gly Asp Ser Ser Trp Thr 
                140                 145                 150 

Cys Gln Lys Ser Gly Lys Trp Asn Lys Lys Ser Asn Pro Lys Cys 
                155                 160                 165 

Met Pro Ala Lys Cys Pro Glu Pro Pro Leu Leu Glu Asn Gln Leu 
                170                 175                 180 

Val Leu Lys Glu Leu Thr Thr Glu Val Gly Val Val Thr Phe Ser 
                185                 190                 195 

Cys Lys Glu Gly His Val Leu Gln Gly Pro Ser Val Leu Lys Cys 
                200                 205                 210 

Leu Pro Ser Gln Gln Trp Asn Asp Ser Phe Pro Val Cys Lys Ile 
                215                 220                 225 

Val Leu Cys Thr Pro Pro Pro Leu Ile Ser Phe Gly Val Pro Ile 
                230                 235                 240 

Pro Ser Ser Ala Leu His Phe Gly Ser Thr Val Lys Val Phe Leu 
                245                 250                 255 

Met 

 
           
             66  
             53  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI2121848.1.orf32001JAN12  
             
           
            66 

Leu His Lys Tyr Asp Asp Cys Ser Lys Ala Phe Thr Ser Arg Ser 
  1               5                  10                  15 

His Leu Ile Arg His Gln Arg Ile His Thr Gly Gln Lys Ser Tyr 
                 20                  25                  30 

Lys Cys His Gln Cys Gly Lys Val Phe Ser Leu Arg Ser Pro Leu 
                 35                  40                  45 

Lys Glu His Gln Lys Ile His Phe 
                 50 

 
           
             67  
             292  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI796992.1.orf32001JAN12  
             
           
            67 

Val Leu Glu Arg Lys Phe Phe Ser Arg Ser Ser Asn Leu Ile Gln 
  1               5                  10                  15 

His Lys Arg Val His Thr Gly Glu Lys Gln Tyr Glu Cys Ser Asp 
                 20                  25                  30 

Cys Gly Lys Phe Phe Ser Gln Arg Ser Asn Leu Ile His His Lys 
                 35                  40                  45 

Arg Val His Thr Gly Arg Ser Ala His Glu Cys Ser Glu Cys Gly 
                 50                  55                  60 

Lys Ser Phe Asn Cys Asn Ser Ser Leu Ile Lys His Trp Arg Val 
                 65                  70                  75 

His Thr Gly Glu Arg Pro Tyr Lys Cys Asn Glu Cys Gly Lys Phe 
                 80                  85                  90 

Phe Ser His Ile Ala Ser Leu Ile Gln His Gln Ile Val His Thr 
                 95                 100                 105 

Gly Glu Arg Pro His Gly Cys Gly Glu Cys Gly Lys Ala Phe Ser 
                110                 115                 120 

Arg Ser Ser Asp Leu Met Lys His Gln Arg Val His Thr Gly Glu 
                125                 130                 135 

Arg Pro Tyr Glu Cys Asn Glu Cys Gly Lys Leu Phe Ser Gln Ser 
                140                 145                 150 

Ser Ser Leu Asn Ser His Arg Arg Leu His Thr Gly Glu Arg Pro 
                155                 160                 165 

Tyr Gln Cys Ser Glu Cys Gly Lys Phe Phe Asn Gln Ser Ser Ser 
                170                 175                 180 

Leu Asn Asn His Arg Arg Leu His Thr Gly Glu Arg Pro Tyr Glu 
                185                 190                 195 

Cys Ser Glu Cys Gly Lys Thr Phe Arg Gln Arg Ser Asn Leu Arg 
                200                 205                 210 

Gln His Leu Lys Val His Lys Pro Asp Arg Pro Tyr Glu Cys Ser 
                215                 220                 225 

Glu Cys Gly Lys Ala Phe Asn Gln Arg Pro Thr Leu Ile Arg His 
                230                 235                 240 

Gln Lys Ile His Ile Arg Glu Arg Ser Met Glu Asn Val Leu Leu 
                245                 250                 255 

Pro Cys Ser Gln His Thr Pro Glu Ile Ser Ser Glu Asn Arg Pro 
                260                 265                 270 

Tyr Gln Gly Ala Val Asn Tyr Lys Leu Lys Leu Val His Pro Ser 
                275                 280                 285 

Thr His Pro Gly Glu Val Pro 
                290 

 
           
             68  
             136  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1183014.7.orf22001JAN12  
             
           
            68 

Thr Ser Phe Phe Thr Ser Thr Asp Ser Tyr His Phe Arg Leu Ser 
  1               5                  10                  15 

Lys Ile Val Ile Phe Gln Gly Ser Val Ser Phe Arg Asp Val Thr 
                 20                  25                  30 

Val Gly Phe Thr Gln Glu Glu Trp Gln His Leu Asp Pro Ala Gln 
                 35                  40                  45 

Arg Thr Leu Tyr Arg Asp Val Met Leu Glu Asn Tyr Ser His Leu 
                 50                  55                  60 

Val Ser Val Gly Tyr Cys Ile Pro Lys Pro Glu Val Ile Leu Lys 
                 65                  70                  75 

Leu Glu Lys Gly Glu Glu Pro Trp Ile Leu Glu Glu Lys Phe Pro 
                 80                  85                  90 

Ser Gln Ser His Leu Gly Glu Leu Val Cys Ala Arg Trp Asn Leu 
                 95                 100                 105 

Lys Glu Gly Arg Ser Gln Arg Val Ser Leu Asp Asn Lys Thr Ile 
                110                 115                 120 

Glu Met Phe Phe Arg Asn His Val Leu Glu Ala Pro Asp Leu Trp 
                125                 130                 135 

Lys 

 
           
             69  
             247  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI1171219.2.orf32001JAN12  
             
           
            69 

Lys Thr Ser Val His Leu Leu Thr Met Arg Leu Pro Ala Gln Leu 
  1               5                  10                  15 

Leu Gly Leu Leu Met Leu Trp Val Ser Gly Ser Ser Gly Asp Ile 
                 20                  25                  30 

Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Glu 
                 35                  40                  45 

Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser 
                 50                  55                  60 

Asn Gly Asn Asn Tyr Leu Asp Trp Phe Leu Gln Lys Pro Gly Gln 
                 65                  70                  75 

Pro Pro Gln Leu Leu Ile Tyr Leu Gly Ser Ser Arg Ala Ser Gly 
                 80                  85                  90 

Val Pro Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr 
                 95                 100                 105 

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 
                110                 115                 120 

Cys Met Gln Val Val Gln Ile Pro Ser Thr Phe Gly Gly Gly Thr 
                125                 130                 135 

Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile 
                140                 145                 150 

Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 
                155                 160                 165 

Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 
                170                 175                 180 

Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser 
                185                 190                 195 

Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 
                200                 205                 210 

Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
                215                 220                 225 

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 
                230                 235                 240 

Ser Phe Asn Arg Gly Glu Cys 
                245 

 
           
             70  
             114  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI428428.4.orf32001JAN12  
             
           
            70 

Met Arg Cys Thr Phe Leu Leu Pro Cys Asp Asp Tyr Val Leu Asn 
  1               5                  10                  15 

Asp Asn Ala Thr Gly Asp Leu Lys Leu Leu Arg Arg Thr Leu Ser 
                 20                  25                  30 

Ala Ile Lys Ser Gln Asn Tyr His Cys Thr Thr Arg Ser Gly Arg 
                 35                  40                  45 

Phe Leu Arg Ser Met Gly Thr Gly Asp Asp Ser Tyr Phe Leu His 
                 50                  55                  60 

Asp Gly Ala Gln Ser Leu Leu Gln Ser Glu Asp Gln Leu Tyr Thr 
                 65                  70                  75 

Ala Leu Trp His Arg Arg Arg Ile Leu Met Gly Lys Ile Phe Arg 
                 80                  85                  90 

Thr Trp Phe Glu Gln Ser Pro Ile Gly Arg Lys Lys Ala Arg Arg 
                 95                 100                 105 

Thr Ile Ser Gly Lys Asn Ser Ser Asn 
                110 

 
           
             71  
             519  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI230711.5.orf22001JAN12  
             
           
            71 

Gly Gln Thr Arg Gln Ser Glu Arg Gln Gly Ser Met Ser Arg Ser 
  1               5                  10                  15 

Pro Leu Asn Pro Ser Gln Leu Arg Ser Val Gly Ser Gln Asp Ala 
                 20                  25                  30 

Leu Ala Pro Leu Pro Pro Pro Ala Pro Gln Asn Pro Ser Thr His 
                 35                  40                  45 

Ser Trp Asp Pro Leu Cys Gly Ser Leu Pro Trp Gly Leu Ser Cys 
                 50                  55                  60 

Leu Leu Ala Leu Gln His Val Leu Val Met Ala Ser Leu Leu Cys 
                 65                  70                  75 

Val Ser His Leu Leu Leu Leu Cys Ser Leu Ser Pro Gly Gly Leu 
                 80                  85                  90 

Ser Tyr Ser Pro Ser Gln Leu Leu Ala Ser Ser Phe Phe Ser Cys 
                 95                 100                 105 

Gly Met Ser Thr Ile Leu Gln Thr Trp Met Gly Ser Arg Leu Pro 
                110                 115                 120 

Leu Val Gln Ala Pro Ser Leu Glu Phe Leu Ile Pro Ala Leu Val 
                125                 130                 135 

Leu Thr Ser Gln Lys Leu Pro Arg Ala Ile Gln Thr Pro Gly Asn 
                140                 145                 150 

Ser Ser Leu Met Leu His Leu Cys Arg Gly Pro Ser Cys His Gly 
                155                 160                 165 

Leu Gly His Trp Asn Thr Ser Leu Gln Glu Val Ser Gly Ala Val 
                170                 175                 180 

Val Val Ser Gly Leu Leu Gln Gly Met Met Gly Leu Leu Gly Ser 
                185                 190                 195 

Pro Gly His Val Phe Pro His Cys Gly Pro Leu Val Leu Ala Pro 
                200                 205                 210 

Ser Leu Val Val Ala Gly Leu Ser Ala His Arg Glu Val Ala Gln 
                215                 220                 225 

Phe Cys Phe Thr His Trp Gly Leu Ala Leu Leu Val Ile Leu Leu 
                230                 235                 240 

Met Val Val Cys Ser Gln His Leu Gly Ser Cys Gln Phe His Val 
                245                 250                 255 

Cys Pro Trp Arg Arg Ala Ser Thr Ser Ser Thr His Thr Pro Leu 
                260                 265                 270 

Pro Val Phe Arg Leu Leu Ser Val Leu Ile Pro Val Ala Cys Val 
                275                 280                 285 

Trp Ile Val Ser Ala Phe Val Gly Phe Ser Val Ile Pro Gln Glu 
                290                 295                 300 

Leu Ser Ala Pro Thr Lys Ala Pro Trp Ile Trp Leu Pro His Pro 
                305                 310                 315 

Gly Trp Ile Ser Ala Ser Gly Ser Leu Ser Gly Ala Thr Leu Arg 
                320                 325                 330 

Gly Ala Trp Thr Leu Pro Gln Val Gly Ser Ala Pro His His His 
                335                 340                 345 

Pro Thr Ala Cys Cys Cys Phe Tyr Leu Ala Asp Ile Asp Ser Gly 
                350                 355                 360 

Arg Asn Ile Phe Ile Val Gly Phe Ser Ile Phe Met Ala Leu Leu 
                365                 370                 375 

Leu Pro Arg Trp Phe Arg Glu Ala Pro Val Leu Phe Ser Thr Gly 
                380                 385                 390 

Trp Ser Pro Leu Asp Val Leu Leu His Ser Leu Leu Thr Gln Pro 
                395                 400                 405 

Ile Phe Leu Ala Gly Leu Ser Gly Phe Leu Leu Glu Asn Thr Ile 
                410                 415                 420 

Pro Gly Thr Gln Leu Glu Arg Gly Leu Gly Gln Gly Leu Pro Ser 
                425                 430                 435 

Pro Phe Thr Ala Gln Glu Ala Arg Met Pro Gln Lys Pro Arg Glu 
                440                 445                 450 

Lys Ala Ala Gln Val Tyr Arg Leu Pro Phe Pro Ile Gln Asn Leu 
                455                 460                 465 

Cys Pro Cys Ile Pro Gln Pro Leu His Cys Leu Cys Pro Leu Pro 
                470                 475                 480 

Glu Asp Pro Gly Asp Glu Glu Gly Gly Ser Ser Glu Pro Glu Glu 
                485                 490                 495 

Met Ala Asp Leu Leu Pro Gly Ser Gly Glu Pro Cys Pro Glu Ser 
                500                 505                 510 

Ser Arg Glu Gly Phe Arg Ser Gln Lys 
                515 

 
           
             72  
             408  
             PRT  
             Homo sapiens  
             
               misc_feature  
               Incyte ID No LI199716.6.orf22001JAN12  
             
           
            72 

Thr Ile Leu Phe Phe Leu Phe Val Ala Ala Asn Ile Leu Ser Ser 
  1               5                  10                  15 

Pro Ser Lys Arg Gly Gln Lys Gly Thr Leu Ile Gly Tyr Ser Pro 
                 20                  25                  30 

Glu Gly Thr Pro Leu Tyr Asn Phe Met Gly Asp Ala Phe Gln His 
                 35                  40                  45 

Ser Ser Gln Ser Ile Pro Arg Phe Ile Lys Glu Ser Leu Lys Gln 
                 50                  55                  60 

Ile Leu Glu Glu Ser Asp Ser Arg Gln Ile Phe Tyr Phe Leu Cys 
                 65                  70                  75 

Leu Asn Leu Leu Phe Thr Phe Val Glu Leu Phe Tyr Gly Val Leu 
                 80                  85                  90 

Thr Asn Ser Leu Gly Leu Ile Ser Asp Gly Phe His Met Leu Phe 
                 95                 100                 105 

Asp Cys Ser Ala Leu Val Met Gly Leu Phe Ala Ala Leu Met Ser 
                110                 115                 120 

Arg Trp Lys Ala Thr Arg Ile Phe Ser Tyr Gly Tyr Gly Arg Ile 
                125                 130                 135 

Glu Ile Leu Ser Gly Phe Ile Asn Gly Leu Phe Leu Ile Val Ile 
                140                 145                 150 

Ala Phe Phe Val Phe Met Glu Ser Val Ala Arg Leu Ile Asp Pro 
                155                 160                 165 

Pro Glu Leu Asp Thr His Met Leu Thr Pro Val Ser Val Gly Gly 
                170                 175                 180 

Leu Ile Val Asn Leu Ile Gly Ile Cys Ala Phe Ser His Ala His 
                185                 190                 195 

Ser His Ala His Gly Ala Ser Gln Gly Ser Cys His Ser Ser Asp 
                200                 205                 210 

His Ser His Ser His His Met His Gly His Ser Asp His Gly His 
                215                 220                 225 

Gly His Ser His Gly Ser Ala Gly Gly Gly Met Asn Ala Asn Met 
                230                 235                 240 

Arg Gly Val Phe Leu His Val Leu Ala Asp Thr Leu Gly Ser Ile 
                245                 250                 255 

Gly Val Ile Val Ser Thr Val Leu Ile Glu Gln Phe Gly Trp Phe 
                260                 265                 270 

Ile Ala Asp Pro Leu Cys Ser Leu Phe Ile Ala Ile Leu Ile Phe 
                275                 280                 285 

Leu Ser Val Val Pro Leu Ile Lys Asp Ala Cys Gln Val Leu Leu 
                290                 295                 300 

Leu Arg Leu Pro Pro Glu Tyr Glu Lys Glu Leu His Ile Ala Leu 
                305                 310                 315 

Glu Lys Ile Gln Lys Ile Glu Gly Leu Ile Ser Tyr Arg Asp Pro 
                320                 325                 330 

His Phe Trp Arg His Ser Ala Ser Ile Val Ala Gly Thr Ile His 
                335                 340                 345 

Ile Gln Val Thr Ser Asp Val Leu Glu Gln Arg Ile Val Arg Gln 
                350                 355                 360 

Val Thr Gly Ile Leu Lys Asp Ala Gly Val Asn Asn Leu Thr Ile 
                365                 370                 375 

Gln Val Glu Lys Glu Ala Tyr Phe Gln His Met Ser Gly Leu Ser 
                380                 385                 390 

Thr Gly Phe His Asp Val Leu Ala Met Thr Lys Thr Asn Gly Ile 
                395                 400                 405 

His Lys Ile